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New iminophosphine ligands were synthesised in good yields from the condensation 
of N-(2-(diphenylphosphino)benzaldehyde with the appropriate amine. All the ligands 
were fully characterised using spectroscopic and analytical techniques, including 
melting point, 1H, 13C, 31P NMR, MS, IR spectroscopy and elemental analysis. A 
series of new metal complexes (Pd, Pt and Au) were obtained by coordination of the 
iminophosphine ligands in good yields. The complexes were characterised using the 
spectroscopic and analytical techniques mentioned above, with the exception of the 
palladium dichloride complexes that are highly insoluble in organic solvents. The 
structures of palladium complexes 74, 79, 80; platinum complexes 84, 86, 88 and  
gold complexes 91, 93 and 94 were unambiguously determined using X-ray 
crystallography. The structures of novel tetradentate ligands 65, 66 and 68 were also 
determined using X-ray crystallography but attempts to complex them with palladium 
or platinum were unsuccessful. 
 
The metal complexes were evaluated for their cytotoxicity against the oesophageal 
cancer cell lines WHCO1 and KYSE450. Platinum and gold complexes block the 
proliferation of WHCO1 and KYSE450 cells with an IC50 range of 2.16 - 9.44µM.  
The platinum and gold complexes exhibited better activity than cisplatin, while the 
chloromethyl palladium complexes were moderately active and exhibited IC50 values 
in the range 10.99 – 68.54µM for both cell lines. Our results show that these mtal 
complexes have little effect on normal fibroblast cells (DMB) exhibiting IC50 values > 
100µM which shows that these novel complexes are selective towards oesophageal 
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According to the International Agency for Research on Cancer (IARC), in the year 
2005, oesophageal cancer was reported as the ninth most common cancer in the 
world, and the sixth leading cause of cancer-related deaths worldwide [1]. A unique 
epidemiological feature of oesophageal cancer is its very uneven geographic 
distribution, with high incidence found within sharply demarcated geographic 
confines [2]. These geographic ‘hot spots’ include areas in Northern Iran, Kazakhstan, 
South Africa, and Northern China [3]. On the African continent, a number of reports 
have documented a very high incidence of oesophageal cancer in South Africa, 
particularly in the Transkei districts [4]. Considering the high incidence of this disease 
in South Africa, oesophageal cancer will be the focus in this thesis. 
 
Cancer is fundamentally a disease, in which the cells proliferate indefinitely, due to 
dysregulated control pathways. Consequently, cancer cells continue to grow and 
divide yielding an ever increasing mass referred to as a tumour [5]. The tumour grows 
invasively, destroying surrounding body tissues. Cancer cells from this primary 
tumour may then spread, or metastasize, to other parts of the body, where new 
tumours may begin to grow. Eventually the tumour load will cause death, often by 
physically blocking or compressing blood vessels or organs such as the brain, or 
disrupting critical processes.  
 
Cancer makes a contribution to morbidity and mortality worldwide, with the 
International Agency for Research on Cancer (IARC) estimating that for 2008, there 
were 12.4 million new cases of cancer, 7.6 million deaths from cancer and 28 million 













about half of the cases and about 60% of the mortalities were from medium and low 
income countries [6].  
 
Transition metal-based anticancer drugs such as cisplatin have found widespread use, 
since they form highly reactive, charged, platinum complexes that bind to 
nucleophilic groups such as GC-rich sites in DNA, inducing DNA cross-links that 
result in apoptosis and cell growth inhibition. In SA, like in other countries 
worldwide, cisplatin is the drug prescribed when treating oesophageal cancer with 
chemotherapeutic agents. However, due to the severe adverse effects of cisplatin, that 
include nephrotoxicity, neurotoxicity, ototoxicity, nausea and vommitting, a second- 
generation of platinum compounds was developed, like carboplatin, nedaplatin, 
satraplatin and other closely related platinum anticancer agents, some of which are 
still used for the treatment of certain types of tumors. 
1.2 Non-metal containing anticancer drugs 
 
 Not all chemotherapeutic agents that are used to treat cancer are metal based 
compounds. Infact, a wide repertoire of agents are used to treat cancers and at present, 
natural products, their derivatives and analogues are used as remedies and represents 
over 50% of all drugs in clinical use, with higher plant-derived natural products 
representing approximately 25% of the total [7]. Natural products have played an 
important role in the development of contemporary cancer chemotherapy.  
 
Between 1960 and 1982 the National Cancer Institute (NCI) screened around 114,000 
extracts from an estimated 35,000 plant samples for anticancer activity [8]. These 












antibodies and other small molecules. In vitro studies done on these compounds have 
resulted in a number of clinically useful drugs that are now available. Among these 
clinically useful drugs are paclitaxel (Taxol), vincristine (Oncovin) [9], 
podophyllotoxin (a natural product precursor) [10] and camptothecin [9, 10]. Besides 
natural products that have found direct application as drug entities, e.g. Taxol (Figure 
1.1), there are many others that have served as chemical models or templates for the 
design, synthesis, and semi-synthesis of novel substances for treating diseases some of 
them include (1-pyrenylmethyl)amino alcohol derivatives, 2-amino-1,3-propanediol 





















































Figure 1.1. Structures of compounds among the clinically useful drugs. 1. Taxol, 2. Vincristine, 3. 














Although significant progress has been made in cancer chemotherapy, some of the 
available drugs are less effective against many common cancers (colon, rectum, lung, 
prostate) [12] and are often very toxic. Paclitaxel (Figure 1.1) and tamoxifen (Figure 





Figure 1.2 The structure of Tamoxifen (R= H) and its derivative Hydrotamoxifen (R= OH). 
 
Despite wide repertoire of drugs other than cisplatin, there is still a place for metal 
containing drugs, inorganic compounds are relatively easy to synthesise whereas, the 
natural product compounds are found in smaller quantities in nature and their 
synthesis in the laboratory is very challenging, (considering it took 12 years to fully 
synthesise taxol). Even though these drugs, e.g. taxol and tamoxifen, have been shown 
to be more useful for certain types of cancer, e.g tamoxifen for breast cancer, further 
research on more effective drugs can be achieved by synthesis of other new metal 
containing compounds. 
 
1.3 History of platinum based drugs 
The first platinum-containing coordination complex to be used in cancer treatment 
was cisplatin (cis-dichlorodiammineplatinum(II)) (6) which was first synthesised 165 












was subsequently deduced by Alfred Werner [14]. In 1965, Rosenberg and colleagues 
reported its inhibitory activity on Escherichi coli division [15]. Cisplatin subsequently 
started being applied for clinical trials in the early 1970’s and was approved for use by 
the US Food and Drug Administration (FDA) in 1978 [19].  
 
In response to the chemotherapeutic effects of cisplatin, thousands of derivatives of 
cisplatin have since been synthesised and tested against cancer cells, but at most only 
about 30 reached clinical trials and more than half of these have already been rejected 
due to poor successes. Four other derivatives are available today and used clinically:  
cisplatin (6), available since 1978, and carboplatin (7), both being used world-wide, 
also oxaliplatin (8) which is available in a few countries, including France, and 
nedaplatin (9) which is available only in Japan and laboplatin (10). These compounds 
are not more active than cisplatin, but they are less toxic, thus they are prefered over 














































Figure 1.3 Structure of the platinum derivatives [16]. 6. Cisplatin, 7. Carboplatin, 8. Oxaliplatin, 9. 














Further developments are shown schematically in Figure 1.4. Clinical use of cisplatin 
started in 1979, of carboplatin in 1989, and of oxaliplatin in 2004 [17]. The other 
compounds are not yet in routine clinical use. The ideas for new compounds arose 
























































Figure 1.4 Schematic history of the development of platinum drugs. Substituting different amine and 
anionic ligands produced variations of cisplatin. Oxaliplatin has at least one H-donor function available 
on one of the amine groups. The steric and ligand exchange characteristics are different, especially for 
Pt(IV) compounds, as they react very slowly. The NH group assists by hydrogen bonding to a DNA 
backbone phosphate and makes the drug less prone to reversion by binding to the S-donor ligands in 
the cell.  
 
Although compounds like cisplatin can effectively kill cancer cells, they have 
drawbacks, including intrinsic or acquired resistance, toxicity, and side effects such as 
gastrointestinal and haematological toxicity. These shortcomings of cisplatin provided 
a forceful impetus to the research on novel platinum complexes [18]. The initial driver 
for further platinum-drug development was the discovery of severe toxicity problems 












Carboplatin (7) was selected for clinical use mainly because of its lower non-
haematological toxicity compared with cisplatin (6) resulting in a more acceptable 
side-effect profile. The decreased toxicity is achieved by the substitution of the 
chloride leaving groups with a bidentate carboxylate, which renders the molecule less 
reactive. Unfortunately, it exhibits cross-resistance with its parent compound. The 
antitumour activity of carboplatin is not superior to that of cisplatin, but it has lower 
toxicity. Together, cisplatin and carboplatin now constitute the most important metal-
based anti-cancer pharmaceuticals in general use.  
 
Oxaliplatin (8) has a higher efficacy and a lower toxicity than cisplatin, and has no 
cross-resistance. It was designed to circumvent resistance, and thereby broaden the 
clinical utility of this class of compounds [19]. Oxaliplatin (8) is a more water-soluble 
variant of carboplatin (7), which retains activity against cancer cells with acquired 
resistance to cisplatin (6). Moreover, it has a broader spectrum of activity than 
cisplatin and carboplatin, proving valuable against colon cancers in combination 
therapy [20]. Oxaliplatin possesses a dicarboxylate leaving group, a bulky and 
hydrophobic chelating 1,2-diaminocyclohexane-carrier ligand, which increases the 
lipophilicity, which subsequently helps the drug to penetrate through cell membranes. 
The DNA adducts of oxaliplatin are more effective than those of cisplatin in inhibiting 
DNA chain elongation. Better cellular uptake and different conformation of DNA 
adducts are believed to help oxaliplatin in circumventing cisplatin resistance 
mechanisms [21, 22]. The hydrophobic chelating ligand is also believed to assist in 














Nedaplatin (9) was developed because it produced better results than cisplatin in 
preclinical studies. Unfortunately, it shows cross-resistance with cisplatin. Other 
developments include the platinum(IV) drug satraplatin (13) (Figure 1.5), which is 
designed to be an orally available drug with a similar pharmacokinetic profile to 
carboplatin (7), and shows promise in this regard in terms of treatment regime, since it 
can be administered without hospitalisation. It shows low nephrotoxicity [26, 27, 28], 
possibly because Pt(IV) complexes are much more inert to ligand substitution 
reactions than their Pt(II) counterparts. It is also known that Pt(IV) complexes are 
reduced to Pt(II) complexes by extracellular and intercellular agents prior to reaction 
with DNA, and thus Pt(IV) complexes act as prodrugs [29, 30].  
 
In solution, the large methylpyridine ligand of picoplatin (12) (Figure 1.5), is tilted 
102° in relation to the platinum plane and this is designed to provide steric hindrance 
around the metal centre, thereby preventing the thiol coupling reactions that represent 
one of the main routes of cisplatin resistance. This hindrance reduces the reactivity of 
the drug towards water while maintaining reactivity with DNA [31]. Indeed, this 
compound has shown promising activity against both cisplatin sensitive and resistant 
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Transplatin compounds follow different patterns of cell killing in comparison to 
cisplatin, thus giving a reason for optimism in their development as a new class of 
platinum-based anticancer drugs [33]. The initial report of anticancer properties of a 
dinuclear platinum complex in 1988 started a new paradigm in platinum-based 
chemotherapy. Several multinuclear platinum complexes have entered clinical trials in 
recent years, with varying results [34, 35]. 
1.3.1 Multinuclear platinum(II) complexes 
Multinuclear platinum complexes comprise a novel class of compounds that have 
shown great potential for cancer chemotherapy [36]. These complexes contain two, 
three or four platinum centers with both cis and/or trans configurations and bind to 
DNA in a manner different from that of cisplatin. They react with DNA more rapidly 
than cisplatin and produce characteristic long-range inter- and intrastrand cross-linked 
DNA adducts [37]. The interstrand crosslinks are insensitive to repair by cellular 
extracts, which could enhance the cytotoxicity of multinuclear complexes [38]. 
 
One of the most popular examples of multinuclear Pt(II) anticancer complexes is 
BBR3464 (Figure 1.6), which exhibits antitumour activity against pancreatic, lung 
and melanoma cancers and is currently in phase II clinical evaluation [39]. The high 
positive charge and amine groups in BBR3464 facilitate the specific recognition of 



























Multi-nuclear platinum complexes are able to overcome both intrinsic and acquired 
resistance to cisplatin by a number of factors, including increased drug accumulation 
as well as forming more drug-DNA adducts [41, 42]. The additional positive charges 
assure a high affinity for polyanion DNA [43]. Therefore, DNA binding is usually 
much faster for cationic complexes as compared to neutral complexes such as 
cisplatin. 
 
1.3.2 Structure/activity relationships of platinum complexes [44‘
45] 
 
In general, for a platinum complex to have above average anticancer activity the 
compound needs to: 
a) have a zero net charge; 
b) have two leaving groups, or one bidentate leaving group; 
c) have chloride leaving groups, or other similar ligands ; 
d) have leaving groups in the cis-configuration; 
e) not contain hydroxy or hydroxo ligands, as these make the complex highly toxic; 
and 
f) have other non-leaving ligands which are inert, preferably amine ligands. 
 
1.3.3 Biochemical mechanism of action of cisplatin 
 
It is widely accepted that the main biochemical mechanism of action of cisplatin 
involves the binding of the drug to DNA in the cell nucleus and subsequent 
interference with transcription and/or DNA replication mechanisms [48]. Interestingly, 












show antitumor activity [46, 47]. A mechanistic explanation of transplatin inactivity has 
been based on the different type of DNA adducts formed by this isomer relative to 
cisplatin [48]. Cisplatin rapidly diffuses into tissues and is strongly bound to plasma 
proteins. Binding to plasma proteins is mainly due to the strong reactivity of platinum 
against sulphur of thiol groups of amino acids such as cysteine. Binding of cisplatin to 
cysteine-rich proteins in the kidney seems to be responsible for the dose-limiting 
nephrotoxic effects of the drug [49]. When cisplatin reaches a cell there are multiple 
potential reactions that could take place, including binding DNA as shown in Figure 
1.7 below. 
 
Figure 1.7 A schematic representation of the reactivity of cis-DDP inside cells. (Figure adapted from 
Fuertes et al [49]). 
 
Available evidence suggests that cisplatin forms covalent adducts to purine bases on 
DNA, primarily guanine. In aqueous solution, the rate-limiting step in cisplatin 
complexation to DNA is ‘activation’ via the hydrolysis of labile Pt-Cl bonds (Figure 
1.7). The kinetics of hydration are strongly dependent on the concentration of chloride 













whereas in the cytosol ([Cl-] ≥ 20 mM) the half-life for hydrolytic scission of a given 
bond is approximately 2 hours [50].  
 
The hydrolysis of platinum drugs is of fundamental importance for the mechanism of 
action of these agents. Hydrolysis of cisplatin is believed to be the key activation step 
before the drug reaches intracellular DNA. Typical hydrolysis reactions of cisplatin 
and its diethylenetriamine (dien) analogue with the solvent effect have been studied 
by computational methods: 
 
cis-[PtCl2(NH3)2] + H2O→ cis-[PtCl(OH2)(NH3)2]
+ + Cl−               eqn 1 
cis-[PtCl(OH2)(NH3)2]
+ + H2O→ cis-[Pt(OH2)2(NH3)2]
2+ + Cl−        eqn 2 
 
The positively charged mono and diaquo species of cisplatin {[Pt(H2O)Cl(NH3)2]
+ 
and [Pt(H2O)2(NH3)2]
2+} are very reactive towards nucleophilic centres of 
biomolecules because H2O is a much better leaving group than chloride 
[51]. Although 
the reactive species of both cisplatin and carboplatin are identical, Pt-O bonds are not 
as labile as Pt-Cl bonds which means that carboplatin is hydrolysed far more slowly 
and possesses a different pharmacologic profile [52]. 
 
The reaction of cisplatin with DNA may lead to the formation of various structurally 
different adducts. Initially, monofunctional DNA adducts are formed, but most of 
these react further to produce inter- or intrastrand cross-links [53, 54, 55]. It has been 
found that 60-65% of the adducts formed by cisplatin are 1,2-GpG intrastrand cross-
links and 20-25% ApG intrastrand crosslinks. Minor adducts, include 1,3 intrastrand 










































L  =  Cl-, H2O, S-R
p  =  purine
 
Figure 1.8 Types of cisplatin-DNA adducts and their frequency of formation [56]. 
 
DNA-protein crosslinks have also been reported [57, 58]. 1,2-intrastrand cross-links 
between two adjacent purine bases are the main adducts formed in the reaction of 
cisplatin with DNA. Therefore, the 1,2-intrastrand adducts are commonly held 
responsible for the anticancer activity of cisplatin, although this is not a proven fact. 
The binding of cisplatin to DNA induces structural distortions in the double helix, and  
attempts to repair cisplatin-DNA adducts may finally end up in the triggering of 
apoptosis (programmed cell death) [59, 60]. However, most cisplatin molecules bind to 
proteins rather than DNA, and there is experimental evidence that the former type of 
damage also plays a role in triggering the apoptotic pathways [60, 61]. Moreover, 
necrosis or cell death due to general cell machinery failure is also reported as a cell 
killing mechanism for cisplatin [60,  62]. 
 
The most important scavenger of cisplatin is the tripeptide glutathione (GSH) which is 













rapidly and irreversibly to cisplatin [63]. The deactivated platinum-GSH adducts are 
excreted from the cell by the glutathione S-conjugate pump [64]. The non-specific toxic 
effects induced by binding to non-DNA targets may contribute to the mechanism of 
cytotoxicity of cisplatin in cancer cells. It is known, for instance, that the reaction with 
cisplatin blocks the enzymatic functions of several proteins [65, 66]. 
 
Cisplatin, and its early successes in the treatment of a variety of tumours, the topics of 
metal-DNA binding and platinum antitumour chemistry have attracted considerable 
interest from chemists, pharmacologists, biochemists, biologists and medical 
researchers. This interest has stimulated much interdisciplinary scientific activity, 
which has already yielded quite detailed understanding of the mechanism of action of 
cisplatin and related drugs. This knowledge has clearly resulted in much improved 
clinical administration protocols, as well as motivated research on other, related drugs 
containing transition metals, and their applications. 
 
The unresolved disadvantages with cisplatin and its derivatives has stimulated 
research on novel non-platinum metal-containing antitumour therapeutics and 
considerable progress has been made in the development of such drugs. Complexes 
that have been tested in clinical phase I and phase II studies include those of 
ruthenium, titanium and gallium. Preclinical research has recently involved metal 
complexes containing metals such as iron, cobalt and gold. 
 
This review describes some of the important and recent examples of new non- 












1.4 Palladium(II) compounds  
 
In the last 3 decades, the interest toward platinum(II) and palladium(II) complexes 
containing N- and S donor ligands has increased, resulting in the development of 
metal-based drugs exhibiting high anticancer activity together with reduced toxicity, 
compared to cisplatin and analogous compounds [67]. 
 
The development of palladium anticancer drugs has not been promising probably 
because their design has been based on structure-activity considerations generated 
from platinum antitumor drugs. Bearing in mind that Pd(II) complexes are about 105 
times more reactive than their Pt(II) analogs, the low antitumoral activity of Pd 
compounds has been attributed to very rapid hydrolysis of the leaving groups that 
dissociate readily in solution [68] leading to reactive species far from their 
pharmacological targets. Palladium is a suitable candidate for metallodrugs because it 
displays structural properties similar to those of platinum and also exhibits promising 
cytotoxicity. Interestingly, the trans-[PdL2Cl2]-type complexes have been found to 
exhibit higher cytotoxicity than their cis-platinum analogues, cis-PtL2Cl2, for the same 
ligand system (L) dimethyl 5-(2-hydroxyphenyl)-1,3-dimethyl-1Hpyrazol-4-
ylphosphonate and methyl 5-(2-hydroxyphenyl)-1,3-dimethyl-1H-pyrazole-4- 
carboxylate) [69, 70]. 
 
Several Pd(II) complexes have been reported to display favourable cytotoxicity at pH 
6.8, a condition common in tumor cells, whereas the pH of normal cells is 7.4 [71]. 
Moreover, hydrolytic and DNA-binding studies on the Pd(II) and Pt(II) complexes 













produce new charged species to interact with DNA, and also bind to DNA at a faster 
rate than the platinum complexes [72]. 
 
The biomedical applications of metal complexes based on N-heterocyclic carbine 
ligand (NHC) [73, 74, 75] are just beginning to unfold, despite such complexes being very                      
successful in homogeneous catalysis [76]. The group of Panda et al report the 
synthesis, structure, and biomedical applications of a series of transition metal-NHC 
complexes. They report two Pd complexes, [Pd(NHC)(pyridine)Cl2] (15) and 
[Pd(NHC)2Cl2] (16), that display strong cytotoxicity against three different types of 

















Figure 1.9 Structures of Palladium(II) compounds displaying strong cytotoxicity against cervical 
cancer, breast cancer and colon adenocarcinoma [77] 
 
The Pd-NHC complexes 15 and 16 exhibit remarkable anticancer properties against 
cervical cancer (HeLa), breast cancer (MCF-7), and colon adenocarcinoma (HCT 
116). 16 had a stronger inhibition effect on the proliferation of HeLa, MCF-7, and 
HCT 116 cells than cisplatin and a slightly lower inhibition of HeLa cell proliferation 
(3% at 10 µM) was observed in the case of 15. 16 was found to be a more potent 
cytotoxic agent than the prevalent benchmark metallodrug, cisplatin. The observation 












ligands with strong electron-donating abilities, as compared to the [Pd(NHC)- 
(pyridine)Cl2] complex 15, containing one NHC ligand, may be correlated to the 
relatively more electron-rich metal center in the former. The mode of action of 16
involves arresting the cells at the G2 phase, thereby preventing the mitotic entry of the 
cells. The blocked cells underwent cell death by a p53-dependent pathway [77]. 
 
Although a number of interesting Pd(II) targets have been investigated [78], the 
biological utility of such agents continues to be questioned, primarily due to the poor 
solubility of common Pd(II) complexes under physiological conditions.  Recently 
Mostafa and Badria [79] have reported a new water-soluble mixed ligand complex 















Figure 1.10 Structure of a water soluble [Pd(bpy)(dahmp)]Cl complex [79]  
 
[Pd(bpy)(dahmp)]Cl is more effective than the free Hdahmp ligand itself, as the 
presence of both bpy and dahmp in the complexes possess a multi-ring planar 
structure with nitrogen bases and hence higher hydrophobicity, which would lead the 
intercalation more deeply into DNA. The reported complex displays significant 
anticancer activity against Ehrlich ascites umor cells (EACs). The higher activity of 














In order to investigate the action of Pd(II) complexes in the tumor DNA, the 
intercalated complexes affecting the structure of the DNA prevent polymerase and 
other DNA binding proteins from functioning properly. As the complexes covalently 
bind to DNA with preferential binding to the N-7 position of guanine and adenine, 
they are able to bind two different sites on DNA, producing cross-links that cause 
increase in the viscosity in comparison to the normal unbound DNA. This results in 
the prevention of DNA synthesis, inhibition of transcription, and induction of 
mutations [80]. 
 
Recently Keter et al [81] reported the study of the pro-apoptotic activity of palladium 
and platinum compounds in Chinese hamster ovary (CHO) cells, human cervical 
epitheloid carcinoma cells (HeLa and CaSki), and human T-cell leukaemia cells 
(Jurkat). The aim of their study was to evaluate the use of these complexes as possible 
anticancer agents in terms of their ability to induce apoptosis. Two palladium 
compounds (complexes 18 and 19) and two platinum compounds (complexes 20 and 
21) were evaluated in this study. The platinum complexes were more cytotoxic than 
the palladium complexes. Platinum compounds (complexes 20, 21 and cisplatin) 
displayed higher pro-apoptotic activity than the palladium compounds (complexes 18 
and 19). In addition, the pro-apoptotic activity of complexes 20 and 21 were also 
higher than for cisplatin. 
 
Despite palladium and platinum being metals of the same group, their respective 
pyrazole complexes exhibit different activities. The authors attribute this to an 
associative substitution mechanism similar to that reported by Rauterkus et al [82] in 












have been reported to be more stable in solution than palladium compounds [83] and 
thus would be less susceptible to translabilization, especially in the biological milieu, 
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Figure 1.11 Palladium and platinum complexes tested for anticancer activity dichlo-
robis(pyrazole)palladium(II) (18), dichloro-bis(3,5-dimethylpyrazole)palladium(II) (19), dichloro-
bis(pyrazole)platinum(II) (20), and dichloro-bis(3,5-dimethylpyrazole)platinum(II) (21) [81]  
 
The authors chose palladium(II) and platinum(II) pyrazole complexes for this study 
for two reasons. Firstly, they all resemble cisplatin structurally and are expected to 
bind biological molecules in a similar manner. Secondly, the electronic properties of 
pyrazole ligands offer metal centres for late transition metals that are quite 
electrophilic to allow coordination to biological molecules. The bulkiness of the 
pyrazole ligands also appears to affect activity. For example the activity of complex 
20 was significantly higher than that of cisplatin. There is a probability that such 
bulky ligands prevent translabilization and undesired displacement of the non-leaving 













mechanism that induces the formation of DNA-adducts, promoting the activation of 
apoptosis. 
1.5 Gold(I) compounds 
 
Auranofin (25), an orally absorbed gold(I) phosphine complex, had been used for the 
treatment of rheumatoid arthritis [32], and early reports also suggested that this 
compound and other gold phosphine complexes were also active against the growth of 
cultured tumour cells [85, 86, 87, 88]. Auranofin itself has proved cytotoxic against HeLa 
cells in vitro and P388 leukaemia cells in vivo [89, 90]. 
 
Gold(I) thiolates employed clinically in the treatment of rheumatoid arthritis display 
some potency against various tumours but a greater potential is found in their 
analogues [91]. In particular, analogues featuring a linear P-Au-S arrangement in which 
the thiolate ligand is derived from a biologically active thiol display high potency. 
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Aurothioglucose (solganol) 22 is neutral, and the charged species aurothiomalate 
(myocrysin) 23, aurothiosulphate (sanocrysin) 24, and aurothiopropanol sulphonate 
(allocrysin) all feature gold in the +I oxidation state. The structures are thought to 
feature linear -S-Au-S-geometries and are also polymeric. The gold(I) thiolates, being 
water soluble owing to the presence of solubilising groups and/or charge, are 
administered parenterally. The gold compounds are functioning as pro-drugs, 
providing a means of delivering ‘gold’ to sites of inflammation [90].
 
More than 60 gold(I) compounds were evaluated against both B16 melanoma and 
P388 leukemia cells and this work showed that a wide variety of phosphine gold(I) 
thiolates display significant cytotoxicity and the presence of a phosphine ligand was 
very important as was shown by the fact that the gold thiolates, i.e. without 
phosphine, had significantly reduced potency [92, 93, 94, 95, 96]. Mirabelli et al proved that 
removal or replacement of the acetyl groups in the thiosugar of auranofin (25) or a 
change to other thiosugars did not significantly influence the potency [97] e.g 
chloro(triethylphosphine)gold(I) (27), an analogue of auranofin, in which the 
thiosugar is replaced by chlorine. Chlorotriethylphosphine gold(I) (TEPAu) (27) is an 
organo-gold compound that has therapeutic activity in animal models of rheumatoid 
arthritis. Initial studies have suggested that TEPAu is a potent cytotoxic compound in 
vitro against a variety of cultured cell types and isolated hepatocytes. Preliminary 
experiments have indicated that triethylphosphine gold chloride (TEPAu) may induce 
the peroxidative decomposition of cellular membrane lipids [98]. 
 
Promising anticancer results were achieved with a series of digold phosphine 













ligand itself exhibits antitumour activity, and it has been suggested that the gold 
serves to protect the ligand from oxidation and aids in the delivery of the active 
species. There is substantial evidence to support a direct role for the gold in the 
anticancer activity of this complex [99]. The digold phosphine complex was shown to 
rearrange to give the tetrahedral complex [Au(dppe)]+ 29 (Figure 1.13) [100]. The 
tetrahedral complex is more stable as the chelate effect stabilises the compound, and 
the phosphine ligand is more inert to substitution by the types of thiolate ligands that 





























29 30  
Figure 1.13 Examples of gold(I) phosphine complexes 
 
Gold complexes with bis(diphenylphosphino)ethane ligands such as cationic 
tetrahedral four coordinated [Au(dppe)2]Cl (30) (Figure 1.13) were found to be 
cytotoxic to tumour cells, produced DNA-protein cross links and DNA strand breaks 
in cells and inhibited protein, DNA and RNA synthesis. [Au(dppe)2]Cl changed the 
inner mitochondrial membrane potential, increased mitochondrial respiration, 
swelling and permeability [101]. Recently, a hydrophilic 
tetrakis((tris(hydroxymethyl))phophine)gold(I) complex (31) was reported to be 












carcinoma, cell cycle studies revealed that inhibition of cell growth may result from 
elongation of the G1 phase of the cell cycle [102]. 
 
A big step in the development of gold compounds as anticancer drugs may be the 
observation that the gold(I) complexes auranofin (25) and aurothioglucose (22) 
significantly inhibit the enzyme thioredoxin reductase [103, 104]. Thioredoxin reductase 
is a selenoenzyme involved in physiological processes and many that are involved in 
cancer cell growth like nucleotide biochemistry [105].  This prevents the repair of 
mitochondrial enzymes damaged by oxidation. More importantly, an excess of the 
oxidized form of thioredoxin is a crucial signal promoting mitochondrion-mediated 
apoptosis [106]. 
1.6 Gold(III) compounds 
 
Whereas the majority of gold(I) compounds feature gold in a coordination geometry 
defined by ‘soft’ (i.e. easily polarisable) sulphur and/or phosphorus atoms, gold(III) 
compounds generally feature ‘hard’ atom donors such as nitrogen, oxygen and carbon. 
Four-coordinate gold(III) is found in square planar geometries and in this regard 
resembles the situation found for cisplatin  and thus gold in the +III oxidation state is 
isoelectronic with platinum(II) and forms similar square-planar complexes. Ligand 
exchange kinetics are relatively slow in both cases, although faster in gold(III) 
complexes.  
 
Since gold(III) complexes have similar chemical characteristics to platinum(II) 
compounds they have been considered as candidates for development and testing as 













solution heavily hindered such studies for a long time. Thus, until the mid-90’s, only a 
few reports existed in the literature describing the cytotoxic properties and the in vivo
antitumor effects of gold(III) complexes [107, 108]. Given that the mammalian 
environment is generally reducing, compounds containing gold(III) may be expected 
to be reduced in vivo to gold(I) and metallic gold. There is a rich literature of anti-
tumour/cytotoxicity investigations for these species. 
 
Through implementation of appropriate ligand selection strategies, a number of 
gold(III) compounds have been obtained, exhibiting sufficient stability under 
physiological-like conditions and manifesting, in some cases, relevant cytotoxic 
properties in vitro [109]. The mononuclear gold(III) complexes that have been 
characterized include: gold(III) polyamines [110], gold(III) polypyridines [111,112], 
gold(III) porphyrins [113], various organogold(III) compounds, and gold(III) 
dithiocarbamate complexes [114, 115]. 
1.6.1 Structural features of some gold(III) complexes  
 
Organogold(III) compounds bearing the bipyridyl moiety have also been synthesised 
by the group of Giovanni Minghetti in Sassari (Italy) and typical compounds of this 




























These complexes are characterized by the presence of a bipyridyl ligand within a 
square planar arrangement of the gold(III) center. In [Au(bipy)(OH)2][PF6], two 
coordination positions of the square planar environment are occupied by two 
nitrogens of the bipyridyl ligand, the remaining positions being occupied by two 
hydroxide groups. [Au(bipy-H)(OH)][PF6] is an organogold(III) complex (bipy) 6-
(1,1 dimethylbenzyl)-2,2’-bipyridine). 
 
The in vitro cytotoxic properties of these gold(III) complexes were first evaluated 
toward the human ovarian carcinoma cell line A2780 either sensitive (A2780/S) or 
resistant (A2780/R) to cisplatin. Both bipyridyl gold(III) complexes show significant 
cell killing effects with IC50 values falling in the micromolar range. [Au(bipy-
H)(OH)][PF6] is the most active with a cytotoxic activity 2 times higher than cisplatin 
in the A2780/R cell line. The cytotoxic properties of the free 2,2’ bipyridyl ligand 
were also tested; this ligand is virtually devoid of toxicity toward the A2780/S cell 
line while it showed some cytotoxicity at high concentrations in SKOV3 cells. 
(another ovarian cancer cell line) [109]. 
 
The interactions of the bipyridyl gold(III) complexes with calf thymus DNA were 
analyzed by a variety of techniques Although some small effects on DNA 
conformation and stability were detected, results suggested that the gold(III) 
chromophore was not significantly modified and that binding of these gold(III) 
complexes to calf thymus DNA was relatively weak and DNA conformation was not 
largely affected. The authors were convinced that since DNA damage was relatively 
modest it was therefore very unlikely to account for the observed cytotoxic properties. 













this was what lead to the observed biological effects. It was observed that binding of 
these complexes to model proteins was tight and might represent the molecular basis 
of the biological action of these gold(III) complexes. 
 
New gold(III) compounds have been synthesised and characterised that show 
sufficient stability under physiological conditions. Such stability has generally been 
achieved by the selection of appropriate ligands and in most cases those bearing 














































































Figure 1.15 Examples of some gold(III) complexes [110] 
 
Given their reasonable stability under physiological conditions, the cytotoxic 
properties of the gold(III) complexes were also evaluated toward the established 
A2780 ovarian human cell line either sensitive (A2780/S) or resistant (A2780/R) to 
cisplatin. The order of the cytotoxic potency of the investigated gold(III) complexes 
from experiments [116] was found to be  the following: Auterpy ≥ Auphen > Auen, 













their cytotoxic properties when tested on the cisplatin-resistant line. They also tested 
the cytotoxic properties of the free ligands and found that terpyridine and o-
phenanthroline also exhibit important cytotoxic properties, whereas the other three 
ligands (ethylenediamine, diethylenetriamine, and cyclam) are virtually devoid of any 
intrinsic cytotoxicity. These results strongly support the view that cytotoxicity, for 
Auen and Audien, can be safely ascribed to the presence of the gold(III) center. One 
approach has been to synthesize complexes with a mono-negative bidentate ligand, 
damp, (2-[(dimethylamino)methyl]phenyl), and two monodentate anionic ligands e.g. 
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 The damp ligand forms part of a five-membered chelate ring in which the nitrogen of 
the amine group a d the carbon of the aryl ring bond to the metal. The monodentate 
ligands are readily hydrolysed and are available for substitution. Biochemical studies 
[117] indicate that these compounds have a mechanism of action significantly different 
to that of cisplatin suggesting that this is a potentially important novel class of metal-
containing antitumour agents.  
 
When the two chloride ligands are replaced by acetate or malonate anions, the 












panel of tumour cell lines and displayed in vivo antitumor activity in human tumor 
xenograft models [118]. These results open the possibility that the substitution of the 
chloride ligands by other anions could lead to new active complexes. In this sense, the 
thiosemicarbazonate anion (TSC-) is a good option because some thiosemicarbazones 
themselves exhibit antineoplastic activity [119]. Preliminary tests showed that 
[Au(damp-C1; N)Cl2] derivatives containing bi- or tridentate thiosemicarbazonate 
ligands showed antitumor activity against human MCF-7 breast cancer cells [120, 121]. 
1.6.2 Structure/function relationships of gold(III) complexes  
 
Analysis of the cytotoxicity data of the gold(III) complexes permitted formulation of 
some preliminary structure/function relationships.  The cytotoxicity of these gold(III) 
complexes is associated with the presence of the gold(III) center. The [Au(en)2]
3+ a d 
[Au(dien)]3+ complexes are significantly more cytotoxic than the corresponding 
platinum compounds. The presence of hydrolysable chloride groups which are good 
leaving groups on the gold(III) center does not represent an essential requirement for 
cytotoxicity. Excessive stabilization of the gold(III) center results in loss of biological 
activity  as seen in the [Au(cyclam)]3+ complex, with the gold(III) center tightly 
bound to the macrocycle cage, is not cytotoxic, probably as a consequence of its low 
reactivity. The amount of gold that enters cells is roughly proportional to the exposure 
time, at least during the first hours. Thus, at least qualitatively, the longer the 
exposure time, the lower the drug concentration required to kill cells [116]. 
 
Most of the gold(III) compounds are able to overcome to a large extent resistance to 
cisplatin as witnessed by the relatively low resistance index values, suggesting a 













1.7 Titanium complexes 
 
The first non-platinum complex tested in clinical trials was cis-
[Ti(IV)(CH 3CH2O)2(bzac)2] (Figure 1.17), it was used against a wide variety of 










Figure 1.17 Structure of a cis isomer of [Ti(IV)(CH3CH2O)2(bzac)2] complex. 
 
However, the medicinal properties of transition metal organometallic complexes were 
not explored until 1979, when Köpf-Maier and Köpf published the first metallocene 







Figure 1.18 Structure of titanocene dichloride. 
Cp2TiCl2 was the most active complex, showing its best activity against colon, lung 
and breast cancers [126]. In contrast to platinum complexes, titanocene dichloride 












titanocene dichloride inhibited DNA synthesis, bound covalently to the DNA and 
induced apoptosis [129].  Based on these medicinal properties, titanocene dichloride 
then went on clinical trials [130, 131, 132, 133, 134]. Unfortunately, the efficacy of Cp2TiCl2 
in Phase II clinical trials in patients with metastatic renal-cell carcinoma [132] or 
metastatic breast cancer [135] was too low to be pursued. The mechanism and 
biological action of Cp2TiCl2 seems to be different from that of cisplatin and any 
other metal-containing drug.  
 
Little synthetic effort has been employed to overcome the mentioned efficacy 
problems. Therefore the research of Tackes’ group focussed on the synthesis of 
substituted titanocene dichloride anti-cancer drugs. By using a novel method starting 
from titanium dichloride and fulvenes [136, 137, 138, 139] highly substituted ansa-
titanocenes [140, 141, 142, 143, 144, 145, 146, 147], containing a carbon-carbon bridge, have been 
synthesised, such as [1,2-bis(cyclopentadienyl)-1,2- bis-(4-N,N 












































The main disadvantages of titanocene compounds, which lead to low activities are 
their poor solubilities in aqueous media and their hydrolytic instability under 
physiological conditions [148, 149]. More recently Allen et al [150] have reported a 
number of new ionic titanocenes and evaluated their cytotoxic properties, which are 
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Figure 1.19 Structures of ionic titanocenes evaluated for cytotoxic activity 
 
In particular they exhibit a potent cytotoxic effect on cisplatin-resistant ovarian 
tumour cell lines. The addition of two trimethylsilyl groups, shown in Scheme 1.2 
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The potency of the functionalised titanocenes is not greatly effected by the addition of 
one trimethylsilyl group, However, the addition of two trimethylsilyl groups, has a 
dramatic effect, increasing the cytotoxic activity significantly against several cell 
lines. The mechanism of action is still unknown for this class of drugs but from the 
experiments carried out it, can be seen that the compounds form interstrand crosslinks 
with cellular DNA [150]. 
1.8 Ferrocene compounds 
 
Ferrocene has long been recognized as an important constituent in the biomedical 
applications of organometallic chemistry [151, 152]. However, ferrocene itself does not 
exhibit anticancer activity [128]. Ferrocene complexes have been investigated for their 
potential biological activity, but these studies have been hampered because ferrocene 
is insoluble in aqueous systems [126]. The insolubility of ferrocene has been overcome 
to some extent by the preparation of the ferrocenium cation or through the preparation 
of ferrocenyl inclusion complexes with cyclodextrin [153] but this does not bring about 
effective anticancer properties [154]. Anticancer activity is however, well documented 
for the oxidized form of ferrocene, the ferrocenium cation [154]. Earlier, several 
cisplatin-type ferrocenyl platinum complexes were prepared and their potential 
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Figure 1.20 Cisplatin-type ferrocenyl platinum complexes [155] 
 
Ferrocene has also been incorporated into water soluble polymers [156], tethered to 
DNA intercalators [157], phosphino compounds [158], vitamin B1 [159], and other 
biomolecules [160]. A variety of other small ferrocenyl molecules [161] have also been 
investigated for anticancer activity. Cytotoxic pathways involving DNA have been 
suggested for the activity of ferrocenyl compounds [162]. 
 
Work by Osella et al. [163, 164] illustrated considerable cytotoxic activity of the 
ferrocenium cation and its more stable decamethylferrocenium derivative against 
Ehrlich ascites tumour cell lines and breast cancer MCF- 7 cell lines, respectively. 
Mechanistic studies indicate that the anticancer activity of the ferrocenium cation can 
be linked to its reactivity with molecular oxygen (or superoxide anions) that causes 
generation of reactive oxygen species (ROS) including •OH radicals. These radicals 
are responsible for DNA degradation and strand-breakage. Results reported by 
Tamura and Miwa [165] confirm these observations and suggest the possibility of DNA 












known as an •OH scavenger) to a ferrocenium cation DNA mixture decreases 
cleavage and addition of dithiothreitol (DTT) triggers an enhanced scission. Thus, it is 
clear that the ferrocenium cations, where the iron atom is in the +3 oxidation state, are 
cytotoxic and efficient DNA cleaving agents. 
 
Some simple ferrocene compounds show excellent cytotoxicities in vitro and inhibit 
the development of tumors in vivo [166]. A more widespread approach pioneered by 
Jaouen is to append biologically active molecules to the ferrocenyl unit which 
increases the potency of the overall compound, possibly due to the combined action of 
the organic molecule with Fenton chemistry of the Fe center [167]. Ferrocene has also 
been linked to both platinum [168, 169] and gold [170] centers in order to achieve 
synergistic effects between the two active metals. 
1.9 Ruthenium compounds 
 
Early reports in the 1970s and 1980s indicated antitumour potential of ruthenium 
complexes [171, 172, 173]. Medicinal ruthenium chemistry was reviewed in 2001 [174] and 
the early work of Clarke was reviewed in 2003 [175]. Recent excellent work from the 
Trieste groups on the NAMI-class compounds [176] which are the new antitumour 
metastasis inhibitor (NAMI)- type compounds. As octahedral complexes the NAMI-A 
complexes, differ structurally significant from the square planar platinum(II) drugs. 
The NAMI-type compounds all contain Ru(III), and it is believed that prior to 
biological, cytostatic action, reduction to Ru(II) may take place [175]. Despite the 
inactivity in vitro NAMI-A type complexes displayed significant anticancer activity in 
vivo [177] and this was attributed to anti-metastatic properties of these agents [178].  The 













that DNA is an important target is not sure as yet [179]. Although the kinetics of 
ruthenium coordination chemistry are comparable to those of platinum, and even 
though a number of active ruthenium compounds do react with DNA and DNA 
fragments, the mechanism of action for the ruthenium compounds is currently far less 
understood. Targets other than DNA may play a role as well here. 
 
Also of interest are the azopyridine compounds, where different isomers show 
significantly different cytostatic activity. The structures and activity indicators are 














































Figure 1.21 Five different isomers of a Ru(azpy)2Cl2 complex and their relative cytostatic activity 
(++++ = very active; t = trans; c = cis for each pair of ligand atoms (anions in parentheses).  
Octahedral ruthenium(II) and ruthenium(III) complexes have shown antineoplastic 
properties on a number of experimental tumors. Tetraammine-, pentaammine-, 
heterocycle-, and dimethylsulfoxide-coordinated ruthenium complexes have been 
synthesized and shown to have high affinity for nitrogen donor ligands in vitro and as 













Many ruthenium complexes with oxidation state +2 or +3 display anti-tumour 
activity, especially against metastatic cancers. The Ru(III) complex trans 
[Na][Ru(Im)(Me2SO)Cl4] (Im = Imidazole) and its analogue, trans 
[ImH][Ru(Im)(Me2SO)Cl4], (Figure 1.22) are currently in  clinical trials 
[175]. For 
Ru(III) compounds, in vivo reduction to Ru(II) is required for activity. This facilitates 
its binding to the highly electrostatically charged DNA molecule. Cellular uptake of 
many ruthenium complexes appears to be mediated by the iron transport protein 
transferring process (stimulated by protein transferrin) into the tumor cells where 
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Figure 1.22 Structures of trans-[Na][Ru(Im)(Me2SO)Cl4] and trans [ImH][Ru(Im)(Me2SO)Cl4] 
complexes active against metastatic cancers  
 
In general, the cytotoxicity of ruthenium complexes and other metals correlates with 
their ability to bind DNA following intracellular activation by their reduction. 
However other researchers have reported complexes that have shown a different mode 
of action. No conclusive explanation as to its mode of action is known but it is 
reported that it does not involve DNA binding but rather it interferes with type IV 
collagenolytic activity and reduces the metastatic potential of the tumors [175]. 
 
Ruthenium compounds exhibit low general toxicity compared to their platinum 













compounds specifically accumulate in rapidly dividing cells, such as tumors, due to 
the ability of ruthenium to mimic iron in binding to transferrin [182], the protein which 
delivers iron to cells, because transferrin receptors are overexpressed in cancer cells 
[183]. Secondly, the majority of ruthenium drugs comprise ruthenium in the +3 
oxidation state, and it has been proposed that in this oxidation state ruthenium is less 
active and reduced in vivo to more active ruthenium(II) complexes, a process favored 
in the hypoxic environment of a tumor [183e, f]. It should however be noted that Ru(II) 
compounds also exhibit a low general toxicity. Since cancer cells can also become 
oxidising at certain stages of their growth cycle, oxidation of the ruthenium cannot be 
ruled out [184]. 
1.10 Vanadium compounds 
 
Other significant metal complexes that have been studied are the vanadium 
complexes. Although speculation (which has been proven) that these metal complexes 
may possess anti-tumour activity had existed since the beginning of the 20th century, 
these complexes were not tested until 1967. The first evidence that vanadium may 
exert chemopreventive effects on experimental carcinogenesis was provided by 
Thompson et al. on 1-methyl-1-nitrosurea (MNU-1) -induced mammary 
carcinogenesisin female Sprague-Dewley rat [185]. They then proposed that the 
chemotherapeutic action of vanadium, in biological terms, was found to be mediated 
through inhibition of altered liver cell foci and hepatic nodule growth during the early 














Vanadocenes are organometallic complexes, with the vanadium(II) linked to organic 
ligands by direct carbon metal bonds. They have been found to exhibit significant 
antitumour properties both in vitro and in vivo.  Bis- 
(cyclopentadienyl)vanadium(II)chloride, [(η5-C5H5)2VCl2] (Figure 1.23), which 
belongs to the metallocene class of antitumour agents, has turned out to be one of the 






Figure 1.23 Bis(cyclopentadienyl)vanadium(II) chloride (vanadocene dichloride) 
 
Vanadocene dichloride has been shown to be a potent antitumour agent against mouse 
tumours and its activity is due to its ability to interact at a molecular level with nucleic 
acids, especially DNA. Furthermore, the antitumor effects of vanadocene dichloride 
against human colon and lung carcinomas were shown to be due to the vanadium 
accumulation in nucleic acid-rich regions and to the inhibition of DNA and RNA 
synthesis in tumor cells suggesting the binding of this compound to the DNA [187]. 
1.11 Other metal-based anticancer compounds 
 
Other transition metals have been used as anticancer drugs, including bismuth(III) 
labelled antibodies for systemic radio immunotherapy [188’
 189], rhenium(I) complexes 
as DNA-binding agents [190], a Zn2+(MTR)2 complex that induces cancer cell death by 













initiate apoptosis in human colon cancer cells through caspase-8 and apoptosis-
inducing factor (AIF) activation in a cytochrome c-independent manner [192]. 
 
Rh(I), Rh(II) and Rh(III) complexes have shown interesting anticancer properties. 
Some rhodium metallointercalators exhibit specific DNA binding, suggesting that 
they represent a new type of DNA-targeting agents [193]. One binds specifically to 
destabilized regions near base pair mismatches and is able to recognize a single 
mismatch in a 2725-base pair plasmid DNA. The most common systemic side-effect 
of rhodium is nephrotoxicity. Its mechanism of action has not yet been studied 
systematically. However, it is possible that the inhibition of DNA synthesis is 
mediated by the inhibition of essential enzymes. 
 
Dimeric µ-acetato dimers of rhodium(II) as well as monomeric square planar 
rhodium(I) and octahedral rhodium(III) complexes have shown interesting antitumour 
properties. The dirhodium tetraacetate complex, [Rh2(CH3COO)4(H2O)2], (Figure 
1.24) is much more inhibitory towards Escherichia coli DNA polymerase I and 
exhibits good antitumour activity against P388 lymphocytic leukemia and sarcoma 
180 but little activity against L1210 and B16 melanoma [194]. Recent structural studies 
suggest that the antitumour activity of di-rhodium(II) carboxylates may bear analogy 
to that of cisplatin by binding to adjacent guanines on DNA [195]. Antitumour activity 
has also been found to increase in the series [Rh2(RCOO)4(H2O)2] (R = alkyl group) 

























Figure 1.24 Six-coordinate cage complex of rhodium(II) carboxylates, [Rh2( COO)4L2], R = alkyl 
group, L = H2O or other donor solvent. 
 
Thus rhodium(II) acetate (R = CH3), propionate (R = CH3CH2), butyrate (R = 
CH3CH2CH2), pentanoate (R = CH3CH2CH2CH2) show a considerable variation in 
their antitumour activity against Ehrlich ascites tumour cells in mice, with the 
pentanoate complex being the most active. Lengthening the carboxylate alkyl (R) 
chain beyond the pentanoate was found to reduce the drugs’ therapeutic efficacy. 
 
Recently, Rajput et al [196, 197] reported the preparation of a series of complexes of the 
type (1,5-cyclooctadiene)(chloro)(L)rhodium(I) with L a substituted pyridine. They 
place particular emphasis on ferrocenyl, phenyl and other aromatic systems as 
substituents on the pyridine ring. The antitumor activity of the complexes was 





R = H, Ph, (C6H4)Fc, (C=N)(C6H4)Fc
57
 
Figure 1.25 Rhodium complexes [RhCl(COD)L] investigated as antitumor agents 
The role played by the position and nature of substituent on the pyridyl ligand was 













WHCO1 and ME180 cancer cell lines. The authors report that it appears that 
derivitisation of the pyridyl ligand is related to enhanced toxic activity. However the 
major drawback was that the rhodium complexes were only partially soluble in 
aqueous environment.  
1.12 Concluding remarks 
 
An enormous amount of work has been done on metals and metal compounds, some 
can induce cancer while others can treat cancer and some can have both properties. It 
appears that research on some metals that had been abandoned for some time is being 
reactivated. The efficacy of cisplatin has given an impetus to research for new metal 
compounds. The results are not yet satisfactory and a great deal of work remains to be 
done. Approximately two-thirds of cancers could be avoided by life style changes 
(cigarettes, alcohol, nutrition, sexual behaviour, etc.). Therefore it is statistically 
easier to avoid cancer than to cure it. It would also be more efficient to protect our 
cells from mutations, rather than focussing exclusively on curing cancer. 
 
Recent advances in medicinal inorganic chemistry demonstrate significant prospects 
for the utilization of Au(I) and Au(III) and their coordination complexes as drugs, 
presenting an interesting arena for inorganic chemistry. Significant progress in gold-
based anticancer agents has been achieved, based in part on a mechanistic 
understanding of the pharmacological effects of classical antitumor drugs. There are 
quite a number of results indicating that gold coordination compounds might be 
developed into future drugs, but it will be a long time before their pharmacological 
potential can be realised. It will take even longer to have a suitable candidate turned 












chemistry of Au(I) and Au(III) and their coordination complexes requires an 
understanding of the physiological processing of gold complexes, to provide a rational 
basis for the design of new gold-based drugs. 
1.13 Aims of the project 
 
This thesis addresses the preparation and anticancer activity of novel platinum group 
metal complexes containing phosphorus and nitrogen-donor groups. Since the 
preparation of cisplatin was first reported [13], numerous reports have appeared 
describing the biological activity of other transition metal complexes. Preliminary 
investigations of the activity of several complexes prepared in this study have been 
carried out and comparison made with related complexes reported in the literature but 
not tested for anticancer activity.  
 
The primary aim of this project is to identify the metal compounds with promising 
anticancer activity, focusing on three metal centres; gold(I), platinum(II) and 
palladium(II). The choice of palladium as one of the metals is based on the fact that it 
is a homologue of platinum and thus is expected to show similar activity, and it is 
relatively cheap. Several complexes especially platinum containing, with N-
heterocyclic ligands such imidazole, thiozole, benziimidazole, benzoxazole and 
benzothiozole have been reported. However it is noted that little has been done on 
complexes based on N and P donor ligands. The choice of gold was based on the fact 
that no complexes of gold have been reported in the literature with these types of 
iminophosphine ligands.  















The major goal of the project is to identify and characterise novel compounds that can 
be used in the treatment of oesophageal cancer, using cultured oesophageal cancer 
cells as a model system. Oesophageal cancer has a high prevalence in South Africa 
and it causes a great number of mortalities and as such there is need for novel 
chemotherapeutic agents to help treat this disease. 
 
1) The project focused on the design, synthesis and characterisation of a series of new 
iminophosphine ligands. 
 
2) The iminophosphine ligands were then complexed with palladium, platinum and 
gold to give novel organometallic complexes. 
 
3) The biology aspect of the project involved evaluating the effect of the complexes 
on cell growth. We determined IC50 values for the different compounds in two 
different oesophageal cancer cell lines, WHCO1 and KYSE450. The activity of the 
complexes was also evaluated against DMB cells which are primary fibroblasts 
derived from a skin biopsy obtained from a normal subject.  
 
4) We also investigated whether the compounds induce apoptosis by employing the 
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During recent years there has been a growing interest in the chemistry of ligands with 
both ‘hard’ nitrogen and ‘soft’ phosphorus donor atoms [1a-c]. Metal complexes with N 
and P donor atoms display a variety of coordination possibilities beyond those of P-P 
or N-N ligands [2].  The hard ligand components can readily dissociate from the soft 
metal centre generating a vacant site on the metal ion for substrate binding. These 
ligands show a particular behaviour in binding to soft metal centres such as 
palladium(II) and platinum(II) that make their complexes good precursors in catalytic 
processes [3a-d]. Among the most studied ligands with this characteristic are the 
pyridylphosphines and iminophosphines which have been widely reported in 
complexes with ruthenium [4], palladium [5], rhodium [10a] and iridium [11b]. 
 
The use of 2-(diphenylphosphino)benzaldehyde as a building block for 
iminophosphines was first reported in the Schiff-base condensation with ethylene- 
diamine [6,7] and has since been extended to a wide variety of other amines [8]. It has 
been well documented that primary amines can react with aldehydes and ketones to 
yield imines. The process is often acid catalysed, involving the nucleophilic attack of 
the amine on the carbonyl group, followed by the proton-transfer from nitrogen to 
oxygen to yield a neutral carbinolamine. Upon the protonation of the carbinolamine 
oxygen by the acid catalyst, the hydroxyl is converted into a good leaving group, so 
that the E1 type loss of water generates an iminium ion. The final imine is formed 



































Scheme 2.1 Mechanism of acid catalysed imine formation 
 
 
Since o-diphenylphosphinobenzaldehyde is a well known precursor it was decided to 
use this phosphine as a starting material for the synthesis of a range of 
iminophosphines.  
 
The general method we employed is shown for synthesis of a primary amine, 
propylamine (Scheme 2.2). The reaction was left to stir at room temperature for ca 16 
hours, in the absence of an acid catalyst. The iminophosphine was obtained in high 
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2.2 RESULTS AND DISCUSSION 
 
2.2.1 Preparation and characterisation of the iminophosphine ligands 
 
The 2-(diphenylphosphino)benzylidene)amines were synthesised in high yields from 
the Schiff-base condensation reaction of 2-(diphenylphosphino)benzaldehyde with the 









R = (CH2)2CH3              58
R = (CH)(CH3)2               59
R = 2,6 iPr C6H3             60
R = (CH2)C6H5               61
R = (CH2)C5H4N            62
R = (CH2)C4H3O            63
R = (CH2)C4H3S             64
 
Scheme 2.3 Synthesis of iminophosphine ligands  
 
Under these conditions, the reaction proceeds smoothly to completion and does not 
require any heating at higher temperature (e.g. refluxing ethanol [6]), r the presence of 
a drying agent (e.g. molecular sieves [9,10]), or the use of a large excess of the amine 
(e.g. neat tert-butylamine [11a,b]). 
 
The resultant iminophosphine ligands shown in Table 2.1 were obtained in good 




















Table 2.1 Iminophosphine ligands synthesised 
































2.2.1.1 1H NMR studies of the iminophosphine  ligands 
 
 
1H NMR spectra of the ligands were consistent with the proposed structures and were 
also in agreement with 1H NMR data reported in the literature for related ligands [12, 
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confirmed that a condensation reaction had taken place between the respective 
aldehyde and amine. The chemical shift of aldehyde protons is normally in the region 
of 9.7 – 10 ppm on a 1H-NMR spectrum [14]. In the case of ligands 58 – 64, a 
characteristic doublet for the aldehyde proton was present at a chemical shift of 8.9 – 
9.1 ppm and with coupling constants of JP-H = 4.9 – 5.8 Hz. The appearance of the 
signal as a doublet is the consequence of a long-range coupling of phosphorus with 
the imine proton – similar to that of phosphorus with corresponding imine protons [15]. 
The chemical shift of imine-protons was observed to be more upfield shifted in 
comparison with the corresponding aldehyde and resonated in the region of 8.9 – 9.1 
ppm.  
 
2.2.1.2 31P NMR data of the iminophosphine ligands 
       
The 31P NMR spectra of the iminophosphine ligands displayed singlet resonances as 
shown in Table 2.2.  
 
Table 2.2 31P NMR data of 58 to 64 









The analysis of starting material and iminophosphine ligands by 31P-NMR analysis 













has characteristic chemical shifts for its +3 and +5 oxidation states. In the low P(III) 
oxidation state, high field signals are usually expected, and when oxidised, low field 
signals are present. The characteristic for phosphorus in the staring material 2-
diphenylphosphinobenzaldehyde is a singlet at -11.7 ppm. The iminophosphine 
ligands 58 – 64 exhibited singlets in the region -13.2 – 15.8 ppm.  This downward 
shift has been well documented in the literature for related iminophosphine ligands 
[16,17]. The appearance of a singlet in the 31P NMR is also an indication that only one 
product has been formed.  
 
2.2.1.3 Infrared spectroscopy and elemental analysis for the iminophosphine ligands 
 
The elemental analysis data obtained for the ligands were in agreement with the 
proposed formulations depicted in Scheme 2.3 (Table 2.3). The ligands show a 
distinctive stretching frequency, ν(C=N) at 1637 cm-1 (as KBr plates) which agrees 
with previously reported values for iminophosphine ligands [11a]. Upon complexation, 
this peak shifts to lower frequencies than in the ligands. This is due to increased 
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Table 2.3: Elemental analysis and IR data for iminophosphine ligands 58 – 64 
Anal Found (Calcd.) IR (cm-1)a Ligand M.p. (°C) Formula 
C H N ν(C=N)  
58 70 - 71 C22H22NP 79.59 (79.74) 6.82 (6.69) 4.12 (4.23) 1637 
59 107 - 108 C22H22NP 79.88 (79.74) 6.52 (6.69) 4.52 (4.23) 1634 
60 108 - 110 C31H32NP 82.69 (82.82) 7.12 (7.17) 3.32 (3.12) 1629 
61 80 - 82 C26H21N2P 82.49 (82.30) 5.62 (5.84) 3.72 (3.69) 1636 
62 79- 82 C25H21N2P 78.82 (78.93) 5.62 (5.56) 7.52 (7.36) 1632 
63 77 - 78 C24H20NOP 78.19 (78.03) 5.22 (5.46) 3.72 (3.79) 1635 
64 70- 72 C24H20NPS 74.59 (74.78) 5.12 (5.23) 3.72 (3.63) 1636 













Table 2.4: Selected1H-NMRa chemical shifts δ (ppm) for iminophosphine ligands 58 - 64 
Ligand HC=N Ar-H  N-(CH2) N-(CH2CH3)/Py-H Fur-H  /Thio-H 
58 
8.91 
(d, 1H, J = 
4.8 Hz) 
8.01 (dd, 1H, J = 7.8, 4.2 Hz), 7.39 – 7.22 (m, 
12H), 6.90 (dd, 1H, J = 7.2, 5.4 Hz) 
 
3.50 (t, 2H, J = 6.8 Hz), 1.54-1.44 (m, 2H), 





6.92 (m, 1H, J = 8.4 Hz); 
7.2 – 7.4 (m, 7H, J = 7.6 Hz) 




6.9 – 7.2 (m, 4H, J = 2.2 Hz); 7.4 (m, 3H, J = 2.2 
Hz) 
1.29 (s, 9H) - - 
61 
9.03 
(d, 1H, J 
=5.8 Hz) 
8.10 (m, 1H), 7.19 – 7.43 (m, 15H), 7.09 (m, 
2H) 6.94 (ddd, 1H, J = 7.7, 4.7, 1.2 Hz) 
4.67 (s, 2H) - - 
62 
9.02(d,1H, 
J =4.9 Hz) 
8.01(ddd,1H, J=1.4, 3.9, 7.6 Hz), 7.24 – 7.43 (m, 
13H), 7.12 (ddd, 1H, J = 0.8, 4.8,7.8 Hz), 6.90 
(ddd, 1H, J = 7.7, 4.7, 1.7 Hz) 
4.67(s,2H) 8.45(dd,1H, J =1.7,4.8z),8.42(d,1H,J =1.7Hz) - 
63 
9.01(d, J = 
5.1 Hz) 
8.07(ddd, 1H, J =7.7, 4.0,1.4 Hz), 7.25 – 7.42 
(m, 13H) 
4.65(s,2H) 3.07 (m, 2H, J = 6.8 Hz) 
6.91(m, 
1H),6.27(m,1H), 
6.05 (dd, 1H, J 





8.11 (m, 1H), 7.25 – 7.45 (m, 12H), 
7.59 (d, 1H, J = 2.6 Hz) 
4.86(s,2H) 
3.11 
(m, 2H, J = 6.6 Hz) 
1.25 
(d, 12H, , J = 7.0 
Hz) 
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2.2.1.4 Mass spectra of the iminophosphine  ligands 
 
 
Fragmentation patterns of the ligands were obtained by EI mass spectrometry. 
Normally the mass spectral fragmentation of the compound is found to give a 
characteristic pattern. Each kind of fragment has a particular ratio of mass to charge, 
or m/z value. For most ions, the charge is 1, so that m/z is simply the mass of the 
fragment. Thus for ligand 63 it exhibited a systematic fragmentation pattern (Scheme 
2.4). It gave a molecular ion peak of m/z =369 with a corresponding base peak (the 
most intense peak signifying a stable fragment) of m/z =287.79 attributed to the loss a 
thiophenyl unit in the ligand. 
 




































Scheme 2.4 Possible fragmentation pattern of 63 
 
The mass spectra data of the iminophosphine ligands are shown in Table 2.5. The 
molecular ion peaks are in good agreement with their empirical formula as indicated 
from elemental analysis. The mass spectra of all the ligands exhibited similar 
fragmentation patterns 
 







58 331.39 331.22 [M] + 
59 331.39 331.24 [M] + 
60 449.57 449.56 [M] + 
61 379.43 379.78 [M] + 
62 380.42 380.80 [M] + 
63 369.40 369.61 [M] + 
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2.2.2 Tetradentate ligands 
 
The chemistry of bidentate compounds (i.e α-diimines and β-diimines) has been well 
explored [18, 19]. A few reports on unconjugated diimines describing their use as 
catalysts [20] and in bio-inorganic chemistry [21] have appeared in literature. Westcott 
and co-workers have prepared unconjugated diimines with boronate esters, and 
complexed them with platinum (Scheme 2.5), to synthesise platinum complexes 











R = 3-Bpin, 4-Bpin, 4-OMe  
Scheme 2.5 Synthesis of unconjugated diimine platinum complexes 
 
The next section discusses the tetradentate ligands that we prepared their 




















2.3.1 Synthesis and characterization of tetradentate ligands 
 
Symmetrical ligands 65 to 68 (Table 2.6) are usually prepared upon condensation of 
dialdehydes with amines [23].  Ligands 65 to 68 were characterised by IR spectroscopy 
as well as 1H, 13C NMR, X-ray crystallography and mass spectrometry. 
OO
X2 NH2
MeOH, RT, 24h,  -2H2O NNX X
X = (CH2)C4H3S   65
X = (CH2)2C4H3S 66
X = (CH2)C5H4N  67
X = (CH2)2C5H4N 68
 
Scheme 2.6: Synthetic route to tetradentate ligands via a Schiff base reaction 
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2.3.1.1 1H NMR spectra  for tetradentate ligands 
         
In the 1H NMR spectra of the tetradentate ligands 65 - 68  the imine protons appear as 
singlets in the range 8.23 – 8.57 ppm, the chemical shifts for the methylene (-CH2-) 
protons appear at 5.00 ppm for 65 and 67 but at ca 3 - 4 ppm for 66 and 68. The 1H 
NMR spectra of the ligands 65 to 68 displayed peaks for the aromatic protons in the 
region of 7.45 - 7.95 ppm. The signals for the pyridyl and thiophenyl rings occur at 
between 6.9 – 7.2 ppm for all the ligands respectively.  
 
The NMR spectra of the ligands indicate that each half of the ligand is equivalent due 
to the presence of internal symmetry. In view of the observed NMR pattern, it may be 
considered that the trans configuration of the ligands is predominant in solution or 















































The 13C NMR spectra of ligand 63 in CDCl3 exhibits 9 distinct carbon peaks as 
expected. The imine carbon appears at 161.27 ppm. The thiophenyl ring carbons 
appear at 142.28, 128.34, 125.18 and 123.61 ppm respectively. The phenyl ring 
carbons appear at 126.72 ppm and the -CH2 carbon signal separately at the upfield 
region at 31.42 ppm. 
 
The assignments in the 13C NMR spectra are consistent with those reported for related 
ligands. By use of selective proton decoupling, the 13C NMR assignments could 














Figure 2.3 13C NMR spectra of ligand 66 in CDCl3 (* residual solvent peak) 
 
2.3.1.2 Physical properties of tetradentate ligands 
 
Ligands 65 to 68 were all air stable solids and were obtained in good yields ranging 
between 70 – 85 % (Table 2.7). The ligands were isolated as white solids with the 
exception of 68 which was cream. Ligand 67 had the lowest melting point range 
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Table 2.7 Yields and physical properties of ligands 65 to 68 
Ligand Yield (%) Colour of Solid Melting point ( °C) 
65 85 White 180-182 
66 80 White 140-142 
67 72 White 126-128 
68 70 Cream 185-187 
 
2.3.1.3 Mass spectra of the tetradentate ligands 
 
The mass spectral data of the tertradentate ligands are given in Table 2.8. The 
molecular ion peaks are in good agreement with their empirical formula as indicated 
from elemental analysis. The other peaks represent fragments of the molecular ion. 
 







65 324.47 103.30 [M-2C5H5SN]
+ 
66 352.52 254.89 [M-C5H8S]
+ 
67 314.38 221.84 [M-C6H6N]
+ 















2.3.1.4 Single crystal X-ray determination of ligand 65 
 
Figure 2.4 The ORTEP plot of the molecular structure of 65 showing the atomic numbering. All non-
hydrogen atoms were presented with ellipsoidal model with probability level 40%. Only half of the 
molecule for each are labelled and another half are generated via centre of symmetry (symmetry code: 
2-x, 1-y, 1-z for molecule A; symmetry code: -x, 2-y, 2-z fro molecule B). 
 
For structure 65, all non-hydrogen atoms, except those of ethanol solvent, were 
refined anisotropically. The solvent molecule showed high thermal motion and was 
refined isotropically with bond length constraints. C8A, C9A, C11A, C12A, C11B 
and C12B also showed high thermal motions, so they were refined with anisotropic 
displacement parameters equal to those of their neighbouring atoms with bond length 
constraints. All hydrogen atoms, except the ethanol hydroxyl hydrogen, were 
positioned geometrically with C-H = 0.94 – 0.99 Å and refined as riding on their 
parent atoms with Uiso (H) = 1.2 - 1.5 Ueq (C). The ethanol hydroxyl hydrogen was 
located in the difference electron density maps and refined with fixed isothermal 
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Table 2.9 Selected bond distances and angles for ligand 65  
Bond Distances (Å)        Bond Angles( º)  
S(1A)-C(1A) 1.704(4) C(1A)-S(1A)-C(4A) 92.42(18) 
S(1A)-C(4A) 1.720(3) C(6A)-N(1A)-C(5A) 117.2(3) 
N(1A)-C (6A) 1.267(4) C(2A)-C(1A)-S(1A) 111.9(3) 
N(1A)-C(5A) 1.467(4) N(1A)-C(5A)-C(4A) 109.3(3) 
C(3A)-C(4A) 1.381(5) N(1A)-C(6A)-C(7A) 121.5(3) 
C(4A)-C(5A) 1.498(5)   
 
The crystal structure reveals that 65 exists as discrete molecules. The C(9)-N(1) 
distance of 1.267 Å is consistent with a C=N double bonding. 
 
2.3.1.5 Single crystal X-ray determination of ligand 66 
 
Figure 2.5 Molecular structure of ligand 66 showing the atomic numbering scheme. All non-hydrogen 
atoms were presented with ellipsoidal model with probability level 40%. Only half of the molecule is 





















Table 2.10 Selected bond distances and angles for ligand 66  
Bond Distances (Å)        Bond Angles(º)  
S(1)-C(2) 1.691(3) C(2)-S(1)-C(5) 93.56(12) 
S(1)-C(5) 1.693(2) C(7)-N(8)-C(9) 117.3(2) 
N(8)-C (7) 1.455(3) S(1)-C(2)-C(3) 111.6(2) 
N(8)-C(9) 1.266(3) S(1)-C(5)-C(6) 121.91(17) 
C(5)-C(6) 1.502(3) N(8)-C(9)-C(10) 122.84(19) 
C(6)-C(7) 1.520(3)   
C(9)-C(10) 1.473   
 
The crystal structure reveals that 66 exists as discrete molecules. The C(9)-N(1) 
distance of 1.266 Å is consistent with a C=N double bonding. 
2.3.1.6 Single crystal X-ray determination of ligand 68 
 
Figure 2.6 The ORTEP plot of the molecular structure of 68 showing the atomic numbering All non-
hydrogen atoms were presented with ellipsoidal model with probability level 40%. Only half of the 
molecule is labelled and another half of the molecule is generated via centre of symmetry (symmetry 
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Table 2.11 Selected bond distances and angles for ligand 68  
Bond Distances (Å)        Bond Angles(º)  
N(1)-C(5) 1.3344(15) C(5)-N(1)-C(1) 117.33(10) 
N(1)-C(1) 1.3395(17) N(1)-C(1)-C(2) 124.19(12) 
N(2)-C (8) 1.2628(14) C(8)-N(2)-C(7) 117.17(9) 
N(2)-C(7) 1.4609(13) N(1)-C(5)-C(4) 122.27(10) 
C(5)-C(6) 1.5023(15) N(1)-C(5)-C(6) 116.12(10) 
C(6)-C(7) 1.5204(16) N(2)-C(8)-C(9) 122.66(9) 
C(8)-C(9) 1.4748(14)   
 
The crystal structure reveals that 68 exists as discrete molecules. The N(2)-C(8)  
distance of 1.2628 Å is consistent with a C=N double bonding. 
 
The ligands 65, 66 and 68 exhibit short C=N bonds with lengths of 1.2628 Å to 1.276 
Å and longer N-C bonds with lengths f 1.455 Å to 1.467 Å. The C=N-C angles in the 
three ligands range from 117.2° to 117.33°, slightly less than the idealised angle of 
120°, as is seen in other structurally characterised imines [24, 25]. Bond distances and 
angles around the sulphur atoms for ligands 65 and 66 are similar to those in related 
compounds [24]. 
2.4 Synthesis and characterization of other Schiff base ligands 
 
The new Schiff base ligands 69 – 72 (Table 2.12) were prepared by condensation of 
aldehydes with diamines. They were characterised by IR spectroscopy as well as 1H 













MeOH, RT, 24hr, -H2O
X = CH3O(C6H3)Cl   69
X = ClNO2(C6H2)     70
X = (CH3O)2(C6H3)  71
X = (CH3O)3(C6H2)  72NH2H2N NN XXCHO2X
 
Scheme 2.7 Synthetic route to Schiff base ligands  
 
The Schiff base ligands 69 – 72 were prepared according to literature procedures and 
are shown in Table 2.12. 
 










Ligands 69 – 72 where fully characterised by IR spectroscopy as well as 1H, 13C 
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Table 2.13 1H-NMRa chemical shifts δ (ppm) and microanalytical data for Schiff base ligands 69-72 





7.95 (d, 2H, J=8.5Hz), 7.24 (dd, 2H, 
J=0.7Hz, J=2.0Hz), 7.27 (dd, 2H, 
J=0.6Hz, J=2.1Hz) 
 




8.22 (s, 2H),7.83 (d, 2H, J=8.3Hz), 
7.58 (d, 2H, J=8.3Hz) 
 




7.51 (d, 2H, J=1.6Hz), 7.03 (t, 2H, 
J=7.8Hz), 6.92(d, 2H, J=1.6Hz, 
J=2.1Hz) 
 
4.00 (s, 4H) 
3.85 (s, 6H) 





7.66 (s, 2H), 6.66 (s, 2H), 3.93 (s, 
4H) 
- 
3.87 (s, 6H), 
3.85 (s, 6H), 
3.83 (s, 6H) 
 
1625 
aSpectra obtained in CDCl3  
bRecorded as KBr plates
                                            
 
 
1H NMR data suggests that the four ligands have symmetrical structure with two 
imine groups. Four methylene protons are found at ca 4.00 ppm as singlets. 
Methylene protons on the methoxy substituant are observed as sharp singlets at 
around 3.77 – 3.87 ppm for ligands 71 and 72 but for ligand 69 the signal is observed 
at 2.17 ppm. The multiplets in the region 6.92 – 7.95 ppm are due to aromatic protons 
and the singlets observed at 8.30 – 8.65 ppm are assigned to the C=N protons. 
 
The infrared spectra of the four ligands show stretching vibrations, (C-H) of the 
phenyl groups are in the region 3115 – 3015 cm-1, while, (C-H) vibrations of the 
=CH- groups are observed as expected in the region 2970-2860 cm-1 [26]. Also strong 
bands appeared at about 1613 cm-1 and these bands are attributed to the C=N 













Table 2.14 13C-NMRa chemical shifts δ (ppm) for Schiff base ligands 69-72 
Ligand HC=N Ar-C N(CH2)2 O(CH3) 













152.89, 149.69, 130.09, 





72 158.09 122.17, 107.70 
 
62.00, 61.81, 60.87 
 
56.03 
                  aSpectra obtained in CDCl3 
 
2.4.1 Physical properties of Schiff base ligands 
 
Ligands 69 - 72 were isolated as crystalline solids which were all air stable solids and 
obtained in very good yields ranging between 83 – 92 % (Table 2.15).  
 
Table 2.15 Yields and physical properties of ligands 69 to 72. 
 
Ligand Yield (%) Colour of Solid Melting point ( °C) 
69 83 White 125-127 
70 85 yellow 135-137 
71 88 yellow 145-147 
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The mass spectra of Schiff base ligands are given in Table 2.16. The molecular ion 
peaks are in agreement with that calculated from their respective elemental analysis 
and fragmentation starts by loss of the methoxy group for ligands 69, 71 and 72 but 
by initial loss of a chloride for ligand 70.  
 







69 365.24 336.74 [M-CH3O]
+ 
70 395.20 363.66 [M-Cl] + 
71 356.42 326.69 [M-CH3O]
+ 





2.5 Synthesis and characterization of palladium(II) complexes 
 
 
2.5.1 Palladium dichloride complexes 
 
Palladium dichloride complexes were obtained from the reaction of ligands 58-64




R = (CH2)2CH3      73
R = (CH)(CH3)2      74
R = (CH3)C6H3     75
R = (CH2)C6H5     76
R = (CH2)C5H4N  77
R = (CH2)C4H3O  78












Scheme 2.8   Synthesis of palladium dichloride complexes 
 
 
The palladium dichloride complexes were not very soluble in most organic solvents 













Table 2.17 Characterization data for palladium (II) dichloride complexes 73 – 79. 
Anal Found (Calcd.) IR spectra (cm-1)a Complex Formula M + (calcd) 
m/z 
C H N ν(C=N) ν(C=N)f 
73 C22H22Cl2NPPd 
b,e437.31 (508.72) 51.69(51.94) 4.12(4.36) 2.72(2.75) 1632 1637 
74 C22H22Cl2NPPd 
c,e474.68 (508.72) 51.79(51.94) 4.12(4.36) 2.52(2.75) 1634 1634 
75 C31H32Cl2NPPd 
c,e591.44 (626.89) 59.19(59.39) 5.12(5.15) 2.42(2.23) 1624 1629 
76 C26H22Cl2NPPd 
c,e531.31 (556.76) 56.26(56.09) 3.72(3.98) 2.72(2.52) 1627 1636 
77 C25H21Cl2N2PPd 
d,e557.71 (557.75) 53.69(53.84) 3.92(3.80) 4.92(5.02) 1626 1632 
78 C24H20Cl2NOPPd 
d,e546.71 (546.72) 52.59(52.72) 3.42(3.69) 2.72(2.56) 1630 1635 
79 C24H20Cl2NPPdS 
d,e562.71 (562.79) 51.48(51.22) 3.32(3.58) 2.72(2.49) 1628 1636 
aRecorded as KBr pellets 
bRepresents m/z for the fragment [M-2Cl]+ 
cRepresents m/z for the fragment [M-Cl]+ 
dRepresents m/z for the fragment [M]+ 
eEI-MS 
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2.5.2 Single crystal X-ray determination of a palladium complex 74 
 
Figure 2.7 Molecular structure of 74 showing the atomic numbering scheme. All non-hydrogen atoms 
were presented with ellipsoidal model with probability level 40%.  The asymmetric unit contains the 
organometallic compound and a dmso solvent molecule. 
 
Table 2.18 Selected bond distances and angles for the palladium complex 74  
Bond Distances (Å)        Bond Angles(º)  
Pd(1)-Cl(2) 2.3838(6) Cl(2)-Pd(1)-Cl(3) 90.74(2) 
Pd(1)-Cl(3) 2.2826(6) Cl(2)-Pd(1)-P(4) 172.6(2) 
Pd(1)-N(24) 2.0726(17) Cl(2)-Pd(1)-N(24) 91.07(5) 
Pd(1)-P(4) 2.2189(6) Cl(3)-Pd(1)-P(4) 92.31(2) 
P(4)-C(11) 1.811(2) Cl(3)-Pd(1)-N(24) 177.29(5) 
P(4)-C(17) 1.820(2) P(4)-Pd(1)-N(24) 86.13(5) 
N(24)-C(23) 1.268(3)   
 
Selected bond distances and angles of 74 are presented in Table 2.18. The 













geometry. The main distortion is the NPdP bite angle of 86.13(5)° similar to other 
palladium complexes with iminophosphines [28]. The Pd-P distance (2.2189(6) Å) is 
within the expected range and the length of the carbon-nitrogen double bond is also 
within the expected range.  
2.5.3 Single crystal X-ray determination of a palladium  complex 79 
 
Figure 2.8 The ORTEP plot of the molecular structure of 79 showing the atomic numbering. 
 
The solid state structure of 79 was obtained by X-ray diffraction (Figure 2.8). Pale 
yellow crystals suitable for single crystal X-ray diffraction were obtained by slow 
evaporation of a dmso-d6-CH2Cl2 solution of the complex. The atomic labels of the 
asymmetric unit are given in the ORTEP picture in Figure 2.8. All non-hydrogen 
atoms were refined anisotropically and all hydrogens are placed geometrically with 
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Table 2.19 Selected bond distances and angles for the palladium complex 79  
Bond Distances (Å)        Bond Angles(º)  
Pd(1)-Cl(2) 2.149(3) Cl(2)-Pd(1)-Cl(3) 88.82(8) 
Pd(1)-Cl(3) 2.3930(12) Cl(2)-Pd(1)-P(4) 91.49(8) 
Pd(1)-P(4) 2.1904(9) Cl(2)-Pd(1)-N(24) 174.37(11) 
Pd(1)-N(24) 2.135(3) Cl(3)-Pd(1)-P(4) 176.40(4) 
P (4)-C(5) 1.820(3) P(4)-Pd(1)-N(24) 86.38(9) 
P(4)-C(11) 1.812(3) Pd(1)-P(4)-C(5) 111.55(11) 
P(4)-C(17) 1.823(3) Pd(1)-P(4)-C(11) 120.74(11) 
N(24)-C(23) 1.276(5) Pd(1)-P(4)-C(17) 109.32(11) 
 
The molecular structure revealed a slightly distorted square planar geometry around 
the palladium metal center. The ligand was shown to bind in the expected K2-P^N 
fashion with a bite angle P(4)-Pd(1)-N(24) of 86.38(9)°. The angle deviated slightly 
from the expected 90°, presumably due to the strain imposed by the six-membered 
chelate ring P(4)-C(17)-C(22)-C(23)-N(24)-Pd(1). This reduction in the bite angle 
was compensated for by an increase in the Cl(2)-Pd(1)-P(4) angle of 91.49(8)°. This 
deviation of the bite angle from 90° has been observed for similar complexes with 
iminophosphines [28]. 
 
2.5.4 Synthesis of palladium methylchloride complexes 80-83 
 
Palladium methylchloride complexes 80 - 83 were obtained from the reaction of 

















R = (CH2)C6H5     80
R = (CH2)C5H4N  81
R = (CH2)C4H3O  82











Scheme 2.9 Synthesis of palladium methylchloride complexes 
 
 
The reaction was allowed to stir in dry CH2Cl2 at room temperature for 8 hours. The 
solvent was reduced and product precipitated out with Et2O. Further precipitation was 
achieved by allowing the products to crystallize slowly at – 16 °C giving pale yellow 
crystals in reasonable yields. These complexes are much more soluble than the 
palladium dichloride complexes. 
2.5.4.1 1H NMR and 31P NMR data of complexes 80 - 83  
 
The 1H NMR spectra of complexes 80 – 83, showed imine protons in the region δ 
8.63 – 8.81 ppm. The observed upfield shifts of 0.21 – 0.28 ppm with respect to the 
free ligands further confirmed coordination of the imine nitrogen to the metal center. 
A downfield shift of δ 0.18 – 0.25 ppm was also observed for the methylene signals, 
due to the coordination of the adjacent imine nitrogen thereby deshielding these 
protons. No significant chemical shifts were observed for the olefinic signals of the 
furyl and the thiophenyl with respect to those of the free ligands, suggesting that these 
groups did not participate in bonding with the metal center. The 31P NMR spectra of 
complexes 80 – 83 showed the expected downfield shift to δ 37.4 – 38.5 ppm with 
respect to the free ligands which appeared at δ -13.2 to -13.9 ppm, due to coordination 
of the phosphine moiety to the palladium metal center. The appearance of one signal 
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Table 2.20 Characterization data for palladium methylchloride complexes 80 – 83. 
Anal Found (Calcd.) IR spectra (cm-1)a Complex Formula M + (calcd) 
m/z 
C H N ν(C=N)ligand ν(C=N) 
80 C27H25ClNPPd 
b521.75 (536.34) 60.72(60.46) 4.51(4.70) 2.81(2.61) 1636 1628 
81 C26H24ClNPPd 
c537.13 (537.33) 58.19(58.12) 4.12(4.50) 5.54(5.21) 1632 1628 
82 C25H23ClNOPPd 
c526.03 (526.30) 57.19(57.07) 4.12(4.40) 2.72(2.66) 1635 1631 
83 C25H23ClNPPdS 
b531.8 (542.37) 55.15(55.36) 4.08(4.27) 2.38(2.58) 1636 1629 
aIR obtained using KBr pellets 
bRepresents m/z for [M-CH3]+ 















2.5.5 Single crystal X-ray determination of a palladium complex 80 
 
Figure 2.9 Molecular structure of 80 showing the atomic numbering scheme. All non-hydrogen atoms 
were presented with ellipsoidal model with probability level 40%.  
 
The slow evaporation of a CH2Cl2-dmso-d6 solution of 80 at room temperature 
afforded pale yellow single crystals suitable for X-ray diffraction. 
 
Table 2.21 Selected bond distances and angles for the palladium complex 80  
Bond Distances (Å)        Bond Angles(º)  
Pd(1)-Cl(2) 2.4035(9) Cl(2)-Pd(1)-P(4) 178.09(8) 
Pd(1)-P(4) 2.1940(7) Cl(2)-Pd(1)-N(24) 94.38(8) 
Pd(1)-N(24) 2.151(2) Cl(2)-Pd(1)-C(3) 88.10(6) 
Pd(1)-C(3) 2.1232(19) P(4)-Pd(1)-N(24) 86.76(6) 
P (4)-C(5) 1.821(3) P(4)-Pd(1)-N(24) 86.38(9) 
P(4)-C(11) 1.824(3) Pd(1)-P(4)-C(5) 111.55(11) 
N(24)-C(23) 1.280(4) Pd(1)-P(4)-C(17) 109.32(11) 
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The Pd-P distances 2.1940(7) Å is within the expected range and close to the values 
determined for the monohalide complex [PdMeCl(L)] (2.1925(9) Å and in the 
dihalide complexes of the same ligand studied by Coleman et al [29, 37]. The Pd-N 
distances are similar to those found for Pd(II) complexes in the same series. The 
methyl group is trans to the nitrogen atom of the ligand. The torsion angle Pd(1)-P(4)-
C(17)-C(22) = 39.9(2) Å indicates that the =CHC6 4- unit lies above the 
PdMeCl(P,N) plane. 
  
2.6 Synthesis and characterization of platinum(II) complexes 
 
2.6.1 Platinum dichloride complexes 
 
Platinum dichloride complexes were obtained from the reaction of ligands 60-64 with 
either [Pt(COD)Cl2] or [Pt(DMSO)2Cl2] as shown in Scheme 2.11. 
N
P
R R = (CH3)4(CH)2C6H4 84
R = (CH2)C6H5           85
R = (CH2)C5H4N        86
R = (CH2)C4H3O        87













Scheme 2.10 Synthesis of platinum dichloride complexes 
 
 
The reagents were taken up in CH2 l2 and stirred at room temperature for 2 hours. 
The solvent was reduced and the complexes precipitated out on addition of hexane 













2.6.1.1 31P NMR spectra of platinum complexes 84-88    
  
The platinum complexes 84 to 88 displayed sharp singlets flanked by platinum 
satellites in their 31P NMR spectra (Table 2.22). 
 
Table 2.22 31P NMR of complexes 84-88 
Ligand δ (ppm) Pt complex δ (ppm) 1J (Pt-P) Hz 
60 -15.8 84 5.83 3661 
61 -13.6 85 8.09 3668 
62 -13.2 86 8.44 3469.9 
63 -13.9 87 5.86 3777.6 
64 -13.8 88 8.06 3758.5 
 (CDCl3, RT, internal standard: H3PO4) 
 
 
The 31P NMR spectra of platinum complexes provides a sensitive probe for the 
structures of complexes. The one-bond coupling 1J(Pt-P) is characteristic of these 
complexes and those which contain Cl atoms trans to phosphorus atoms have been 
found to possess coupling constants greater than 3500 Hz [30]. 
 
There were downfield shifts of approximately 20 ppm from ligand to complex, with 


















Figure 2.10 31P NMR spectrum of 84 (CDCl3, RT, internal standard: H3PO4). 
 
 
31P NMR data for the complexes 84-88 show a downfield shift of between 19.76 and 
21.86 ppm on complexation of the ligands to the metal centre, with the most 
significant shift arising from formation of complex 88 as shown in Table 2.22 
indicating that the P centre of the ligand is coordinated to the metal. The coordination 
chemical shift observed for complexes 84-88 is comparable to that reported 
previously [32]. There is a st ong similarity  in chemical shift observed among all the 
complexes e.g δp values for the platinum complexes are almost identical, indicating 
that the substituents on the aldehyde constituent of the iminophosphine ligand have 
little influence on the value of the shift. This observation is also consistent with 
previous reports of similar types of ligands [32]. The signal due to the P centre in the 
platinum complexes is shifted ca 20 ppm upfield. This trend was also noted 
previously for platinum complexes of the [P, N, O] ligand 2-
[Ph2PC6H4CH=N]C6H3OH 
[31]. The presence of Pt satellites in the spectra of 
complexes 84-88, Table 2.22, is further evidence of coordination by the P centre. 
  













2.6.1.2 Mass spectra 
 
Figure 2.11 shows the mass spectrum (EI) obtained for complex 84. The spectrum 
shows a strong peak corresponding to the parent ion with loss of a chloride ion (Table 
2.23). The complex fragments by loss of the remaining chloride ion(m/z = 640.46) 
and subsequent loss of a two isopropyl units (m/z = 562.50). This is followed by 
sequential loss of the phenyl group (m/z = 453.47). 
 
  Figure 2.11 Mass Spectrum (EI) of 84 
 
Table 2.23 Assignment of fragment ions in the mass spectrum of 84 
Fragment ion m/z 
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2.6.1.3 Physical properties of platinum dichloride complexes 
 
The platinum dichloride complexes 84 to 88 were all air stable, yellow solids which 
did not melt or decompose below 250 °C. The data obtained agrees with those 
previously reported [20]. Experimental yields obtained varied between 68 to 72 % as 
shown in Table 2.24. 
 
Table 2.24 Yields and physical properties of  platinum complexes 84-88 
Complex Yield (%) Colour Melting point ( οC) 
84 72 yellow 272-273 
85 68 Light yellow >300 
86 70 Dark orange 258-260 
87 71 Yellow/orange >300 
88 70 Pale yellow >300 
 
2.6.1.4 IR spectroscopy 
 
The elemental analysis data obtained for the ligands were in agreement with the 
proposed formulations depicted in Scheme 2.11. The most informative peak in the IR 
spectra of iminophosphine complexes of platinum is that of the C=N group occurring 
in the 1600 cm-1 region, Table 2.25. Comparison of the position of this peak in 
complexes 84-88 with that of the corresponding ligands 60-64 shows a shift to lower 
wavenumber on complexation of between 5 and 9 cm-1. The direction and magnitude 
of this shift is in agreement with previous observations on metal complexes of similar 
types of ligands [32]. A shift to lower wavenumbers indicates a weakening of the bond 
between C and N, in this case due to the coordination of the imine to the metal centre. 













Table 2.25 Elemental analysis and IR data for platinum complexes 84 – 88 
Anal Found (Calcd.) IR (cm-1)a Complex Formula 
C H N ν(C=N) 
84 C31H32Cl2NPPt 52.19 (52.03) 4.74 (4.51) 1.99 (1.96) 1624 
85 C26H22Cl2NPPt 48.19 (48.38) 3.12 (3.44) 2.17 (2.47)       1632 
86 C25H21Cl2N2PPt 46.45 (46.19) 3.27 (3.12) 4.33 (4.72) 1630 
87 C24H20Cl2NOPPt 48.83 (48.69) 3.77 (3.52) 2.28 (2.52) 1633 
88 C24H20Cl2NPPtS 44.19 (44.25) 3.12 (3.09) 2.42 (2.15) 1631
 
aIR obtained using KBr pellets 
2.6.1.5 Single crystal X-ray determination of platinum dichloride complex 84 
 
 
Figure 2.12 The ORTEP plot of the molecular structure of 84 showing the atomic numbering. All the 
H atoms are omitted for clarity and are presented with ellipsoidal model with probability level 35%.  
 
The slow evaporation of a CH2Cl2 solution of 84 at room temperature afforded pale 
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The platinum complex is of distorted square planar geometry with the P–Pt–N angle 
at 89.80(5)° and the corresponding angle between the chloride ligands has also been 
reduced to 87.92(2)°. As phosphorus ligands have higher trans influence than amine 
ligands, the Pt – Cl bond trans to P is slightly elongated compared to the chloride 
bound cis to P [33]. 
 
Selected bond lengths and angles are listed in Table 2.26 
 
Table 2.26 Selected bond distances and angles for the platinum complex 84  
Bond Distances (Å)        Bond Angles( º)  
Pt(1)-N(1) 2.0421(18) N(1)-Pt(1)-P(1) 89.80(5) 
Pt(1)-P(1) 2.2128(6) N(1)-Pt(1)-Cl(2) 178.85(5) 
Pt(1)-Cl(2) 2.2901(6) P(1)-Pt(1)-Cl(2) 91.25(2) 
Pt(1)-Cl(1) 2.3512(6) N(1)-Pt(1)-Cl(1) 90.98(5) 
P(1)-C(15) 1.809(2) P(1)-Pt(1)-Cl(1) 174.20(2) 
P(1)-C(26) 1.816(2) Cl(2)-Pt(1)-Cl(1) 87.92(2) 















Figure 2.13 Projection of 84 viewed along [100]. All H atoms are omitted for clarity. 
 
A similar geometrical arrangement of the ligands was observed by McIsaac et l [34] 
for novel iminophosphino rhodium(I) complexes including [Rh(K2-o-
Ph2PC6H4CH=N-2,6-
iPr2C6H3)(µ-Cl)]2. In comparison to the related compound o-
Ph2PC6H4CH=NC6H4OMe-o 
[35], both iminophosphines have a very similar 
arrangement with planar C(14)–C(19)=N(20)–C(21) imino units with an E 
configuration with respect to the diphenylphosphine group. These structures are in 
contrast to o-Ph2PC6H4CH=NC6H4OH-o 
[36] where the nitrogen is closer to the 
phosphorus atom as the molecule assumes a Z configuration. The N(1)=C(13) double 
bond of complex 84 is 1.287(2) Å is well within the range observed for these types of 
compounds [36]. There is little variation observed in the bond lengths of the ligand 
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backbone carbon-carbon distances for the complex are comparable with that of the 
free ligand. The average Pt-N and Pt-P bond lengths of 2.0421(18) and 2.2128(6) Å, 
respectively are in the range expected for iminophosphine platinum(II) complexes [37]. 
The torsion angle Pt(1)-P(1)-C(15)-C(14) = -35.5(2)° indicates that the =CHC6H4- 
unit lies below the PtCl2(P,N) plane. 
 
2.6.1.6 Single crystal X-ray determination of platinum complex 86 
 
Figure 2.14 The ORTEP plot of the molecular structure of 86 showing the atomic numbering. All non-
hydrogen atoms were presented with ellipsoidal model with probability level 40%. All hydrogen atoms 
are omitted for clarity. 
 
The slow evaporation of a CH2Cl2 solution of complex 86 at room temperature 













Table 2.27 Selected bond distances and angles for the platinum complex 86 
Bond Distances (Å)        Bond Angles(º)  
Pt(1)-N(1) 2.040(4) N(1)-Pt(1)-P(1) 88.47(12) 
Pt(1)-P(1) 2.1999(13) N(1)-Pt(1)-Cl(2) 176.70(12) 
Pt(1)-Cl(2) 2.2840(12) P(1)-Pt(1)-Cl(2) 91.76(5) 
Pt(1)-Cl(1) 2.3806(14) N(1)-Pt(1)-Cl(1) 91.27(12) 
P(1)-C(20) 1.803(5) P(1)-Pt(1)-Cl(1) 178.20(5) 
P(1)-C(14) 1.815(5) Cl(2)-Pt(1)-Cl(1) 88.60(5) 
 
The platinum is in a square-planar environment and it is bound to the ligand using a 
K
2-N,P interaction in a cis fashion, with the chlorides located at the two remaining 
sites. However the square-planar geometry of the platinum environment is distorted 
with the angles being less than 180°, N(1)-Pt(1)-Cl(2) and P(1)-Pt(1)-Cl(1) of 
176.70(12)° and 178.20(5)°, respectively. The average Pt-N and Pt-P bond lengths of 
2.040(4) and 2.1999(13) Å, respectively are in the range expected for iminophosphine 
platinum(II) complexes. The torsion angle Pt-P-C(9)-C(8) = -36.5(4)° indicates that 
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2.6.1.7 Single crystal X-ray determination of platinum complex 88 
 
 
Figure 2.15 The ORTEP plot of the molecular structure of 88 showing the atomic numbering. All non-
hydrogen atoms were presented with ellipsoidal model with probability level 40%. The thiophene ring 
was disordered over two places and only one ring is shown here. One solvent water molecule and all 
hydrogen atoms are omitted for clarity. 
 
The slow evaporation of a CH2Cl2 solution of complex 88 at room temperature 
afforded pale yellow single crystals suitable for X-ray diffraction. 
 




















Table 2.28 Selected bond distances and angles for the platinum complex 88 
Bond Distances (Å)        Bond Angles(º)  
Pt(1)-N(1) 2.032(5) N(1)-Pt(1)-P(1) 86.13(14) 
Pt(1)-P(1) 2.2084(13) N(1)-Pt(1)-Cl(2) 178.42(14) 
Pt(1)-Cl(2) 2.2901(15) P(1)-Pt(1)-Cl(2) 95.36(5) 
Pt(1)-Cl(1) 2.3639(14) N(1)-Pt(1)-Cl(1) 89.48(14) 
P(1)-C(20) 1.811(5) P(1)-Pt(1)-Cl(1) 174.05(5) 
P(1)-C(9) 1.823(5) Cl(2)-Pt(1)-Cl(1) 89.06(6) 
 
In complex 88 the ligand adopts a KP, KN coordination mode in a square-planar 
coordination geometry for the platinum center. The Pt(1)-N(1), Pt(1)-P(1), Pt(1)-Cl(2) 
and the Pt(1)-Cl(2) are in the normal range [38]. The Pt-Cl bond length trans to the P 
atom (2.3639(14) Å) is longer than that trans to the N atom (2.2901(15) Å) owing to 
the stronger trans influence of a tertiary phosphine with respect to an imine. The bond 
angle at the Pt(1) atom exhibits only minor deviations from a right angle. The torsion 
angle Pt(1)-P(1)-C(9)-C(8) = 44.8(5)° indicates that the =CHC6H4- unit lies above the 
PtCl2(P,N) plane.  
2.6.1.8 Synthesis of platinum methylchloride complexes 89-90 
 
Platinum methylchloride complexes were isolated from the reaction of ligands 63-64 
with PtClMe(COD) as shown in the Scheme 2.12. 
N
P
R R = (CH2)C4H3O        89
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The reagents were taken up in CH2 l2 and stirred at room temperature for 2 hours. 
The solvent was reduced and the complexes precipitated out on addition of hexane, 
before washing with Et2O affording pale yellow complexes in good yields. 
Spectroscopic and analytical data were in agreement with the proposed structures. 
 
2.6.1.9 NMR data for platinum chloromethyl complexes 
 
The 1H NMR spectroscopy of 89 showed a doublet assignable to the group at δ 0.19 
(trans to the PPh2 moiety, JPH = 73.9 Hz) respectively. Complex 90 exhibited a 
doublet at δ 0.38  cis to PPh2, JPH = 3.8 Hz). As expected, the Pt-H coupling is larger 
for the MePt trans to PPh2 than for the MePt cis to P. The signal for the azomethine 
proton in the 1H NMR spectra of the complexes is shifted downfield from that of the 
free ligand, indicating that imine nitrogen is coordinated to the metal centre. Previous 
data for almost similar complexes reported the azomethine peaks as singlets; in the 
present work, the spectra were obtained at a slight higher field with Pt satellites JPtH = 
101.3 Hz and JPtH = 109.8 Hz. The 
1H NMR spectra of the complexes shows a set of 
resonances in the region 6.90 – 7.99 ppm arising from the aromatic protons of the 
iminophosphine ligand 
 
The 31P NMR spectroscopy in dmso-d6 of 89 exhibited a singlet at δ 9.28, showing 
that the Pt-coordinated phosphine is considerably de-shielded compared to the free 
ligand 63. The singlet has two pairs of 195Pt satellites ascribed to isomers in solution 
with coupling constants JPtP = 2322.7 Hz and JPtP = 3782.6 Hz. The presence of 













coordination by the P centre. Furthermore the JPtP coupling constants are of the order 
of magnitude expected in such complexes.  
 
Table 2.29 Characterization data for platinum complexes 89 – 90 
 
Anal Found (Calcd.) Complex Formula M+ (calcd) 
m/z 
C H N 
89 C25H23ClNOPt 
a598.94 (614.96) 47.29(47.44) 3.69(3.98) 2.08(2.21) 
90 C25H23ClNPPtS 
b595.45 (631.03) 48.26(48.58) 3.83(3.67) 2.28(2.15) 
aRepresents m/z for [M-CH3]+ 
bRepresents m/z for [M-Cl]+ 
 
2.6.1.10 Mass spectrometry of complex 90 
 
The complex displays a peak corresponding to the parent ion (m/z = 630.32, [M]+) 
with loss of a chloride ion (m/z = 595.45, [M–Cl]+. The complex fragments by initial 
loss of the chloride ion and subsequent loss of the methyl group (m/z = 580.54, [M–
Cl–CH3]
+) This is followed by sequential loss of one phenyl group (m/z = 502.62, 
[M–Cl–CH3–Ph]




Table 2.30 Assignment of ragment ions in the mass spectrum of complex 90 
Fragment ion m/z 
[M] + 630.32 
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2.6.1.11 Infrared spectroscopy of platinum chloromethyl complexes 
 
Ligands 63 and 64 show distinctive stretching frequencies, ν(C=N) at 1635 and 1633 
cm-1 (KBr plates) which agrees with previously reported values for iminophosphine 
ligands [11]. Upon complexation, these peaks shift to 1625 and 1627 cm-1. This is due 
to increased electron density on the metal upon coordination of the imine moiety to 
the metal centre. The direction and magnitude of this shift is in agreement with 
previous observations on metal complexes of similar types of ligands [11]. A shift to 
lower wavenumbers indicates a weakening of the bond between C and N, in this case 
due to the coordination of the imine nitrogen to the metal centre. 
 
2.7 Synthesis and characterization of gold(I) complexes 
 
2.7.1 Synthesis of gold(I) chloride complexes 
 
Gold(I) chloride complexes were obtained from the reaction of ligands 60, 62-64 with 




R = (CH3)C6H3     91
R = (CH2)C5H4N  92
R = (CH2)C4H3O  93










Scheme 2.12   Synthesis of gold(I) chloride complexes 
 
 
Reagents were dissolved in CH2Cl2 and stirred at room temperature for 2 hours before 
reducing the solvent and precipitating out the complex with hexane and then washing 













the reaction of an equimolar amount of triphenylphosphine with Au(tht)Cl  in CH2Cl2 
at room temperature. 








Figure 2.16 1H NMR and 31P NMR spectrum of complex 93 
 
 
1H NMR and 31P NMR data of complexes 91 – 94 
The 1H NMR spectra of complexes 91 – 94, showed imine protons in the region δ 
8.54 – 8.90 ppm. The observed slight upfield shifts observed with respect to the free 
ligands further confirmed no coordination of the imine nitrogen to the metal center. 
This was also further unambiguously confirmed by the X-ray structural analysis of 91, 
93 and 95 shown in Figures 2.18, 2.19 and 2.20. No significant chemical shifts were 
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of the free ligands, suggesting that these groups did not participate in bonding with 
the metal center. 
 
The free ligands manifested singlet resonances at -13.8 to -15.8 ppm respectively in 
their 31P NMR spectra. Upon complexation, a significant downfield shift of these 
signals from 26.64 to 31.93 ppm for complexes 91 – 94, respectively, was observed 
with the disappearance of the original free ligand, providing a diagnostic analytical 
tool by which the complexation process could be followed. The appearance of one 
signal in the 31P NMR spectra of the complexes proved the formation of one species 
in all cases. 
  
2.7.3 Mass spectrometry of complex gold complexes 
 
 
The gold complexes display a peak corresponding to the parent ion [M]+, a loss of a 
chloride ion [M–Cl]+. The complexes then fragment by subsequent loss of the gold 
atom [M–Cl–Au]+.  
 
The mass spectra of the gold complexes are summarised in Table 2.31. The molecular 
ion peaks are in good agreement with their empirical formula as indicated by their 























Table 2.31 Fragmentation patterns of gold complexes 91-95 
 
 
aFragment ion m/z                                     Complex 
 
 91 92 93 94 95 
[M] + 
 
679.85 612.84 601.77 618.25 494.14 
[M–Cl] + 
 
643.77 576.89 563.87 581.38 459.10 
[M–Cl–Au]+ 
 
449.31 379.89 367.44 385.73 262.10 
aEI-MS 
 
Figure 2.17 shows the mass spectrum (EI) obtained for complex 93. The spectrum 
shows a peak corresponding to the molecular ion peak (m/z = 601.77). The complex 
fragments by loss of a chloride ion(m/z = 563.87) and finally by the subsequent loss 
of a gold atom (m/z = 376.44).  
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Table 2.32 Characterization data for gold complexes 91 – 95 
Anal Found (Calcd.) IR spectra (cm-1)a Complex Formula M + (calcd)d 
m/z 
C H N ν(C=N)ligand ν(C=N) 
91 C31H32ClNPAu 
b449.31 (681.99) 54.88(54.60) 4.57(4.73) 1.97(2.05) 1629 1628 
92 C25H21ClN2PAu 
c577.37 (612.82) 49.22(49.00) 3.23(3.45) 4.54(4.57) 1632 1630 
93 C24H20ClNOPAu 
c563.87 (601.81) 46.77(46.90) 3.48(3.35) 2.09(2.33) 1635 1634 
94 C24H20ClNPSAu 
c581.38 (617.88) 46.80(46.65) 3.42(3.26) 2.45(2.27) 1636 1634 
95 C18H15ClPAu 
c459.10 (494.70) 43.39(43.70) 3.12(3.06) - - 1625 
                                          aRecorded as KBr pellets 
                                          bRepresents m/z for [M-Cl-Au]+ 
                                          cRepresents m/z for [M-Cl]+ 
                          dEI-MS 













2.7.4 Infrared spectroscopy of gold(I) complexes 
 
For the gold complexes 91-94 containing iminophosphine ligands the position of the 
ν(C=N) peak (ca. 1628 to 1635 cm-1 is comparable to that of the uncomplexed ligand 
suggesting that there is no interaction between this group and the metal center. For 
complex 95 the peak occurs at 1625 cm-1. The peaks are shown in Table 2.32. 
 
2.7.5 Single crystal X-ray determination of gold complex 91 
 
 
Figure 2.18 The ORTEP plot of the molecular structure of 91 showing the atomic numbering. There 
are two crystallographic independent molecules labelled as A and B in the asymmetric unit. All non-
hydrogen atoms were presented with ellipsoidal model with probability level 25%. There is one solvent 
molecule ethanol and all hydrogen atoms are omitted from the picture.  
 
The solid state structure of 91 was obtained by X-ray diffraction (Figure 2.18). Dark 
yellow crystals suitable for single crystal X-ray diffraction were obtained by slow 
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Table 2.33 Selected bond distances and angles for the gold complex 91 
 Bond Distances 
(Å) 
       Bond Angles(º)  
Molecule 1 Au(1A)-P(1A)   2.2350(13)  P(1A)-Au(1A)-Cl(1A) 177.17(5) 
 Au(1A)-Cl(1A)   2.2783(14)  C(26A)-P(1A)-C(20A) 105.2(2) 
 P(1A)-C(26A)   1.805(6)  C(26A)-P(1A)-C(15A) 105.3(2) 
 P(1A)-C(20A)   1.825(6)  C(26A)-P(1A)-Au(1A) 110.80(18) 
 P(1A)-C(15A)   1.834(6)  C(20A)-P(1A)-Au(1A) 116.84(17) 
 N(1A)-C(13A)   1.231(7)   
     
Molecule 2 Au(1B)-P(1B)   2.2272(13)  P(1B)-Au(1B)-Cl(1B) 178.55(6) 
 Au(1B)-Cl(1B)   2.2709(15)  C(26B)-P(1B)-C(20B) 106.4(2) 
 P(1B)-Cl(26B)   1.810(5)  C(26B)-P(1B)-C(15B) 106.4 (2) 
 P(1B)-Cl(20B)   1.814(6)  C(26B)-P(1B)-Au(1B) 110.01(17) 
 P(1B)-C(15B)   1.828(5)  C(20B)-P(1B)-Au(1B) 115.51(19) 
 N(1B)-C-(13B)   1.259(7)   
 
 
The crystallographic asymmetric unit contains two independent molecules which are 
essentially identical structurally. The main differences concern the arrangement of the 
phenyl groups. No unusual bond angles or distances were observed and the complex 
91 showed a virtually linear P – Au – Cl system (bond angle of 177.17°). Williams et 
al report the preparation and characterisation of three new complexes of gold(I) with 
bidentate P – N ligands where the ligand binds to gold(I) either in a mono- or 
bidentate fashion to form the corresponding gold(I) complexes [39]. For the 













Cl – Au and P – Au bonds and the complex had a linear P – Au – Cl geometry with a 
bond angle of 177°. 
 
2.7.6 Single crystal X-ray determination of gold complex 93 
 
 
Figure 2.19 Molecular structure of 93 showing the atomic numbering scheme. All non-hydrogen atoms 
were presented with ellipsoidal model with probability level 40%. 
 
The solid state structure of 93 was obtained by X-ray diffraction (Figure 2.19). Pale 
yellow crystals suitable for single crystal X-ray diffraction were obtained by slow 
evaporation of a CH2Cl2 solution of the complex at room temperature. Selected bond 
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Table 2.34 Selected bond distances and angles for the gold complex 93 
Bond Distances (Å)        Bond Angles(º)  
Au(2)-Cl(1)   2.2821(12)  Cl(1)-Au(2)-P(3) 176.54(4) 
Au(2)-P(3)   2.2336(11)  Au(2)-P(3)-C(4) 112.50(13) 
P(3)-C(4)   1.805(6)  Au(2)-P(3)-C(10) 112.51(14) 
P(1A)-C(20A)   1.819(4)  Au(2)-P(3)-C(10) 112.53(14) 
P(3)-C(10)   1.813(3)  C(4)-P(3)-C(10) 105.22(18) 
P(3)-C(16)   1.8284(7) C(4)-P(3)-C(16) 103.38(18) 
N(23)-C(22)   1.252(5)   
 
 
Complex 93 showed a virtually linear Cl – Au – P system (bond angle of 176.54°) as 
is anticipated for two-coordinate Au(I) compounds. The Au – P bond distances of 
2.2336(11) Å agrees with that reported by Williams et al [39] (2.244(2) Å). The length 
of the carbon-nitrogen bond (1.252(5) Å) is also within the expected range. The 
torsion angle Au(2)-P(3)-C(16)-C(21) = 52.2(3)° indicates that the =CHC6H4- unit 



























Figure 2.20 Molecular structure of 94 showing the atomic numbering scheme. All non-hydrogen atoms 
were presented with ellipsoidal model with probability level 40%. There are two 94 molecules in the 
asymmetric unit. Both have thiophene rings which are disordered over two positions. 
 
The solid state structure of 94 was obtained by X-ray diffraction (Figure 2.20). Pale 
yellow crystals suitable for single crystal X-ray diffraction were obtained by slow 
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Table 2.35 Selected bond distances and angles for the gold complex 94 
 Bond Distances 
(Å) 
       Bond Angles(º)  
Molecule 1 Au(2A)-Cl(1A)   2.2873(19)  Cl(1A)-Au(2A)-P(3A) 177.39(8) 
 Au(2A)-P(3A)   2.2343(19)  C(4A)-P(3A)-C(10A) 102.6(3) 
 P(3A)-C(4A)   1.827(8)  C(4A)-P(3A)-C(16A) 104.4(4) 
 P(3A)-C(16A)   1.835(7)  Au(2A)-P(3A)-C(10A) 114.2(3) 
 P(3A)-C(10A)   1.824(8)  Au(2A)-P(3A)-C(4A) 111.6(2) 
 N(23A)-C(22A)   1.257(12)   
     
Molecule 2 Au(2B)-P(3B)   2.2356(19)  Cl(1B)-Au(2B)-P(3B) 172.64(8) 
 Au(2B)-Cl(1B)   2.290(2)  C(4B)-P(3B)-C(16B) 104.9(3) 
 P(3B)-Cl(4B)   1.820(7)  Au(2B)-P(3B)-C(4B) 121.6 (3) 
 P(3B)-Cl(16B)   1.840(8)  Au(2B)-P(3B)-Cl(6B) 114.9(2) 
 P(3B)-C(10B)   1.833(7)  Au(2B)-P(3B)-C(10B) 103.7(2) 
 N(23B)-C(22B)   1.255(10)   
 
Complex 94 also showed a virtually linear Cl – Au – P system (bond angle of 
177.39°) for molecule 1 as is anticipated for two-coordinate Au(I) compounds. 
Suprisingly molecule 2 has an even very lower bite angle of 172.64(8)°.  The Au – P 
bond distances of 2.2343(43) Å for molecule 1 and 2.2356(19) Å for molecule 2 
agrees with that reported by Williams et al. (2.244(2) Å) and also for our previous 
complexes 91 and 93. The length of the carbon-nitrogen bond (1.257(12) Å) for 
molecule 1 and 1.255(10) Å for molecule 2 are also within the expected range and 
close to the values determined for complexes 91 and 93. The torsion angle for 













unit lies above the AuCl(P,N) plane, but for molecule 2 the torsion angle Au(2B)-
P(3B)-C(16B)-C(21B) = -66.0 (6)° indicating that the =CHC6 4- unit lies below the 
AuCl(P,N) plane. 
2.8 Complexation of tetradentate ligands with platinum and palladium   
 
Despite similar type of ligands having been used to synthesise platinum(II)  
complexes as reported by Bekhit et al [40], our efforts to synthesis the palladium and  
platinum analogues that are water soluble complexes were futile as the products 
obtained were insoluble solid products (yellowish in colour) and therefore could not 
















Where M = Pd, Pt
            X = CH3, Cl  
Scheme 2.13 Attempted synthesis of palladium and platinum complexes with tetradentate ligands 
 
We could only postulate that the desired complexes were formed. However, it must be 
pointed out that the microanalysis data found were in agreement with the calculated 
values for mass spectra data. Both the dichloropalladium and the dichloroplatinum 
complexes were insoluble in common chlorinated organic solvents and only slightly 
soluble in dmso-d6 and proved to be very difficult to characterise fully and therefore 
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Although the ligands possess several donating sites but for geometry reasons it is 
plausible that the most active basic site is the azomethine (imine) one. Hence 
coordination of these ligands would be expected to occur via the lone pair of electrons 
available on the N atom of the imine group [41]. 
2.9 Complexation of Schiff base ligands with platinum and palladium  
 
Similar attempts as those for the tetradentate ligands to complex the Schiff base 
ligands with either palladium or platinum precursors also gave mixtures of products 
which were difficult to characterise due to their insolubility in organic solvents. 
NN RR




W here M  = Pd, P t
            X  =  C l, M e
CH2C l2, R T , 24hr
Scheme 2.14 Attempted synthesis of palladium and platinum complexes with Schiff base ligands 
 
These complexes could not be evaluated for biological activity as we were not able to 
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The observation that cisplatin remains a drug of choice in the treatment of diseases 
like oesophageal cancer, despite the many potential drawbacks associated with its use, 
makes a strong case for the need to develop better therapies. In Chapter 2 we 
described the synthesis and characterisation of a group of novel iminophosphines that 
were complexed to palladium, platinum and gold. The structures of these compounds 
were established by X-ray crystallography, confirming the novelty of these newly 
developed compounds. 
 
In this study we examined these palladium, platinum and gold complexes for their 
activity in WHCO1 and KYSE450 oesophageal cancer cell lines and normal cultured 
cells. The oesophageal cancer cell lines were selected for the cytotoxic assays because 
one of the objectives of this project is to identify agents that have activity against this 




3.2.2 IC50 determination 
The palladium, platinum and gold complexes synthesised and characterised in Chapter 
2 were evaluated for their cytotoxic activity using the MTT assay to determine IC50 
values against the oesophageal cancer cell lines WHCO1, KYSE450 and also in 
normal human fibroblasts (DMB cells) for selected complexes. Dose response curves 
for each of the complexes were performed against the cell lines as outlined in 
Experimental Details in Chapter 4 Section 4.8. Each experiment was performed in 












3.2.2.1 Palladium complexes 
  
The structures of the palladium complexes that were investigated are shown in Table 
3.1. Complexes 73 and 74 have been reported in the literature [1, 2] but had not been 
tested for anticancer activity but complexes 80 - 83 are novel and a crystal structure of 
80 was determined. 
Table 3.1 Palladium complexes evaluated for anticancer activity in WHCO1 and KYSE450 cell lines 
Complex IC 50 in 
WHCO1 (µM) 










































































































































The palladium complexes 73 and 74 were the dichlorides which were very soluble in 
DMSO as compared to the other dichloride complexes 75 - 79 which were insoluble 
(see Section 2.5.1). Complexes 80 – 83 were the chloromethyl derivatives and these 
were very soluble in DMSO. Introduction of a methyl group into the dichloride 
complexes increased the solubility of the complexes. As described in Section 4.8.1, 
WHCO1 cells were treated with various concentrations of the indicated compounds (0 
– 200 µM) for 48 hr, and then subjected to the MTT assay to determine the effects of 
these compounds on cell proliferation. Results of treatment in WHCO1 and KYSE450  
cells with palladium complexes are shown in Table 3.1.   
 
In WHCO1 cells the palladium complexes displayed low activity with the most active 
having an IC50 of 19.02 µM and the least active 45.27 µM. The values in the adjacent 
column show the 95% confidence intervals for the IC50 values.  













































Figure 3.1 Cytotoxicity results for the palladium complexes 80 (A) and 83 (B) on KYSE450 cells. 
Cells in 96 well plates were treated with the indicated concentrations of compounds for 48 hr and then 
processed for the MTT assay (Section 4.8.1). IC50 values were calculated using GraphPad Prism 
software. The graph shows log drug concentration plotted versus OD at 595 nm. The corrected OD 
(OD- background) is shown. The experiments were all done in triplicate and were repeated 3 times. A 
typical experiment is shown and each data point represents the mean ±SD (standard deviation). 
 
 Although complexes 74 and 83 displayed significant activity against KYSE450 cells 
with IC50 values of 10.03 and 10.99 µM respectively the activity of the other 












as shown in Table 3.1. The highest concentration tested nearly caused 100% cell death 
as seen in Figure 3.1.  
3.2.2.2 Platinum complexes 
 
Several platinum complexes investigated as anticancer agents are shown in Table 3.2. 
All the platinum complexes reported here are novel and we were able to determine the 
crystal structures of complexes 84, 86 and 88 respectively. 
 
Table 3.2 Platinum complexes evaluated for anticancer activity in WHCO1 and KYSE450 cell lines 
Complex IC 50 in 
WHCO1 (µM) 


































































































































































Table 3.2 shows the IC50 values and 95% confidence intervals for the platinum 
complexes 84 - 90 in WHCO1 and KYSE450 cell lines, respectively. 
 
Typical cytotoxicity curves obtained for these complexes are shown in Figure 3.4 for 
complexes 87 and 88, respectively, in KYSE 450 cells. 
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Figure 3.2 Cytotoxicity results for the platinum complexes 87 (A) and 88 (B) on KYSE450 cells. 96 
well plates were treated with the indicated concentrations of compounds for 48 hr and then processed 
for the MTT assay (Section 4.8.1). IC50 values were calculated using GraphPad Prism software. The 
graph shows log drug concentration plotted versus OD at 595 nm. The corrected OD (OD- background) 
is shown. The experiments were all done in triplicate and were repeated 3 times. A typical experiment 
is shown and each data point represents the mean ±SD (standard deviation). 
 
 
The results show that platinum complexes show significant cytotoxic activity (< 10 
µM) against both WHCO1 and KYSE450 cell lines with the exception of complexes 
89 and 90. These two complexes were less effective against WHCO1 cells (IC50 > 20 
µM). The curves in Figure 3.2 show that the complexes 87 and 88 induced > 90% cell 

















3.2.2.3 Gold complexes 
 
 
Several gold(I) complexes were evaluated as anticancer agents (Table 3.3). The gold 
complexes were all novel and crystal structures of three of them (91, 93 and 94) were 
determined by X-ray crystallography confirming that they existed in a linear 
coordination mode. 
 
Table 3.3 Gold complexes evaluated for anticancer activity in WHCO1 and KYSE450 cell lines 
Complex IC 50 in 
WHCO1 (µM) 





























































































































































Figure 3.3 Cytotoxicity results for the gold complexes 93 (A) and 94 (B) onWHCO1 cells. 96 well 
plates were treated with the indicated concentrations of compounds for 48 hr and then processed for the 
MTT assay (Section 4.8.1). IC50 values were calculated using GraphPad Prism software. The graph 
shows log drug concentration plotted versus OD at 595 nm. The corrected OD (OD- background) is 
shown. The experiments were all done in triplicate and were repeated 3 times. A typical experiment is 
shown and each data point represents the mean ±SD (standard deviation). 
 
 
Tables 3.3 shows the IC50 values for the gold complexes in WHCO1 and KYSE450 
cell lines, respectively. Typical cytotoxicity curves obtained for these complexes are 
shown in Figure 3.3 for complexes 93 and 94 in WHCO1 cells. The results show that 
all the gold complexes have significant cytotoxicity against both WHCO1 and 
KYSE450 cell lines with IC50 values < 10 µM, with the exception of complex 95 
which has IC50 values > 10 µM for both cell lines. Complexes 93 and 94 were the 
most effective in both cell lines, respectively. 
 
All the gold complexes with the exception of complex 95 showed very good activity 
against both cancer cell lines. We then selected four complexes to explore further 
studies in normal fibroblasts. The compounds were selected on the basis that they 
displayed high cytotoxic activity in the cancer cell lines, they had the same ligands 
and the only difference was the metal center (platinum or gold). The structures of the 


































91 93  
Figure 3.4 Structures of compounds tested in normal cells 
 
In order to investigate whether the complexes were selective towards cancer cells, 
normal fibroblast cells were treated with the complexes 84, 87, 91 and 93 and typical 
IC50 values and 95% CI obtained are as shown in Table 3.4. 
 
Table 3.4 Treatment of DMB cell lines with the most active complexes 
 
COMPOUND IC50 (µM) 95% CI 
84 100.79 95.44 – 112.78 
87 134.50 118.70 – 152.40 
91 134.10 112.69 – 200.40 
93 119.80 102.60 – 139.90 
 
The results show that the complexes do not show significant cytotoxic activity against 
normal fibroblast cell lines, with IC50 values > 100 µM for both platinum (84, 87) and 
gold complexes (91, 93).  The cytotoxicity curves that were used to calculate the IC50 










































































































Figure 3.5 Cytotoxicity results for the complexes 84 (A), 87 (B), 91 (C) and 93 (D) on normal 
fibroblast cells (DMB). 96 well plates were treated with the indicated concentrations of compounds for 
48 hr and then processed for the MTT assay (Section 4.8.1). IC50 values were calculated using 
GraphPad Prism software. The graph shows log drug concentration plotted versus OD at 595 nm. The 
corrected OD (OD- background) is shown. The experiments were all done in triplicate and were 
repeated 3 times. A typical experiment is shown and each data point represents the mean ±SD (standard 
deviation). 
 
The results show that the platinum and gold complexes show substantially reduced 
cytotoxic activity against the normal fibroblast cells (DMB) and that these complexes 
induced > 90% cell death only at the highest drug concentrations for complexes 91 
and 93. In contrast the highest drug concentration tested for complexes 84 and 87 only 

















3.2.3 Effects of complexes 87, 84, 91 and 93 on cell morphology 
 
 
We observed the effect of the selected complexes 84, 87, 91 and 93 on the 
morphology of WHCO1 cells. WHCO1 cells were treated with 2X IC50 of the selected 
complexes (84, 87, 91 and 93) for 24 hours and 48 hours, and then photographed 
using phase contrast microscopy, with a   Zeiss Telaval 31 with an Axiocam camera 





Figure 3.6 Morphology of WHCO1 cells untreated, or treated with 5 µM doxorubicin for 24 and 48 hr. 
Cells were plated in 60 mm dishes and after an overnight incubation. Photographs of the cells were 
captured using a Zeiss Telaval 31 with an Axiocam camera and Motic Images Plus 2.0 ML image 
software.  
 
As a positive control, WHCO1 cells were also treated with doxorubicin, which is an 
agent that is known to cause cell death. In the cells that have been treated with 
doxorubicin most cells appear dead after 24 hours, with all cells dead after 48 hours. 














The cells subjected to treatment with complexes 87, 93, 84 and 91, are shown in 
Figures 3.7 and 3.8.  
Figure 3.7 Morphology of WHCO1 cells treated with complexes 87 or 93 for 24 and 48 hr. Cells were 
plated in 60 mm dishes and after an overnight incubation, 87 and 93 were added at 2 X IC50 
concentration. Photographs of the cells were captured using a Zeiss Telaval 31 with an Axiocam 
camera and Motic Images Plus 2.0 ML image software after 24 and 48 hr. (A) Rounded cells. 
  
 
In the cells treated with compounds 87 and 93 more than 50% of cells are dead at 24 
hours and all the cells are dead after 48 hours for both compounds. A lot of rounded 




























Figure 3.8 Morphology of cells treated with complex 84 or 91 for 24 and 48 hr. Cells were plated in 60 
mm dishes and after an overnight incubation, and 84 and 91 were added at 2 X IC50. Photographs of the 
cells were captured using a Zeiss Telaval 31 with an Axiocam camera and Motic Images Plus 2.0 ML 
image software. (A) shows the rounded cells and (B) membrane blebbing. 
 
The morphology of the cells treated with the platinum and gold complexes were 
distinctly different from the untreated cells. The cells are shrunken and rounded, with 
membrane blebbing also observed in cells treated with complex 91 (Figure 3.8). Cells 
treated with complex 91 were not as obviously affected as a few live cells can be seen 
after treatment for 24 hours, but on a closer examination the morphology of cells was 
altered and there were more floating cells than in the untreated cells with few 












cells are dead on treatment with complexes 84 and 91. From our results, the 
complexes apparently have a toxic effect on the WHCO1 cells tested as evidenced by 
the difference in cell morphology of untreated cells compared to the morphology of 
cells treated with complexes 84, 87, 91 and 93. There also seems to be a reduction in 
cell density and an increase in the number of floating cells, an indication that cells are 
dying.  
3.2.4 Effect of compounds on DNA damage and induction of apoptosis 
 
 
Since the morphology of the WHCO1 cells treated with complexes 84, 87, 91 and 93 
clearly showed that the complexes were killing the oesophageal cancer cells, we 
investigated the effect of these complexes on DNA damage and the induction of 
apoptosis in the cancer cells. Phosphorylation of H2AX was used as a marker of 
Double Strand Breaks (DNA). H2AX by itself cannot repair the damage, but it acts as 
a recruiter, and collects other repair site of damage to initiate repair. The results show 
that complexes 84 and 91 very strongly induce the phosphorylation of H2AX, 
suggesting that these complexes induce DNA damage in the form of DSB’s. Our 
Western blot shows that complexes 87 and 93 also induce DNA damage although to a 
lesser extent than in complexes 84 and 91. 
 
Considering that treatment with these complexes resulted in DSB’s we determined 
whether these compounds also induced apoptosis in treated cells. PARP cleavage was 
investigated by Western blot analysis in order to determine the mode of cell death 
induced by the complexes 84, 91, 87 and 93. PARP is a known caspase substrate and 
cleavage of PARP into two distinct fragments serves as a marker of apoptosis. 












biochemical steps resulting in morphological changes to the cell membrane including 
cell shrinkage, nuclear fragmentation and chromosomal DNA fragmentation. 
 
From the results, there is very little evidence that treatment of the WHCO1 cells with 
complexes 84, 87, 91 and 93 resulted in PARP cleavage and hence apoptosis (Figure 
3.9). 
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Figure 3.9 Western blots for WHCO1 cells treated with complexes 84, 91, 87 and 93. Cell lysates from 
cells treated with 2 X IC50 for complexes 84 and 91 and 4 X IC50 for complexes 87 and 93 were 
harvested at 12, 24 and 48 hr and analysed by Western blot (as outlined in Experimental Details). p38 
was used as a loading control. Treatment of cells with 10 µM doxorubicin served as a positive control. 
These results are representative of two independent experiments.  
 
The system that we used to detect PARP cleavage was clearly working since we could 














3.2.5 Effects of complexes 87, 84, 91 and 93 on the cell cycle 
 
 
Since the complexes 84, 87, 91 and 93 exhibited significant DNA damage as 
evidenced by the phosphorylation of histone H2AX we further explored the effect of 
the complexes on the cell cycle as it is well documented that DNA damage triggers 







Figure 3.10 Morphology of WHCO1 cells 24 hr after treatment with 87, 84, 91 and 93, prior to 
harvesting cells for FACS analysis photographs were captured using a Zeiss Telaval 31 with an 
Axiocam camera and Motic Images Plus 2.0 ML image software.  
 
From the photographs in Figure 3.10 we can clearly see that the compounds have 
altered the morphology of the cells. The cells appear more rounded, with condensed 
nuclei and there is membrane blebbing on some cells. There are also a number of 







































G2/M 12.01 10.09 9.99 8.45 10.15
S 37.22 41.13 37.52 43.63 50.50
G1 50.77 48.12 52.49 47.93 39.35
untx 84 87 93 91
 
Figure 3.11 Cell cycle profiles of cells treated with 2X IC50 for compounds 84, 87, 93 and 91 for 24 hr. 
They were trypsinised, counted and then processed for cell cycle analysis as described in the 
Experimental details (Section 4.9). The x-axis indicates identity of the compounds, and the y-axis the 
percentage of cells in the respective phase of the cell cycle. Results are representative of two 
independent experiments. 
 
Cell cycle analysis was performed on cells treated with complexes 84, 87, 91 and 93 
to determine the effect these complexes might have on the cell cycle. From Figure 
3.11 it appears that the compounds do not affect the cell cycle significantly except for 
complex 91. Cattaruzza et al report that gold(III)-dithiocarbamato derivatives cause 
cell damage, slightly affecting the cell cycle, thus suggesting a different mechanism of 




A preliminary investigation into the antitumour activity of several metal-containing 












cytotoxicity assays on two separate cancer cell lines – human oesophageal cancer cell 
lines WHCO1 and KYSE450 and normal fibroblasts (DMB cells). The structures of 
the palladium, platinum and gold complexes that were evaluated for anticancer 
activity are shown in Tables 3.1, 3.2 and 3.3 respectively. 
 
The complexes that were synthesised initially were not very soluble in a range of 
solvents and thus proved very difficult to characterise. Consequently biological testing 
could not be performed on these complexes. These complexes included the palladium 
and platinum complexes of both the tetradentate and Schiff base ligands as described 
in Section 2.8 and 2.9 of this thesis. Other workers have reported soluble complexes 
of Schiff base ligands complexed to metals like zinc, copper, nickel and silver [4]. 
These complexes have been applied mainly to catalytic reactions [5]. Monobasic 
bidentate Schiff base complexes of palladium and platinum have also been 
investigated for their antimicrobial effects on different species of pathogenic fungi 
and bacteria and have been found to possess significant fungicidal and bacterial 
properties [6].  The synthesis of tetradentate ligands was relatively simple and could be 
generalised to a large variety of other aromatic dialdehydes [7, 8] but their major 
drawback was their insolubility in solvents. The results described in this project 
confirmed the poor solubility of these complexes, and their unsuitability for further 
biological testing in the current form. 
 
The new iminophosphine ligands were synthesised as an alternative using a range of 
amines and their complexes with platinum and gold were very soluble in organic and 
inorganic solvents. The dichloropalladium complexes were not as soluble but their 












literature a whole range of iminophosphine complexes have been synthesised with 
palladium and platinum but only a few have been reported for gold [17]. 
 
3.3.1 Cytotoxic activity of complexes and structure/ function relationships 
 
 
The antitumour activity of a range of palladium complexes was discussed in Section 
1.4 . The palladium complexes are less active than related platinum complexes under 
the same conditions [9, 10]. These reports show the palladium complexes as having at 
best marginal success. From a previous study in our laboratory it has been shown that 
platinum complexes are more active than their palladium analogues with similar 
pyridyl ring ligands [11]. A series of new multinuclear complexes containing 
ferrocenyl groups and platinum group metals were successfully prepared and 
characterized using an array of analytical techniques. Some of the new complexes 
were tested for cytotoxic activity and a comparison was made to that of cisplatin. 
Several of the complexes displayed significant cytotoxic activity against the cancer 
cell line WHCO1 and two of the complexes displayed growth inhibitory activities 
similar to that of cisplatin. The major drawback with the palladium complexes was 
their poor solubility in biological media [11]. 
 
The dichoropalladium complexes that we synthesised in this project were poorly 
soluble and proved to be difficult to characterise and were not tested for biological 
activity except for the complexes with isopropyl and propyl substituents (73 and 74). 
However the chloromethyl palladium complexes (80-83) were more soluble in DMSO 
than the dichloropalladium complexes (75-79) and were evaluated for biological 
activity. The complexes displayed similar cytotoxic activity in both cell lines and 












complex 74 with IC50 values of 19.02 and 10.03 µM, respectively, and the least active 
was complex 82 in both cell lines with IC50 values of 45.27 and 68.54 µM, 
respectively. 
 
The use of platinum in antitumour drugs has been well established and cisplatin is the 
most prominent of this class of drugs [7]. Despite the success of cisplatin, some 
tumours have developed natural as well as acquired resistance to the drug. These 
effects may only be partially reversed upon termination of treatment. Since the 
discovery of cisplatin, numerous platinum-containing compounds have been prepared 
and their efficacy investigated with a view to the reduction of side effects and toxicity 
and these have been mentioned in Chapter 1 of this thesis including some of the most 
recent ones. Over 3000 platinum compounds have been synthesised and tested in vitro 
in the past 30 years [12, 13]. However, less than 1% of these have entered clinical trials 
and very few have as yet emerged as clinically acceptable. 
 
The cytotoxicity of several platinum complexes was examined (see Figure 3.3). These 
complexes have been fully characterised and here we report three crystal structures of 
these new complexes 84, 86 and 88. In WHCO1 cell lines complex 86 had the highest 
activity with an IC50 value of 5.49µM and the least active was complex 84 with an 
IC50 value of 9.47 µM. In comparison to cisplatin which has an IC50 of 13 – 15 µM in 
WHCO1 cell lines, all the novel platinum complexes described here displayed 
significant activity against oesophageal cancer cell lines.  
 
The gold(I) complexes exhibited very good activity against both cancer cell lines. 












complex 95 was the least active with an IC50 of 14.44 µM respectively. A similar 
trend was also observed in the KYSE450 cell lines.  
 
 
Considering the close structural relationships between the iminophosphine ligands 
used here, which were complexed to either palladium, platinum or gold, we may be in 
a position to comment on the structure/function relationships of the complexes studied 
here. This may allow us to identify those structural motifs which may be important for 
biological activity either on their own or in combination with others. Based on 
information available in the literature, the majority of the vast amount of platinum 
complexes synthesised fit a set of structure-activity relationships. For a platinum drug 
to exhibit antiproliferative activity, the Pt(II) complex should have a cis geometry and 
the general formula of cis-[PtX2(Am)2], where X is a leaving group and Am is an inert 
amine with at least one N-H functionality [14, 15]. The leaving group should have 
intermediate binding strength to platinum and should have a weak trans effect to 
avoid labilising the amine.  In recent years, however, a large number of new 
compounds that do not satisfy the classical SARs have been reported to show 
antitumour activity. The demonstration of antitumour activity for these complexes 
indicates that cisplatin-like DNA lesions are not the only cause of cytotoxicity [16].   
 
Not much work has been reported in the literature especially on gold(I) complexes 
with iminophosphine ligands except for the work reported by Williams et al [17]. They 
report the preparation and characterisation of three new gold(I) complexes with  
bidentate P-N ligands where, depending on its nature, the ligand binds to Au(I) either 













The principle question arising from the study of complexes with iminophosphine 
ligands is to establish the role of the side chain on the phenyl – PPh2 moiety of the 
iminophosphine ligand. The complexes have similar iminophosphine ligands, 
coordinated in a square planar fashion to palladium and platinum but in a linear 
manner in gold as shown in Figure 3.12. Platinum complexes were more active than 
palladium complexes, confirming previous observations that platinum complexes 
perform better than palladium complexes (based on identical ligands). Despite 
palladium and platinum being elements of the same group and that their ionic radii are 
nearly the same as a result of lanthanoid contraction, their respective iminophosphine 
complexes exhibited varied activities with platinum compounds showing higher 
activity than palladium compounds. This observation is attributed to the associative 
substitution mechanism of the respective complexes suggesting that their kinetic 
behaviour is quite different even though they show similar coordinative behaviour [18]. 
Thus palladium complexes are less kinetically stable and as a result could undergo 
translabilization and undesired displacement of the non-leaving ligand by other 
nitrogen donors easily (especially those coordinated in a monodentate fashion) 
whereas platinum compounds are known to be kinetically inert [19]. This implies that 
palladium compounds are not stable and therefore in the cellular environment will be 
caused to dissociate easily by other biomolecules such as GSH and hence reacting to 
give other intermediates hence hindering it from forming the palladium-DNA adducts.  
 
However, the gold compounds howed higher activity compared to platinum 
complexes. Gold complexes are mainly known for their use in treating rheumatoid 
arthritis, but some gold(I) complexes have been reported to show anticancer activity 












ligands have shown to display a wide spectrum of anticancer activity [21]. In this 
project the gold(I) complexes exhibited IC50 values in the lower micromolar ranges of 
3.41 and 3.61 µM for complexes 93 and 94. However complex 95 with three phenyl 
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Figure 3.12 Changes in activity based on structure of the side chain for gold complexes 
 
From the above data we can observe that in terms of activity, the complexes can be 
ranked in the order 93 ≥ 94≥ 92 ≥ 91. On performing a two tailed student t-test on the 
IC50 values of the complexes we observe that p > 0.05 when comparing the IC50 
values of complex 93 with those of complexes 94 and 92, suggesting that the 
difference in IC50 values of the complexes are not statistically significant. This 
suggests that the side chain has no significant effect on the cancer cell killing 
properties of complexes 92, 93 and 94. However for complex 91, the bulkiness 
exerted by the diisopropyl group reduces cytotoxicity activity 2-fold. In complex 95 
cytotoxicity is further reduced (5 times) with an IC50 value of 14.44 µM because of 












94 and 92 were significantly different from the IC50 value for 91 (p < 0.05) and 95 (p 
< 0.05).  
 
A similar trend was observed for the platinum complexes against WHCO1 cells and is 
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Figure 3.13 Changes in activity based on structure of the side chain for platinum complexes 
 
The IC50 values for platinum complexes 86, 88, 87 and 84 are almost identical in both 
the WHCO1 and KYSE450 cell lines. Student t-tests performed on the IC50 values of 
the platinum complexes show that p > 0.05 indicating that differences in IC50 values 
are not statistically significant and the IC50 values can be regarded as equal. 
 
Inorder to fully establish the role played different metals (palladium, platinum and 
gold) we then compared the IC50 values of the different metal complexes which 
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 Figure 3.14 Changes in activity based on metal center in WHCO1 cells 
 
The gold complex 94 is the most active in WHCO1 cells with an IC50 value of 3.61 
µM followed by the platinum complex 88 with an IC50 value of 6.66 µM, and the least 
active is the palladium complex 83 with an IC50 of 45.27 µM. From this data we can 
conclude that in terms of the metal present in the ligand, activity of the complexes 
follows the order of Au ≥ Pt > Pd. The low activity of palladium complexes may be 
attributed to very rapid hydrolysis of the leaving groups that dissociate readily in 
solution leading to reactive species far from their pharmacological targets [22]. 
 
The complexes exhibited low cytotoxicity/activity against the normal DMB cells and 
the IC50’s were very large in the range of 100.79 to 134.50 µM for the most active 
gold and platinum complexes. This is a very significant result since it suggests that 
these complexes may display a therapeutic window, causing selective cell death in 
cancer cells, leaving normal cells unaffected at low concentrations. 
 
These findings are highly significant, since most organometallic complexes display a 
low selectivity against cancer cells (compared to normal cells). Clearly a number of 
additional experiments would need to be performed to explore this observation in 













3.3.2 Effects of compounds on DNA damage and apoptosis 
 
Cisplatin, that quintescential organometallic chemotherapeutic agent is thought to kill 
cancer cells by causing the formation of DNA adducts, which is associated with 
Double strand breaks in the DNA molecule, followed by cell death. In this project we 
monitored the phosphorylation status of the H2AX histone as a marker of DSB’s in 
DNA, in response to treatment with the novel complexes synthesised here. DSBs arise 
by an exposure to ionizing radiation or drugs, but they are also generated as part of 
normal metabolic processes [23]. Our results demonstrate that some of the complexes 
tested (84, 91 and 93) also induce DSB’s in the cancer cells tested. Although these 
compounds do induce DNA damage as seen by the phosphorylation of H2AX, only 
minor effects on the cell cycle profile was observ d. The biggest effect on the cell 
cycle was seen with complex 91 but this was not the most active compound tested, 
since it was the least active in WHCO1 cells.  
 
Coronnello et al  reported that some organogold(III) compounds produced significant 
antiproliferative effects to a greater extent than platinum drugs while causing only 
modest cell cycle modifications [24]. Most recently Ronconi et al described the 
mechanistic studies that have provided insights into the mechanism of action of 
gold(III)-dithiocarbamato derivates, and these show that these complexes have a slight 
effect on the cell cycle [25]. Metal containing complexes can react with different 
macromolecules, producing a wide range of biological effects, including DNA 
damage. The DNA-damaging potential of the two most commonly studied mercury 
compounds (mercury chloride and methyl mercury chloride), two nickel compounds 
(nickel chloride and potassium hexafluoronickelate), two palladium compounds 












tellurium compounds has led to the conclusion that, the ability of inducing DNA 
damage these metal-containing compounds in cancer cells is dependent on the 
chemical form and, in general, compounds containing the metal in the lower valence 
state displayed the greater DNA-damaging ability [26]. Kawanishi et al reported that 
various metal compounds, such as cobalt, nickel, and ferric nitrilotriacetate, directly 
cause site-specific DNA damage in the presence of H2O2. They also found that 
carcinogenic metals could cause DNA damage through indirect mechanisms. 
Endogenous metals, copper and iron, catalyse ROS generation from various organic 
carcinogens, resulting in oxidative DNA damage [27].
 
The compounds 84 and 91 however do show slight PARP cleavage as was also seen 
in the morphology of the cells with a few apoptotic bodies. From these results we see 
no obvious apoptosis for the compounds tested and therefore the compounds are 
killing the cells through some other mechanism. It might therefore be interesting to 
investigate whether the compounds trigger cell death in WHCO1 cells by necrosis 
(premature death of cells usually induced by disruption of cell membrane), induce 
senescence (loss of cell’s ability to divide due to DNA double strand breaks or toxins) 
or autophagy (degradation of a cell by autolysomes).  
 
The lack of a sub-G1 peak in the cell analysis in Figure 3.11 is most likely due to the 
extended processing of cells for this assay (multiple washes and spins), during which 
the population may have been lost. The cell-cycle disturbances were associated with 
inhibition of cell proliferation in agreement with results reported by Martin et al [28] in 
their cell-cycle disturbance studies. This suggests that the reduction in G1-phase cells 












apoptosis by compounds in test. The cells were trapped in G1-phase and therefore 
paused their progress in the cycle and subsequently entered an indefinite phase. This 
is attributed to the complex binding to DNA in G1-phase and therefore disrupting its 
programme of passing the DNA for replication in the S-phase. This then caused the 
cell receptors to detect the anomaly hence triggering apoptosis. Selenium compounds 
are the most extensively studied cancer chemopreventive agents, and induce apoptotic 
death of tumor cells and the selenite-induced apoptosis involves DNA damage. 
Selenite has also been shown to stimulate phosphorylation of H2AX [29, 30].
 
The complexes discussed above were studied or their cytotoxicity on oesophageal 
cancer cells. The morphological changes observed showed that the complexes induced 
cell death, however apoptosis was not observed and cell death is occurring by some 
other mechanism. Further analysis of cytotoxicity activities of these complexes by 
FACS analysis showed that the complexes do not affect the cell cycle. The complexes 
also displayed selectivity against oesophageal cancer cells and this is a significant 
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4.1 GENERAL EXPERIMENTAL DETAILS 
 
All manipulations were carried out under an atmosphere of nitrogen or argon using 
standard Schlenk techniques unless otherwise stated. All other glassware was 
thoroughly dried at 210 º C for at least four hours prior to use. 
 
4.1.1 Solvents and reagents 
 
Hexane and  pentane were refluxed and distilled from calcium hydride (CaH2), 
tetrahydrofuran (THF), diethyl ether (Et2O) and toluene were dried over sodium-wire 
and benzophenone, dichloromethane was dried over P2O5 under nitrogen. After the 
purification procedures the solvents were stored under nitrogen in Teflon sealed 
storage bottles. All reagents were purchased from Aldrich and used without further 
purification. Palladium and platinum were obtained as chloride salts from Johnson-
Matthey and gold metal obtained from Mintek. Other starting materials such as 
[PdCl2(COD)] 
[1, 2] , [PdClMe(COD)] [3], [PtCl2(COD)] 
[4, 5], [PtCl2(DMSO)]2 
[6, 7, 8] 
[PtClMe(COD)] [3, 9] and [Au(tht)Cl] [10] were prepared according to known literature 
procedures. Anhydrous magnesium sulphate or sodium sulphate were used for drying 
reaction solutions. 
 
4.1.2 Instrumentation  
 
Melting points were determined on the Kofler hotstage microscope (Reichart 
Thermovar) and are uncorrected. Microanalysis data was obtained from the University 
of Cape Town’s Microanalytical Laboratory using a Carlo Erba EA1108 elemental 












at the University of Cape Town, as KBr discs for solids. All data are given in 
wavenumbers (cm-1) 
 
1H, 13C and 31P NMR spectra were recorded on either a Varian Unity-400 1H: 400 
MHz; 13C: 100.6 MHz) or Varian Mercury-300 (1H: 300 MHz; 13C: 75.5 MHz) 
spectrometer at ambient temperatures. 1H NMR spectra were referenced internally 
using residual protons in the deuterated solvent (CDCl3: δ 7.27; DMSO: δ 2.50 ppm) 
and values reported relate to tetramethylsilane (δ 0.00). 13C NMR were similarly 
referenced internally to the solvent resonance CDCl3: δ 77.0; DMSO: δ 39.4 and with 
values reported relative to tetramethylsilane (δ 0.00). 31P NMR spectra were 
referenced externally to H3PO4. All chemical shifts are quoted in δ (ppm) and 
coupling constants, J, in Hertz (Hz). Mass spectra (EI) were recorded using a JEOL-
MATE(II) GC-MS instrument at UCT. 
 
X-ray intensity data were collected on a Nonius Kappa-CCD diffractometer with 1.5 
kW graphite monochromated Mo-Kα radiation. The structures were solved by direct 
methods using SHELXS-97 and refined employing full-matrix least-squares with the 





















4.2 SYNTHESIS OF LIGANDS 
 
4.2.1 Iminophosphine ligands 
 
4.2.1.1 General procedure for the synthesis of iminophosphine ligands 58 - 64 
 
To 2-(diphenylphosphino)benzaldehyde was added an equimolar amount of desired 
amine in freshly distilled CH2Cl2. Na2SO4 or MgSO4 was added to remove water 
formed as a by-product. The reaction was allowed to stir at room temperature for ca 
16 hours after which the drying agent was removed by filtration and solvent removed 
under reduced pressure yielding an oil. The oils were solidified by addition of hot 
hexane and filtering whilst hot before allowing to cool at -16 ºC overnight. The 
respective precipitates were then filtered under gravity and washed with dry Et2O 
before drying under vacuum for 4 hours. 
 
Preparation of 58 [13] 
Product was obtained as a yellow crystalline powder in 
85% yield                                                                                                              
M.p.: 70-71 ºC 
1H NMR: (400M Hz, CDCl3): δH 8.91 (d, 1H, J = 4.8 Hz, HC=N), 8.01 (dd, 1H, J =  
                7.8, 4.2 Hz, ArH), 7.39 – 7.22 (m, 12H, ArH), 6.90 (dd, 1H, J = 7.2, 5.4 Hz,  
                ArH), 3.50 (t, 2H, J = 6.8 Hz, Hc), 1.54-1.44 (m, 2H, Hb), 0.82 (t, 3H, J  
                =7.2 Hz, Ha) 
31P NMR: -13.4 
EA:         Calc. for C22H22NP: C, 79.74 %; H, 6.69 %; N 4.23 %;  
                Found:                     C, 79.59 %; H, 6.82 %; N 4.12 %;  























EI-MS:      m/z 321.22 [M]+   
 
Preparation of 59 [14,15] 
The product was obtained as a pale yellow crystalline solid 
in 76% yield.  
M.p.: 107-108 °C 
  
1H NMR: (400 MHz, CDCl3): δH 8.11 (s, 1H, HC=N), 7.8 -  6.2 (m, 14H, C6H4, Ph),  
                 5.5 (m, 1H, - CHMe2) 1.1 (d, 6H, J = 7.6 Hz, - CHMe2)   
31P NMR: -13.2  
EA:         Calc. for C22H22NP: C, 79.74 %; H, 6.69 %; N 4.23 %;  
                  Found:                   C, 79.88 %; H, 6.52 %; N 4.52 %;  
IR (KBr): 1634s (C=N, imine)  
EI-MS:      m/z 321.24 [M]+ 
 
Preparation of 60 [16] 
 
Product was obtained as a yellow crystalline powder in 80% 
yield                                                                                                              
M.p.: 108-110 °C 
 
1H NMR: (400 MHz, CDCl3): δH 8.94 (d, 1H, J = 5.7 Hz, HC=N),  
                8.34 (dd, 2H, J = 4.0 Hz, J = 7.7 Hz, ArH); 7.51 (t, 2H, J = 7.5 Hz, ArH),  
                7.42 (d, 2H, J = 1.4 Hz, ArH), 7.40 (d, 2H J = 1.5 Hz, ArH), 7.37 (d, 2H,  
               J = 1.4 Hz,  ArH), 7.31 (ddd, 2H J = 2.0 Hz, J = 5.0 Hz,  J = 9.0 Hz, ArH),  
              7.22 (m, 2H, ArH), 7.07 (m, 2H, C6H3), 6.96 (ddd, 1H J = 0.8 Hz, J = 4.4 Hz,  












31P NMR; -15.8 
EA:         Calc. for C31H32NP: C, 82.82 %; H, 7.17 %; N 3.12 %;  
                  Found:                   C, 82.69 %; H, 7.12 %; N 3.32 %;  
IR (KBr): 1629 (s) (C=N, imine) 
EI-MS:      m/z 449.56 [M]+ 
 
Preparation of 61 [17] 
Product was obtained as a pale white powder in 78% 
yield 
M.p.: 80-82 °C 
1H NMR: (400 MHz, CDCl3): δH 8.91(d, 1H, J = 4.8 Hz, Ha), 8.10 (m, 1H, ArH), 7.19  
                 – 7.43 (m, 15H, ArH), 7.09 (m, 2H, ArH) 6.94 (ddd, 1H, J = 7.7, 4.7, 1.2  
                  Hz, ArH), 4.67 (s, 2H, Hb) 
31P NMR: δ -13.6 (s) 
EA:          Calc. for C26H22NP: C, 82.30 %; H, 5.84 %; N 3.69 %;  
                 Found:                     C, 82.49 %; H, 5.62 %; N 3.72 %;  
IR (KBr): 1636s (C=N, imine)   
EI-MS:      m/z 379.78 [M]+ 
 
 Preparation of 62 
Product was obtained as a pale white solid in 85% yield 
M.p.: 79-82 °C 
1H NMR: (400 MHz, CDCl3): δH 9.02 (d,1H, J  = 4.9 Hz, Ha),  8.45 (dd,1H, J = 1.7  
                Hz, 4.8 Hz, C6H4N), 8.42 (d,1H, J = 1.7 Hz, C6H4N) 8.01 (ddd,1H, J = 1.4,  



















               J = 4.8 Hz, J = 7.8 Hz, ArH), 6.90 (ddd, 1H, J = 7.7, 4.7, 1.7 Hz), 4.67 (s,  
                2H, Hb),  
31P NMR: δ -13.2 (s)  
EA:          Calc. for C25H21N2P: C, 78.93 %; H, 5.56 %; N 7.36 %;  
                  Found:                      C, 78.82 %; H, 5.62 %; N 7.52 %;  
IR (KBr): 1632 (s) (C=N, imine)  
EI-MS:      m/z 380.80 [M]+ 
 
Preparation of 63 
Product was obtained as a pale white powder in 85% 
yield 
M.p.: 77-78 °C 
1H NMR: (400 MHz, CDCl3): δH 9.01 (d, 1H J = 5.1 Hz, Ha), 8.07 (ddd, 1H, J = 7.7  
                 Hz, J = 4.0 Hz, J = 1.4 Hz, ArH), 7.42 – 7.25 (m, 13H, ArH), 6.91 (m, 1H,  
                 C4H3O), 6.27 (m,1H, C4H3O ), 6.05 (dd, 1H, J= 3.3 Hz, J = 0.7 Hz,  
                 C4H3O), 4.65 (s, 2H, Hb) 
31P NMR: δ -13.9 (s)  
EA:         Calc. for C24H20NOP: C, 78.03 %; H, 5.46 %; N 3.79 %;  
                Found:                        C, 78.19 %; H, 5.22 %; N 3.72 %;  
IR (KBr): 1635 (s) (C=N, imine)   
EI-MS:      m/z 369.61 [M]+ 
 
Preparation of 64 





















M.p.: 70-72 °C  . 
1H NMR: (400 MHz, CDCl3): δH 9.02 (br d, 1H, J = 4.9 Hz, Ha), 8.11 (m, 1H, ArH),  
                 7.25 – 7.45 (m, 12H, ArH), 7.59 (d, 1H, J = 2.6 Hz), 6.95 (m, 2H, ArH),  
                 6.78 (dd, 1H, J = 3.1 Hz, J = 1.0 Hz, C4H3S), 4.86 (s, 2H, Hb)  
31P NMR: δ -13.8 (s) 
EA:         Calc. for C24H20NPS: C, 74.78 %; H, 5.23 %; N 3.63 %; S, 8.32  
                Found:                        C, 74.59 %; H, 5.12 %; N 3.72 %; S, 8.11  
IR (KBr): 1636 (s) (C=N, imine) 
EI-MS:      m/z 385.32 [M]+ 
 
4.2.2 Tetradentate ligands 
 
4.2.2.1 General procedure for the synthesis of tetradentate ligands 65 - 68 
 
The tetradentate ligands were prepared by the addition of one equivalent of aromatic 
dialdehyde (terephthalaldehyde) to two equivalents of the appropriate amine 
previously dissolved in methanol and the mixture stirred at room temperature for ca 
36 hours. The formed compound precipitated out alone without adding any solvent, 
washed with dry Et2O and dried under vacuum for 4 hours.  
 
 
Preparation of 65 
 
Product was obtained as a pale white microcrystalline 
powder in 85% yield 
M.p.: 180-182 °C   
 
1H NMR: (400 MHz) δH 8.38 (t, 2H, J = 1.3 Hz, Hc) 7.82 (s, 2H, Hf) 7.25 (m,  























13C NMR: (400 MHz, CDCl3) δ 161.54 (Cc), 141.72 (Ce), 138.10 (Cb), 128.55 (Cg),  
                 126.88 (Ca), 125.11 (Ch), 124.80 (Cf), 59.28 (Cd) 
EA:          Calc. for C18H16N2S2: C, 66.63 %; H, 4.97 %; N, 8.63 %; S, 19.77  
                 Found:                        C, 66.59 %; H, 4.62 %; N, 8.72 %; S, 19.65  
IR (KBr): 1612 cm-1 (C=N, imine) 
EI-MS:      m/z 103.30 [M - 2C5H5SN]
+ 
 
Recrystallisation by slow diffusion of Et2O into a concentrated CH2Cl2 of the solution 
gave crystals of 65 suitable for X-ray structure determination. 
 
Preparation of 66 
Product was obtained as off white shiny crystals in 75% yield. 
M.p.: 240-242 °C   
 
1H NMR: (400 MHz, CDCl3) δH 8.23 (d, 2H, J = 1.3Hz,  
                  Hc) 7.76 (s, 2H, Ha) 7.13 (dd, 2H, J = 3.4 Hz, J = 5.1Hz, Hg) 6.92 (dd, 2H,  
                  J = 1.1 Hz, J = 5.1 Hz, Hi) 6.84 (dd, 4H, J = 1.3 Hz, J = 2.1Hz, Hh) 3.91  
                  (dt, 4H, J = 1.1 Hz, J = 7.0Hz, Hd) 3.25 (t, 4H, J = 7.0 Hz, He) 
13C NMR: (400 MHz, CDCl3) δ 161.27 (Cc), 142.28 (Cf), 138.15 (Cb), 128.34 (Ch),  
                  126.72 (Ca), 125.18 (Ci), 123.61 (Cg), 62.90 (Cd), 31.42 (Ce) 
 EA:        Calc. for C20H20N2S2: C, 68.14 %; H, 5.72 %; N, 7.95 %; S, 18.19  
                Found:                        C, 68.19 %; H, 5.52 %; N, 7.72 %; S, 18.44  
IR (KBr): 1613 cm-1 (C=N, imine) 


























Recrystallisation by slow diffusion of Et2O into a concentrated CH2Cl2 of the solution 
gave crystals of 66 suitable for X-ray structure determination. 
 
Preparation of 67 
 
Product was obtained as a white solid in 85% yield 
M.p.: does not melt below 260 °C 
 
1H NMR: (400 MHz, CDCl3) δH 8.57 (d, 2H, J = 4.8 Hz, Hi) 8.50 (s, 2H, Hc) 7.86 (s,  
2H, Ha) 7.68 (dt, 2H, J = 1.8 Hz, J = 7.7 Hz, Hg) 7.44 (d, 2H, J = 7.8 
Hz, Hf) 7.26 (m, 2H, Hh) 7.18 (dd, 2H, J = 4.6 Hz, J = 7.2 Hz, Hf) 4.97 
(s, 4H, Hd) 
13C NMR: (400 MHz, CDCl3) δ 162.67 (Cc), 159.28 (Ce), 149.54 (Ci), 138.43 (Cb), 
136.90 (Cg), 128.78 (Ca), 122.56 (Ch), 122.29 Cf), 67.12 (Cd) 
EA:                 Calc. for C20H18N4: C, 76.41 %; H, 5.77%; N, 17.82 %;  
                        Found:                    C, 76.19 %; H, 5.52 %; N, 17.72 %;  
IR (KBr): 1605 cm-1 (C=N, imine) 
EI-MS:      m/z 221.84 [M – C6H6N]
+ 
 
Preparation of 68 
Product was obtained as a white solid in 85% yield 
M.p.: does not melt below 260 °C 
1H NMR: (400 MHz, CDCl3) δH 8.55 (ddd, 2H, J =0.8  
                 Hz,  J = 1.7Hz, J = 4.8 Hz) 8.21 (t, 2H, J = 1.3Hz) 7.69 (s, 2H) 7.55 (dt,  




































                  3.19 (t, 4H, J = 7.2Hz) 
13C NMR: (400 MHz, CDCl3) δ 161.05 (Cf), 159.45 (Cc), 149.37 (Cj), 138.88 (Cb),  
                  136.13 (Cb), 128.21 (Ca), 123.67 (Cg), 121.24 (Ci), 61.18 (Cd), 39.61 (Ce) 
EA:         Calc. for C22H22N4: C, 77.16 %; H, 6.48 %; N, 16.36 %;  
               Found:                     C, 77.19 %; H, 6.22 %; N, 16.52 %;  
IR (KBr): 1610 cm-1 (C=N, imine) 
EI-MS:      m/z 249.90 [M – C6H6N]
+ 
 
Recrystallisation by slow diffusion of Et2O into a concentrated CH2Cl2 of the solution 
gave crystals of 68 suitable X-ray structure determination. 
 
4.2.3 Schiff base ligands 
 
4.2.3.1 General procedure for the synthesis of schiff base ligands 69 – 72 
 
 
Schiff bases were prepared according to the known method from the condensation of 
the respective diamine with the corresponding aldehyde in a molar ratio 1:2, 
respectively, using methanol as a solvent at ca. 45 °C. The reaction mixture was 
stirred for 3 hours. The precipitates were filtered off, washed several times with 
methanol and finally dried under vacuum for 4 hours. 
 
Preparation of 69 
Product was obtained as a white crystalline 
powder in 83% yield 





























1H NMR: (400 MHz, CDCl3) δH 8.64 (s, 2H, Hb), 7.95 (d, 2H, J = 8.5 Hz, Hd), 7.24  
                (dd, 2H, J = 0.7 Hz, J = 2.0 Hz, Hg), 7.27 (dd, 2H, J = 0.6 Hz, J = 2.1  Hz,  
                 He), 4.01 (s, 4H, Ha),  2.17 (s, 6H, Hi) 
13C NMR: (400 MHz, CDCl3) δ 158.45 (Cf), 136.96 (Cb), 135.57 (Cc), 131.73 (Ch),  
                 129.52 (Cd), 129.27 (Cg), 127.50 (Ce), 61.34 (Ca) 
EA:           Calc. for C18H18Cl2N2O2: C, 59.19 %; H, 4.97 %; N 7.67 %.  
                  Found:                              C, 59.39 %; H, 4.72 %; N 7.42 %. 
IR (KBr): 1617 cm-1 (C=N, imine) 
EI-MS:      m/z 336.74 [M - CH3O]
+ 
 
Preparation of 70 
Product was obtained as a yellow 
crystalline solid in 85% yield 
M.p.: 145-147 °C 
1H NMR: (400 MHz, CDCl3) δH 8.30 (s, 2H, Hb), 8.22 (s, 2H, Hh), 7.83 (d, 2H,  
                  J = 8.3 Hz, Hd), 7.58 (d, 2H, J = 8.3 Hz, He), 4.03 (s, 4H, Ha) 
13C NMR: (400 MHz, CDCl3) δ 158.81 (Cb) , 149.86 (Cg) 135.93 (Cc),  132.14 (Ce),  
                 131.89 (Cf), 128.80 (Cd), 124.53 (Ch), 61.11 (Ca) 
EA:           Calc. for C16H12Cl2N4O4: C, 48.58 %; H, 3.04 %; N 14.18 %.  
                  Found:                              C, 48.19 %; H, 3.12 %; N 14.42 %. 
IR (KBr): 1614 cm-1 (C=N, imine) 





























Preparation of 71 
Product was obtained as a yellow 
crystalline solid in 88% yield 
M.p.: 145-147 C° 
1H NMR: (400 MHz, CDCl3) δH 8.65 (s, 2H, Hb), 7.51 (d, 2H, J = 1.6 Hz, Hf), 7.03 (t,  
                 2H, J = 7.8 Hz, Hd), 6.92(d, 2H, J = 1.6 Hz, J = 2.1 Hz, He), 4.00 (s, 4H,  
                  Ha), 3.85 (s, 6H, Hj), 3.77 (s, 6H, Hh) 
13C NMR: (400 MHz, CDCl3) δ 158.54 (Cb), 152.74 (Cg), 149.36 (Ci), 129.96 (Cc),  
                 124.04 (Ce), 118.88 (Cd), 114.24 (Cf), 61.91 (Cj), 61.67 (Ca), 58.85 (Ch) 
EA:          Calc. for C20H24N2O4: C, 67.40 %; H, 6.79 %; N, 7.86 %.  
                 Found:                        C, 67.19 %; H, 6.12 %; N, 7.72 %. 
IR (KBr): 1618 cm-1 (C=N, imine) 
EI-MS:      m/z 326.69 [M - CH3O]
+ 
 
Preparation of 72 
Product was obtained as a yellow crystalline solid in 
92% yield 
M.p.: 154-155 °C 
 
1H NMR: (400 MHz, CDCl3) δH 8.52 (s, 2H, Hb), 7.66 (s, 2H, Hd), 6.66 (s, 1H, He),  
                  3.93 (s, 4H, Ha), 3.87 (s, 6H, Hi), 3.85 (s, 6H, Hg), 3.83 (s, 6H, Hk) 
13C NMR: (400 MHz, CDCl3) δ 158.10 (Cb), 122.90 (Cd), 122.17 (Cc), 107.70 (Ce),  
                  62.01 (Ci), 61.81 (Ck), 60.87 (Ca), 56.03 (Cg) 
EA:          Calc. for C22H28N2O6: C, 63.45 %; H, 6.78 %; N, 6.73 %.  











































IR (KBr): 1625 cm-1 (C=N, imine) 
EI-MS:      m/z 386.44 [M - CH3O]
+ 
 
4.3 PREPARATION OF PALLADIUM COMPLEXES 
 
4.3.1 General procedure for synthesis of complexes 73 – 79: To a dry CH2Cl2 (10 ml) 
solution of the precursor Pd[COD]Cl2 (0.095 g, 0.3 mmol)  was added the calculated 
amount of iminophosphine in CH2Cl2 solution, and the reaction was stirred at room 
temperature for 1 hour. The yellow solution was then concentrated under reduced 
pressure to half volume and the addition of hexane caused precipitation of complexes, 
which were filtered off, washed with Et2O and drying under vacuum for 4 hours. 
Yellow crystals of the compounds 73 – 79 were obtained in high yield by 
recrystallization from CH2Cl2-hexane. 
 
Preparation of 73 [14] 
Product was obtained as a yellow crystalline solid in 70% 
yield 
M.p.: 158-160 °C 
1H-NMR: (400 MHz, CDCl3) δH 8.85 (s, 1H, Ha) 7.89 (m, 3H, ArH) 7.66 (dd, 4H, J =  
                 6.3 Hz, J = 7.9 Hz, ArH) 7.55 (ddd, 7H, J = 2.0 Hz, J = 5.2 Hz, J = 8.5 Hz,  
                ArH) 2.95 (dddd, 2H, J = 5.4Hz, J = 8.3Hz, J = 13.8 Hz, J = 16.7 Hz, Hb)  
                1.18 (m, 2H, Hc) 0.53 (t, 3H, J = 7.3 Hz, Hd)    
31P NMR: δ 30.85 (s)  
EA:          Calc. for C22H22Cl2NPd: C, 51.94 %; H, 4.36 %; N, 2.75 %.  





















IR (KBr): 1632 cm-1 (C=N, imine) 
EI-MS:      m/z 437.30 [M - 2Cl]+ 
 
Preparation of 74 [14] 
Product was obtained as a yellow crystalline solid in 82% 
yield 
M.p.: 168-170 ° 
1H-NMR: (400 MHz, CDCl3) δH 8.02 (s, 1H, Ha) 7.72 (m, 2H, ArH)  7.51 (m, 11H,  
                ArH) 6.94 (ddd, 1H, J = 0.5 Hz, J = 7.7 Hz, J = 10.6 Hz, Ar) 5.57 (dtd, 1H,  
                 J = 0.6 Hz, J = 6.4 Hz, J = 13.0 Hz, Hb)  1.16 (d, 6H, J = 6.6 Hz, Hc, Hd)   
31P NMR: δ 31.62 (s) 
EA:          Calc. for C22H22Cl2NPPd: C, 51.94 %; H, 4.36 %; N, 2.75 %.  
                 Found:                              C, 51.79 %; H, 4.12 %; N, 2.52 %. 
IR (KBr): 1634 cm-1 (C=N, imine) 
EI-MS:      m/z 474.68 [M - Cl]+ 
 
Crystals suitable for single crystal X-ray diffraction were obtained by slow 
evaporation of a dmso-d6-CH2Cl2 solution of the complex at room temperature. 
 
Preparation of 75 
Product was obtained as a yellow crystalline powder in 75% 
yield 
M.p.: 200-202 °C 
1H NMR: (400 MHz, dmso-d6) δH 8.74 (s, 1H, HC=N ) 7.58 (m, 14H ArH) 7.16 (m,  



























13C NMR: (400 MHz, dmso-d6) δ 169.31, 135.28, 133.94 (d, J CP = 11.0 Hz), 132.89,  
                  129.74 (d, JCP=11.8Hz), 128.90, 123.80, 28.73, 27.99, 24.31, 23.42 
31P NMR: δ 33.34 (s) 
EA:           Calc. for C31H32Cl2NPPd: C, 59.39 %; H, 5.15 %; N 2.23 %.  
                  Found:                              C, 59.19 %; H 5.12 %; N 2.42 %. 
IR (KBr): 1624 cm-1 (C=N, imine) 
EI-MS:      m/z 591.44 [M - Cl]+ 
 
Preparation of 76 
Product was obtained as a yellow powder in 76% 
yield 
M.p.: 200-202 °C  . 
1H-NMR: (400 MHz, d6-dmso ) δH 7.81 (m, 1H) 7.63 (m, 1H) 7.49 (m, 1H) 7.09 (m,  
               1H) 7.08 (m, 1H)  6.91 (dd, 1H, J = 4.6 Hz, J = 10.9 Hz) 6.49 (dd, 1H, J =  
                1.1 Hz, J = 8.1 Hz) 4.22 (t, 2H, J = 12.6 Hz)   
31P NMR: δ 34.11 (s) 
EA:           Calc. for C26H22Cl2NPPd: C, 56.09 %; H, 3.98 %; N, 2.52 %.  
                  Found:                              C, 56.26 %; H 3.72 %; N, 2.72 %. 
IR (KBr): 1627 cm-1 (C=N, imine) 
 
Preparation of 77 
Product was obtained as a yellow powder in 70% 
yield 
M.p.: 210-212 °C  . 
































                 (d, 1H, J = 3.8 Hz, Hf), 8.34 (s, 1H, Ha) 7.91 (dd, 1H, J = 4.1 Hz, J = 7.3  
                 Hz, He)  7.68 (m, 2H, ArH)  7.55 (dd, 4H, J = 6.7 Hz, J = 8.3 Hz, ArH)  
                 7.43 (m, 4H, ArH)  7.14 (m, 1H, Hd)  5.45 (s, 2H, Hb)     
31P NMR: δ 37.4 (s) 
EA:          Calc. for C25H21N2PPd: C, 53.84 %; H, 3.80 %; N 5.02 %.  
                 Found:                           C, 53.69 %; H 3.92 %; N 4.92 %. 
IR (KBr): 1626 cm-1 (C=N, imine) 
EI-MS:      m/z 557.75 [M]+ 
 
Preparation of 78 
Product was obtained as a yellow powder in 78% 
yield 
M.p.: 200-202 °C 
1H-NMR: (400 MHz, d6-dmso) 8.72 (s, 1H, Ha) 7.98 – 8.08 (m, 1H, ArH) 7.75(t, 1H,   
                 J = 1.5  Hz, J = 7.7 Hz, ArH) 7.58 (m, 2H, ArH)  7.45 (td, 4H, J = 2.9 Hz,  
                 4.8 Hz, ArH)  7.05 (dd, 1H, J = 8.1 Hz,  J = 1.8 Hz, Hf) 7.24 (m, 5H, ArH)  
                 6.55 (d, 1H, J = 2.9 Hz, He) 6.38 (dd, 1H, J = 2.9 Hz, Hd) 5.78 (t, 1H, J =  
                 1.5 Hz, J = 7.7 Hz, ArH) 5.56 (s, 2H, Hb)
31P NMR: δ 32.3(s) 
EA:           Calc. for C24H20Cl2NOPPd: C, 52.72 %; H, 3.69 %; N, 2.56 %.  
                  Found:                                 C, 52.59 %; H, 3.42 %; N, 2.72 %. 
IR (KBr): 1630 cm-1 (C=N, imine) 
EI-MS:      m/z 546.71 [M]+ 


























Preparation of 79 
Product was obtained as a yellow powder in 65% 
yield 
M.p.: 234-235 °C 
1H-NMR: (400 MHz, d6-dmso) δH 8.80 (s, 1H, Ha) 8.03 – 7.92 (m, 1H, ArH) 7.86 –   
                7.93 (m, 1H, ArH)  7.74 (m, 1H, ArH) 7.52 – 7.60 (m, 2H, ArH) 7.40 (td,  
                4H, J = 4.9 Hz, J = 2.9 Hz, ArH) 7.18 (dd, 4H, J = 7.8 Hz, J = 4.9 Hz, ArH)   
                6.99 – 7.07 (m, 2H, Hf) 6.90 (dd, 1H, J = 2.9 Hz, J = 2.0 Hz, Hd) 5.66 (s,  
                2H, Hb)    
31P NMR: δ 31.8(s) 
EA:           Calc. for C24H20Cl2NPPdS: C, 51.22 %; H, 3.58 %; N, 2.49 %, S, 5.70  
                  Found:                                 C, 51.48 %; H, 3.32 %; N, 2.72 %, S, 5.86 
IR (KBr): 1628 cm-1 (C=N, imine) 
EI-MS:      m/z 562.73 [M]+ 
 
Crystals suitable for single crystal X-ray diffraction were obtained by slow 
evaporation of a DMSOd6-CH2Cl2 solution of the complex at room temperature. 
 
4.3.2 General procedure for synthesis of complexes 80 – 83: To a dry CH2Cl2 (10 ml) 
solution of the precursor PdClMe[COD] (0.07 g, 0.27 mmol)  was added the 
calculated amount of iminophosphine in CH2Cl2 solution, and the reaction was stirred 
at room temperature for 1 hour. The yellow solution was then concentrated under 
reduced pressure to ca half the volume and the addition of hexane caused precipitation 
























4 hours. Yellow crystals of the compounds 80 – 83 were obtained in high yield by 
recrystallization from CH2Cl2-hexane. 
 
Preparation of 80 
Product was obtained as a pale yellow powder in 
85% yield 
M.p.: 168-170 °C 
1H-NMR: (400 MHz, CDCl3) δH 8.81 (s, 1H, Ha) 7.91 (dd, 1H, J = 4.3 Hz, J = 46.3  
                Hz, ArH) 7.83 (t, J = 7.6 Hz, ArH) 7.69 (t, 1H, J = 7.4 Hz, ArH) 7.56 (m,  
                2H, ArH) 7.45 (dt, 4H, J = 2.3Hz, 7.6Hz, ArH) 7.29 (m, 1H, ArH)  7.18 (m,  
                8H, ArH) 7.09 (dd, 1H, J = 7.7Hz, J = 10.5 Hz, ArH) 5.10 (s, 2H, Hb) 0.18  
               (d, 3H, J = 1.2 Hz, CH3)    
31P NMR: δ 38.5 (s) 
EA:           Calc. for C27H25ClNPPd: C, 60.46 %; H, 4.70 %; N, 2.61 %.  
                  Found:                              C, 60.72 %; H, 4.51 %; N, 2.81 %. 
IR (KBr): 1628 cm-1 (C=N, imine) 
EI-MS:      m/z 521.75 [M - CH3]
+ 
 
Crystals suitable for single crystal X-ray diffraction were obtained by slow 
evaporation of a DMSOd6-CH2Cl2 solution of the complex at room temperature. 
 
Preparation of 81 
Product was obtained as a pale yellow powder in 
85% yield 

































1H NMR: (400 MHz, CDCl3) δH 8.80 (d, 1H, J = 1.6 Hz, Hf) 8.63 (s, 1H, Ha)  8.47  
               (dd, 1H, J = 1.6 Hz, J = 4.8 Hz, Hg) 7.88 (ddd, 1H, J = 1.3 Hz, J = 4.1 Hz, J  
                = 7.6 Hz, ArH) 7.66 (m, 2H, ArH) 7.79 (tt, 1H, J = 1.4 Hz, J = 7.6 Hz, ArH)  
                7.52 (m, 2H, ArH) 7.39 (ddd, 4H, J = 2.0 Hz, J = 5.1 Hz, J = 7.3 Hz, ArH )  
                5.41 (s, 2H, Hb) 7.11 (m, 6H) 0.26 (d, 3H, J = 3.3Hz, CH3)             
31P NMR: δ 37.4 (s) 
EA:           Calc. for C26H24ClN2PPd: C, 58.12 %; H, 4.50 %; N, 5.21 %.  
                  Found:                              C, 58.19 %; H, 4.12 %; N, 5.54 %. 
IR (KBr): 1628 cm-1 (C=N, imine) 
EI-MS:      m/z 537.13 [M]+ 
 
Preparation of 82 
Product was obtained as a pale yellow powder in 
75% yield. 
M.p.: 195-196 °C 
1H-NMR: (400 MHz, CDCl3) δH 8.65 (s, 1H, Ha) 7.86 (ddd, 1H, J = 1.2 Hz, J = 4.1  
                 Hz, J = 7.4 Hz, ArH) 7.77 (t, 1H, J = 7.5 Hz, ArH) 7.66 (t, 1H, J = 7.5 Hz,  
                 ArH)  7.51 (m, 6H, ArH) 7.34 (m, 4H, ArH)   7.18 (m, 1H, Hf ) 6.43 (m,  
                 1H, Hd) 5.39 (s, 2H, Hb) 0.23 (d, 3H, J = 3.2 Hz, CH3)    
31P NMR: δ 37.6 (s) 
EA:          Calc. for C25H23ClNOPPd: C, 57.07 %; H, 4.40 %; N, 2.66 %.  
                 Found:                                C, 57.19 %; H, 4.12 %; N, 2.72 %. 
IR (KBr): 1631 cm-1 (C=N, imine) 

























Preparation of 83 
Product was obtained as a pale yellow powder in 
80% yield. 
M.p.: 186-188 °C 
1H-NMR: (400 MHz, CDCl3) δH 8.76 (s, 1H, Ha) 7.87 (m, 1H)  7.80 (t, 1H, J = 7.5  
                 Hz) 7.69 (t, 1H, J = 7.5 Hz, Hf) 7.54 (dd, 2H, J = 6.5 Hz, J = 8.2 Hz, ArH)   
                 7.44 (m, 5H, ArH) 7.17 (td, 5H, J = 6.1 Hz, J = 12.2 Hz, ArH) 7.07 (d, 1H,  
                 J = 2.4 Hz, He) 6.96 (dd, 1H,  J = 3.5Hz, J = 5.1Hz, Hd)   5.57 (s, 2H, Hb)   
                 0.25 (d, 3H, J = 3.3Hz, CH3)   
31P NMR: δ 37.6 (s) 
EA:         Calc. for C25H23ClNPPdS: C, 55.36 %; H, 4.27 %; N, 2.58 %; S, 5.91  
                Found:                               C, 55.19 %; H, 4.08 %; N, 2.38 %; S, 6.05  
IR (KBr): 1629 cm-1 (C=N, imine) 
EI-MS:      m/z 531.8 [M - CH3]
+ 
 
4.4 PREPARATION OF PLATINUM COMPLEXES 
 
4.4.1 General procedure for synthesis of complexes 84 – 88: To a dry DCM (10 ml) 
of the appropriate ligand (60 - 64) was added an equimolar amount of Pt[COD]Cl2 or 
Pt[DMSO]2Cl2 also in dry CH2Cl2 (10 ml). The reaction was allowed to stir at room 
temperature for 4 hours before reducing the solvent to ca 5 ml and precipitating out 
the products with hexane, filtering under gravity and washing the precipitate with 



























Preparation of 84 
Product was obtained as a yellow powder in 76% yield 
M.p.: 201-203 °C  . 
1H NMR: (400 MHz, CDCl3) δH 8.95 (d, 1H, J = 111.3 Hz)  
                 8.18 (dd, 1H,  J = 4.2 Hz, J = 9.0 Hz) 7.90 (m, 2H) 7.60 (m, 10H) 7.18 (m,  
                4H) 3.01 (m, 2H) 1.24 (d, 6H, J = 6.8 Hz) 0.83 (d, 6H, J = 6.8 Hz)   
31P NMR: δ 5.83 J(Pt-P) = 3661 Hz 
EA:         Calc. for C31H32Cl2NPPt: C, 52.03 %; H, 4.51 %; N 1.96 %   
                Found:                              C, 52.19 %; H 4.74 %; N 1.99 %  
IR (KBr): 1624 cm-1 (C=N, imine) 
EI-MS:      m/z 678.34 [M - Cl]+ 
 
Crystals suitable for X-ray structure determination were obtained by recrystallisation 
form a CH2Cl2-hexane mixture at room temperature.  
 
Preparation of 85 
Product was obtained as a light yellow powder in 
65% yield 
M.p.: 180-183 °C 
1H-NMR: (400 MHz, CDCl3) δH 7.79 (m, 1H) 7.60 (t, 1H, J = 7.4 Hz) 7.47 (t, 1H,  
                 J = 7.4 Hz) 7.07 (t, 1H, J = 8.6 Hz)   6.90 (t, 1H, J = 7.7 Hz) 6.49 (d, 1H,  
                 J = 7.2 Hz) 4.13 (t, 1H, J = 12.8 Hz)     
31P NMR: δ 8.09 J(Pt-P)=3668 Hz 
EA:         Calc. for C26H22Cl2NPPt: C, 48.38 %; H, 3.44 %; N 2.17%;  


























IR (KBr): 1632 cm-1 (C=N, imine) 
EI-MS:      m/z 609.36 [M - Cl]+ 
 
Preparation of 86 
Product was obtained as a yellow powder in 76% 
yield 
M.p.: 168-169 °C   
1H-NMR: (400 MHz, CDCl3) δH 9.19 (m, 1H) 8.64 (m, 1H) 8.53 (d, 1H, J = 4.3Hz)  
                 8.05 (dd, 1H, J = 4.1 Hz, J = 6.9 Hz) 7.92 (t, 1H, J = 7.5 Hz) 7.84 (t, 1H,  
                 J = 7.4 Hz) 7.60 (m, 2H) 7.41 (m, 3H)  7.09 (m, 5H)  5.80 (d, 2H, J = 18.7  
                 Hz)        
31P NMR: δ 8.44 J(Pt-P) = 3469.9 Hz 
EA:         Calc. for C25H21Cl2N2PPt: C, 46.45 %; H, 3.27 %; N 4.33 %;  
                Found:                               C, 46.19 %; H 3.12 %; N 4.72 %;  
IR (KBr): 1630 cm-1 (C=N, imine) 
EI-MS:      m/z 610.92 [M - Cl]+ 
Crystals suitable for X-ray structure determination were obtained by recrystallisation 
form a CH2Cl2-hexane mixture at room temperature.  
 
Preparation of 87 
Product was obtained as a dark yellow powder in 72% 
yield 
M.p.: 198-199 °C  . 
1H NMR: (400 MHz, CDCl3) δH 9.06 (m, 1H) 8.02 (m, 1H) 7.88 (td, 2H, J = 7.4 Hz,  




































                J = 15.4 Hz, J = 23.5 Hz, J = 30.5 Hz)  6.55 (m, 2H)  5.80 (d, 2H, J =  
                13.0 Hz)   
31P NMR: δ 5.66 J(Pt-P) = 3777.6 Hz 
EA:         Calc. for C24H20Cl2NOPPt: C, 48.83 %; H, 3.77 %; N 2.28 %;  
                Found:                                C, 48.69 %; H 3.52 %; N 2.52 %;  
IR (KBr): 1633 cm-1 (C=N, imine) 
EI-MS:      m/z 599.91 [M - Cl]+ 
 
Preparation of 88 
Product was obtained as a pale yellow powder in 72% 
yield 
M.p.: 201-203 °C 
1H  NMR: (400 MHz, CDCl3 ) δH 8.73 (s, 1H) 7.86 (m, 1H) 7.60 (m, 1H) 7.44 (m,  
                  1H) 7.24 (dd, 1H, J = 1.2 Hz, J = 5.1 Hz) 7.06 (ddd, 1H, J = 1.6Hz, J =  
                  7.2Hz, J = 10.6 Hz) 6.77 (dd, 1H, J = 3.4 Hz, J = 5.1 Hz) 6.50 (dd, 1H, J =  
                 1.0 Hz, J = 3.4 Hz) 4.77 (t, 1H, J = 7.4 Hz) 
 31P NMR: δ 8.06 J (Pt-P)=3758.5 Hz 
EA:          Calc. for C24H20Cl2NPPtS: C, 44.25 %; H, 3.09 %; N, 2.15%; S, 4.92  
                 Found:                                C, 44.19 %; H, 3.12 %; N, 2.42 %; S, 5.03  
IR (KBr): 1631 cm-1 (C=N, imine) 
EI-MS:      m/z 616.01 [M - Cl]+ 
 
Crystals suitable for X-ray structure determination were obtained by recrystallisation 

























4.4.2 General procedure for synthesis of complexes 89 – 90 
 
To a dry CH2Cl2 (10 ml) of the appropriate ligand (63 - 64) was added an equimolar 
amount of PtClMe[COD]Cl2 also in dry CH2Cl2 (10 ml). The reaction was allowed to 
stir at room temperature for 4 hours before reducing the solvent to ca 5 ml and 
precipitating out the products with hexane, filtering under gravity, washing the 
precipitate with Et2O and drying under vacuum for 4 hours. 
 
Preparation of 89 
Product was obtained as a pale yellow powder in 
73% yield. 
M.p.: 220-221 °C 
1H-NMR: (400 MHz, dmso-d6) δH 9.005 (s, 1H, Ha) 7.99 (ddd, 2H, J = 1.5 Hz, J = 4.0  
                 Hz, J = 7.1 Hz, ArH) 7.77 (m, 1H, ArH) 7.51 (m, 1H, ArH) 7.33 (dd, 1H, J  
                  = 0.9 Hz, J = 1.8 Hz, ArH) 7.23 (m, 1H, ArH) 7.12 (ddd, 1H, J = 3.6 Hz, J  
                  = 10.1 Hz, J = 8.8 Hz, ArH) 6.53 (dd, 1H, J = 0.6 Hz, J = 3.2 Hz, Hd) 6.41  
                  (m, 1H, He) 5.785 (s, 2H, Hb) 0.19 (d, 3H, J = 3.7 Hz, CH3) 
31P NMR: δ 9.28 J(Pt-P) = 3782.6 Hz 
EA:         Calc. for C25H23ClNOPPt: C, 47.44 %; H, 3.98 %; N, 2.21 %;  
                Found:                               C, 47.29 %; H, 3.69 %; N, 2.08 %;  
IR (KBr): 1625 cm-1 (C=N, imine) 




























Preparation of 90 
Product was obtained as a pale yellow powder in 
75% yield. 
M.p.: 230-233 °C 
1H-NMR: (400 MHz, dmso-d6) δH 8.73 (s, 1H, Ha) 7.69 (m, 10H, ArH) 7.17 (m, 2H,  
                ArH) 6.90 (dd, 1H, J = 3.5 Hz, J = 5.1 Hz, ArH) 6.75 (ddd, 1H J = 3.4 Hz, J  
                = 5.1 Hz, J= 12.1 Hz, Hf) 6.51 (dd, 1H J = 1.0 Hz, J = 3.4 Hz, Hd), 6.46  
               (dd, 1H J= 1.0 Hz, J = 3.4 Hz, He) 5.824 (s, 2H, Hb) 0.31 (dd, 3H J = 3.7  
                Hz, J = 40 Hz, CH3)  
31P NMR: δ 8.20 (s) J (Pt-P) = 3748 Hz 
EA:         Calc. for C25H23ClNOPPt: C, 48.58 %; H, 3.67 %; N, 2.15 %; S, 4.92 % 
                Found:                               C, 48.26 %; H, 3.83 %; N, 2.28 %; S, 4.88 % 
IR (KBr): 1627 cm-1 (C=N, imine) 
EI-MS:      m/z 595.45 [M - Cl]+ 
 
4.5 PREPARATION OF GOLD COMPLEXES 
 
4.5.1 General procedure for synthesis of complexes 91 – 94: To a dry CH2Cl2 (10 ml) 
of the appropriate ligand (60, 62 - 64) or PPh3 for 95 was added Au(tht)Cl also in dry 
CH2Cl2 (10 ml) in a ratio of 1 : 0.9. The reaction was allowed to stir at room 
temperature for 2 hours before reducing the solvent to ca 5 ml and precipitating out 
the products with hexane, filtering under gravity and washing the precipitate with dry 


























Preparation of 91 
Product was obtained as a pale yellow powder in 73% 
yield. 
M.p.: 200-201 °C   
1H-NMR: (400 MHz, CDCl3) δH 8.90 (s, 1H, Ha) 8.41 (dd,  
                 1H, J = 4.5 Hz, J = 7.2 Hz, ArH) 7.60 (t, 1H, J = 7.5 Hz, ArH)   7.41 (m,  
                 11H, ArH) 6.94 (m, 3H, ArH) 6.79 (dd, 1H, J = 7.8Hz,  J = 13.2Hz, He)  
                 2.47 (td, 2H, J = 6.8Hz, J = 13.7Hz, -CHMe2)  0.89 (d, 12H, J = 6.8Hz, - 
                 CHMe4) 
31P NMR: δ 26.64 (s) 
EA:         Calc. for C31H32AuClNP: C, 54.60 %; H, 4.73 %; N, 2.05 %;  
                Found:                              C, 54.88 %; H, 4.57 %; N, 1.97 %;   
IR (KBr): 1628 cm-1 (C=N, imine) 
EI-MS:      m/z 449.31 [M – Cl - Au]+ 
 
Crystals suitable for X-ray structure determination were obtained by recrystallisation 
form a CH2Cl2-hexane mixture at room temperature.  
 
Preparation of 92 
Product was obtained as an off-white powder in 53% 
yield. 
M.p.: 215-217 °C  . 
1H-NMR: (400 MHz, CDCl3) δH 8.64 (s, 1H, Ha) 8.33 (d, 1H, J = 4.5 Hz, Hg) 8.28 (d,  
                 1H, J = 5.8 Hz, Hf) 8.04 (m, 1H, ArH) 7.78 (m, 1H, Hd) 7.55 (m, 1H, ArH)  


































                 ArH) 6.79 (dt, 1H, J = 8.3 Hz, J = 13.6 Hz, ArH) 4.70 (s, 1H, ArH) 4.60 (s,  
                 2H, Hb) 
31P NMR: δ 31.38 (s) 
EA:         Calc. for C25H21AuClN2P: C, 49.00 %; H, 3.45 %; N, 4.57 %;  
                Found:                               C, 49.22 %; H, 3.23 %; N, 4.54 %;  
IR (KBr): 1630 cm-1 (C=N, imine) 
 
Preparation of 93 
Product was obtained as a pale yellow powder in 
59% yield. 
M.p.: 220-221 °C  . 
1H-NMR: (400 MHz, CDCl3) δH 8.54 (d, 1H, J = 1.4 Hz, Ha) 7.82 (dd, 2H, J = 4.8 Hz,        
                   J = 7.1 Hz, ArH) 7.37 (m, 3H, ArH) 7.17 (m, 2H, ArH) 7.13 (dd, 4H,  
                  J = 0.8 Hz, J = 1.8 Hz, ArH) 6.75 (dd,2H, J = 7.8 Hz, J = 13.1 Hz, Hf)  
                  6.13 (dd, 1H, J = 1.9 Hz, J = 3.1 Hz, He) 5.91 (d, 1H, J = 3.2 Hz, Hd)  4.53    
                 (s, 2H, Hb)   
31P NMR: δ 30.51 (s) 
EA:         Calc. for C24H20AuClNOP: C, 46.90 %; H, 3.35 %; N, 2.33 %;  
                Found:                                 C, 46.77 %; H 3.48 %; N, 2.09 %;  
IR (KBr): 1634 cm-1 (C=N, imine) 


























Preparation of 94 
Product was obtained as an off-white powder in 55% 
yield. 
M.p.: 230-232 °C  . 
1H-NMR: (400 MHz, CDCl3) δH 8.59 (d, 1H, J = 1.4 Hz, Ha) 8.35 (m, 1H, ArH) 7.84  
                (m, 2H, ArH) 7.68 (dd, 3H, J = 4.6 Hz, J = 7.2 Hz, ArH) 7.39 (m, 2H, ArH)   
                7.17 (m, 4H, ArH)   7.04 (dd, 2H, J = 1.1 Hz, J = 5.1 Hz, ArH) 6.96 (dd,  
                1H, J = 1.1 Hz, J = 5.1 Hz, Hf)  6.77 (m, 1H, He)  6.55 (m, 1H, Hd) 4.74 (s,  
                2H, Hb)                                  
31P NMR: δ 31.93 (s) 
EA:         Calc. for C24H20AuClNPS: C, 46.65 %; H, 3.26 %; N, 2.27 %; S, 5.19  
                Found:                                C, 46.80 %; H, 3.42 %; N, 2.45 %; S, 4.97  
IR (KBr): 1635 cm-1 (C=N, imine) 
EI-MS:      m/z 581.38 [M - Cl]+ 
 
Preparation of 95 [18] 
Product was obtained as a white powder in 98% yield. 
M.p.: > 240 °C 
1H-NMR: (400 MHz, CDCl3) δH 7.48 (m, 15H, ArH) 
13C NMR: (400 MHz, CDCl3) δ 134.20, 134.02, 131.98, 131.95, 129.29, 129.14  
31P NMR: δ 32.95 (s) 
EA:         Calc. for C18H15ClPAu:       C, 43.70 %; H, 3.06 % 
                Found:                                 C, 43.39 %; H, 3.12 % 
IR (KBr): 1625 cm-1 (C=N, imine) 





























Summaries of crystal data and collection parameters of crystal structures of ligands 
65, 66 and 68 are given in Table 4.1. Those of complexes 74, 79 and 80 in Table 4.2, 
84, 86 and 88 in Table 4.3, 91, 93 and 94 in Table 4.4. 
 
X-ray single crystal intensity data for structures were collected on a Nonius Kappa-
CCD diffractometer using graphite monochromated MoKα radiation (λ = 0.71073 Å). 
Temperature was controlled by an Oxford Cryostream cooling system (Oxford 
Cryostat). The strategy for the data collections was evaluated using the Bruker Nonius 
"Collect” program. Data were scaled and reduced using DENZO-SMN software 
(Otwinowski & Minor, 1997). An empirical absorption correction using the program 
SADABS (Sheldrick, 1996) was applied.  
   
The structures were solved by direct methods and refined employing full-matrix least-
squares with the program SHELXL-97 (Sheldrick, 1997) refining on F2. Packing 





















Table 4.1: Crystallographic data for ligands 65, 66 and 68  
 65 66 68 
Empirical formular C34H30N4O2S4 C20H20N2S2 C22H22N4 
Formular weight 654.86 352.52 342.44 
T/K 173(2) 173 173(2) 
λ/Å 0.7103 0.7103 0.71073 
Space group Triclinic Monoclinic Monoclinic 
a 8.8517(3) 9.8592(10) 6.0078(6) 
b 10.3937(5) 7.1533(3) 26.023(3) 
c 10.5763(4) 25.678(2) 6.1319(7) 
α(deg) 63.836(2) 90 90 
β(deg) 69.023(2) 96.646(5) 106.009(2) 
γ(deg) 72.394(2) 90 90 
V(Å3) 803.22(6) 1798.8(3) 921.47(17) 
Z 1 8 2 
Densitycalc(mg/ml) 1.354 1.302 1.234 
Absorption coefficient (mm-1) 0.334 0.299 0.075 
F(000) 342 744 364 
Crystal size (mm) 0.22x0.20x0.13 0.04x0.20x0.22 0.26x0.24x0.17 
Theta range for data 
collection (deg) 
2.50 – 26.44 3.2 – 28.3 3.13 – 28.34 






Reflections Collected/ Unique 3283 / 3283 [R(int) = 
0.0000] 
16248 / 2230 [R(int) = 
0.045] 
11941 / 2288 [R(int) = 0.0238 
Completeness of theta max. 
and min. transmission 
26.44 (99.2%) 28.3 (99.8%) 28.34 (99.9%) 




Full-matrix least-squares on 
F2 
Data / Restraints/ Parameters 3283 /0 / 199 2230/0/109 2288 / 0 / 118 















Table 4.2: Crystallographic data for palladium complexes 74, 79 and 80  
 74 79 80 
Empirical formular C24H28Cl2NOPPdS C24H20Cl2NPPdS C27H25ClNPPd 
Formular weight 586.81 562.74 536.30 
T/K 173(2) 173(2) 173(2) 
λ/Å 0.71073 0.71073 0.7103 
Space group Triclinic Monoclinic Monoclinic 
a 8.9935(2) 9.8892(5) 10.0147(8) 
b 10.0413(2) 21.6512(12) 21.8935(18) 
c 13.9439(3) 10.7050(6) 10.7478 
α(deg) 91.189(10) 90 90 
β(deg) 97.957(10) 94.7860(10) 94.192(2) 
γ(deg) 94.869(10) 90 90 
V(Å3) 1241.93(5)) 2284.1(2) 2350.2(3) 
Z 2 4 4 
Densitycalc(mg/ml) 1.569 1.637 1.516 
Absorption coefficient (mm-1) 1.128 1.220 0.986 
F(000) 596 1128.0 1088 
Crystal size (mm) 0.05x0.1x0.20 0.10x0.26x0.46 0.03x0.12x0.13 
Theta range for data collection 
(deg) 
3.0 – 28.7 1.9 – 30.7 2.1 – 28.3 







Reflections Collected/ Unique 45019 / 6342 [R(int) = 
0.057] 
50973 / 7032 [R(int) = 
0.021] 
32545 / 5809 [R(int) = 0.043] 
Completeness of theta max. and 
min. transmission 
28.66 (99.2%) 30.670 (99.5%) 28.25 (99.6%) 
Refinement method Full-matrix least-
squares on F2 
Full-matrix least-squares 
on F2 
Full-matrix least-squares on 
F2 
Data / Restraints/ Parameters 6342 /0 / 284 7032 / 0 / 271 6590 / 8/ 270 















Table 4.3 Crystallographic data for platinum complexes 84, 86 and 88  
 84 86 88 
Empirical formular C31H32Cl2NPPt C25H21Cl2N2PPt C25H24Cl2NOPtS 
Formular weight 715.54 646.40 683.47 
T/K 173(2) 173(2) 173(2) 
λ/Å 0.71073 0.71073 0.7103 
Space group Monoclinic Triclinic Monoclinic 
a 12.0686(7) 9.9684(14) 9.9635 
b 13.4007(7) 10.4129(15) 19.0185 
c 17.8182 12.526(3) 13.5321 
α(deg) 90 97.687(5) 90 
β(deg) 105.8190(10) 98.363(5) 95.5100(10) 
γ(deg) 90 114.499(3) 90 
V(Å3) 2772.6(3) 1143.1(4) 2552.4(3) 
Z 4 2 4 
Densitycalc(mg/ml) 1.714 1.878 1.779 
Absorption coefficient (mm-1) 5.333 6.457 5.869 
F(000) 1408 624 1328 
Crystal size (mm) 0.22x0.11x0.09 0.07x0.06x0.04 0.08x0.05x0.03 
Theta range for data collection 
(deg) 
1.83 – 29.60 2.20 – 27.09 2.14 – 28.72 






Reflections Collected/ Unique 40326 / 7788 [R(int) = 
0.0000] 
16090 / 4994 [R(int) = 
0.0580] 
30138 / 6590 [R(int) = 
0.0524] 
Completeness of theta max. and 
min. transmission 
29.6 (99.9%) 27.09 (99.3%) 28.72 (99.7%) 
Refinement method Full-matrix least-squares 
on F2 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Data / Restraints/ Parameters 7788 /0 / 326 4994 / 0 / 280 6590 / 8/ 270 















Table 4.4 Crystallographic data for gold complexes 91, 93 and 94  
 91 93 94 
Empirical formular C32H35AuClNP C24H20AuClNOP C25H22AuClNPS 
Formular weight 705.00 601.80 631.88 
T/K 173(2) 173(2) 173(2) 
λ/Å 0.7103 0.71073 0.71073 
Space group Triclinic Monoclinic Monoclinic 
a 13.0315(3) 13.4559(4) 11.866(2) 
b 13.3638(2) 10.3917(2) 10.625(2) 
c 19.3489(5) 17.2641(4) 36.452(7) 
α(deg) 96.358(2) 90 90 
β(deg) 99.2290(10) 111.751(10) 92.63(3) 
γ(deg) 116.1910(10) 90 90 
V(Å3) 2921.15(11) 2242.16(10) 4590.9(15) 
Z 4 4 4 
Densitycalc(mg/ml) 1.603 1.783 1.829 
Absorption coefficient (mm-1) 5.205 6.766 6.699 
F(000) 1396 1160 2448 
Crystal size (mm) 0.21x0.18x0.12 0.02x0.011x0.16 0.06x0.13x0.14 
Theta range for data collection 
(deg) 
2.31 – 26.38 2.20 – 27.09 1.8 – 29.1 






Reflections Collected/ Unique 119370 / 11941 [R(int) = 
0.0534] 
74304 / 5534 [R(int) = 
0.0680] 
115921 / 12327 [R(int) = 
0.115] 
Completeness of theta max. 
and min. transmission 
26.38 (99.8%) 28.28 (99.7%) 29.13 (99.7%) 
Refinement method Full-matrix least- squares 
on F2 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Data / Restraints/ Parameters 11941 / 9/ 604 4994 / 0 / 280 6590 / 8/ 270 
















4.7 BIOLOGICAL STUDIES 
 
Biological studies were carried out in the Cancer Laboratory (Prof Hendricks and Dr 
Leaner) in the Division of Medical Biochemistry in the Faculty of Health Sciences at 
the University of Cape Town. Unless otherwise stated, all chemicals were AnalR 
grade, and purchased from Sigma or Merck. 
 
4.7.1 Cell Culture 
 
All cell lines were maintained at 37 °C, in a 5 % CO2, humidified incubator. 
 
 
4.7.1.1 Cell lines and media requirements 
 
The human oesophageal cancer cell line WHCO1 derived from a South African 
patient with squamous cell carcinoma of the oesophagus was obtained from Prof 
Veale [20]. The human oesophageal cancer cell line KYSE450 was derived from a 
Japanese patient with squamous cell carcinoma of the oesophagus and was purchased 
from DSMZ . DMB cells are primary fibroblasts derived from a skin biopsy obtained 
from a normal subject. 
 
Table 4.5 Cell lines and media requirements 
Cell line 
 




























4.7.1.2 Subculturing protocols 
 
All cell lines were subcultured by removing media, rinsing once with 2 ml PBS (or 
0.5 % trypsin), then trypsinising with 3 ml trypsin. Once cells had rounded, 3 ml of 
media were added to neutralize the trypsin, and cells were centrifuged out of the 
trypsin:media mix. Cells were then suspended in media and a portion added to a fresh 
dish in a 1 in 6 split ratio. 
 
4.7.1.3 Freezing and thawing protocols 
 
For all cell lines, a confluent dish was trypsinised, neutralized with complete media, 
then cells were centrifuged out of the trypsin/media solution. Cells were resuspended 
in 3-4 ml of cold (4 °C) freezing media (70% DMEM, 20% Fetal Calf Serum, 10% 
DMSO), and aliquoted into cryotubes (1 ml per tube). Tubes were placed in -70 °C 
overnight and then transferred to liquid nitrogen. Cells are thawed by placing the 
tubes in a water bath at 37 °C for ca 2 min.  
 
4.7.1.4 Mycoplasma test 
  
All cell lines were tested for mycoplasm contamination every three months. Cells 
were grown in culture media free of antibiotics for at least one week, then trypsinised 
and plated onto coverslips in 60 mm dishes. Following an overnight incubation to 
allow cells to settle onto coverslips, 5 ml fixative was added to the culture media, then 
discarded and replaced with another 2-5 ml fixative. The cells were then immediately 












mycoplasm staining solution was added for 30 seconds and then thoroughly washed 
with water. Finally the coverslip was mounted on a slide, using a drop of mounting 
fluid, and cells were observed using fluorescence microscopy. Cell nuclei stain bright 
green, and mycoplasm contamination is visualized as minute punctate fluorescence 
distributed throughout the cytoplasm [21]. 
 
4.8 Cytotoxicity screening 
 
4.8.1 MTT assay 
 
1500 cells were seeded per well in 90 µl DMEM in 96 well plates. Cells were 
incubated for 24 hours, then test samples were plated at a range of concentrations in 
10µl media, with a final concentration of 0.2 % DMSO. After 48 hours of incubation, 
the cells were observed under a phase contrast microscope and the general appearance 
of the cells together with confluency status and presence of precipitate if any was 
recorded. 
 
10 µl of MTT reagent was added per well at the end of the experiment, and the plates 
incubated for 4 hours at 37 °C. 100 µl of solubilisationsolution was then added to 
each well, and plates were incubated at 37 °C overnight. After 16 hours, the plates 
















4.8.2 IC50 data analysis 
 
The resulting dose-response curve was analysed by non-linear regression analysis 
(Non-linear regression (Sigmoidal dose response with variable slope)) using 
GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego 
Carlifornia USA, www.graphpad.com) to yield an IC50 value which is specific for the 
compound against that particular cell line. The formular used is as follows:                                     
                                     
                    (top- bottom) 
              ___________________ 
Y = bottom +    1 + 10(logIC50
 – X) x hillslope 
 
Where Y is the absorbance reading, X is the concentration of the compound, top is the 
maximum absorbance, bottom is the minimum absorbance ( also the absorbance of the 
medium blank), and the hillslope is the gradient of the curve. 
 
All experiments were done three times and all experimental points within an 
experiment were done in triplicate. 
 
4.9 Cell cycle analysis 
 
Cells were seeded in 60 mm dishes at 0.25 x 106 cells per dish. Following an 
overnight settling period, compounds were added to culture media (to avoid the loss 
of cycling cells that had detached during division). At appropriate time points, cells 
were harvested by trypsinisation (taking care to collect all washes to avoid discarding 
floating cells), resuspended in 1 ml PBS, and counted. 9 ml of ice cold 100% EtOH 
was then added to each sample, and samples were stored at -20 °C for up to 2 weeks. 












cells/ml were incubated in 50 µg/ml RNAse A in PBS for 30 minutes at room 
temperature. Cell Cycle Staining solution was added to bring the cell concentration to 
1x106 cells/ml, and following a 30 minute incubation in the dark, cells were analysed 
on a Beckman Coulter FACS-calibur flow cytometer. Analysis of cell cycle results 
was carried out using ModFit 3.0 (Verity Software House).  
 
4.10 Western blotting 
 
Cells prepared for western blotting were routinely plated at 500 000 cells/ 60 mm 
dish. Cells were incubated for 24 hours, then treated with the indicated concentrations 
of compounds for the indicated times 
 
 
4.10.1 Protein harvest 
 
Media was removed from the cells and the cells rinsed with cold 1xPBS twice. 60 µl 
RIPA buffer with protease and phosphatase inhibitors, was added to the dish, and cells 
were lysed manually with a cell scraper. The lysate was transferred to a clean 
eppendorf tube and placed on ice.  
 
4.10.2 Protein quantitation 
 
The lysates were thawed and sonicated at 4 °C. Protein quantitation was performed in 
96 well plates using the BCA kit (Pierce). Various volumes of lysate were pipetted 
into each well in duplicate, and made up to 10 µl with RIPA buffer. 10 µl of each 
BSA standard (range 0.1 mg/ml to 2 mg/ml) were pipetted in duplicate for a standard 












kit were mixed at a 1:50 ratio, and 100 µl of this solution was added to each well. 
Following a 30 minute incubation at 37 °C, the absorbance at 595 nm was measured 
on an Anthos microplate reader 2001. A standard curve was plotted using Prism, and 
the protein concentrations of the samples were calculated from this curve.  
 
4.10.3 SDS-PAGE 
10% Acrylamide gels with 5% stacking gel were poured using the Protean II minigel 
casting apparatus (BioRad). Protein samples were prepared by mixing equal amounts 
of protein with loading dye, and boiled for 10 minutes to denature the proteins. 
Samples were loaded onto the SDS-PAGE, and the gel was run at 100 volts. 




SDS-PAGE gels were removed from between the glass plates, and the transfer 
apparatus was assembled. Protein was transferred from the gel onto the nitrocellulose 
membrane, and these were sandwiched between filter paper and sponges, and inserted 
into a transfer cassette. The cassette and an ice pack were inserted into the transfer 
apparatus, which was filled with transfer buffer, and transfer was carried out at 200 
volts for 1 hour. 
 
4.10.5 Ponceau S (membrane) and Coomasie (gel) stains 
Following transfer, membranes were stained with Ponceau-S for 10 minutes, then 













4.10.6 Washes, blocking and primary antibody 
Following Ponceau-S staining, membranes were washed with TBS/0.1% Tween, and 
then blocked in blocking solution. Blocking solution was discarded, and the 
membrane was then washed with TBS/0.1% Tween, with shaking for three sets of 5 
minutes, changing TBS/0.1% Tween each time. Primary antibody was added in the 
appropriate buffer and incubated with shaking overnight at 4 °C. 
 
4.10.7 Secondary antibody 
The primary antibody was removed from the membrane, and the membrane was again 
washed for three sets of 5 minutes, chaging TBS/0.1% Tween each time. The 
secondary antibody was removed, and a final set of 5 minute washes with TBS0.1%/ 
Tween were performed to remove excess antibody. Detection reagent was added, and 
light emission was detected on X-ray film. The bands were visualized by developing 
the film in developer for 1 minute, washing for 1 minute with water, then fixed for 5 
minutes in fixative. 
 
4.11 Prepared Solutions 
 
4.11.1 Cell culture 
 
Cell-freezing media 
70 % DMEM 
20 % Fetal Calf Serum 
10 % DMSO 
 
MTT (5 mg/ml) 












20 ml 1 X PBS 
Vortex and incubate at 37 °C for 15 min 
Filter through a 0.2 µm filter  
Wrap in foil and store at 4 °C for up to one month 
 
Solubilisation Reagent for MTT assay  
25 g of Sodium Lauryl Sulphate (SLS) 
Make up to 250 ml with dH2O 
Add 76.6 µl conc. HCl 
 
Trypsin-EDTA 
0.5 g trypsin 
8 g NaCl 
1.45 g Na2HPO4.2H2O 
0.2 g KCl 
0.2 g KH2PO4 
10 mM EDTA (pH8.0) 
Make up to 1 L with PBS 
 
PBS 
40 g NaCl 
1 g KCl 
1.6 g Na2HPO4.2H2O (pH7.4) 
1 g KH2PO4 













Add 5 million units Penicillin G Sodium to 5 ml PBS. Add 5 g 214S Streptomycin to 
15 ml PBS. Combine the two and make volume up to 500 ml. Aliqout 5 ml volumes. 
Add 5 ml to each 500 ml media. 
 
Mycoplasm detection fixative 
1 part glacial acetic acid to 3 parts methanol 
 
Mycoplasm detection Stain solution 
0.5 µg/ml Hoeschst No. 33258 in Hanks Buffered Saline Solution (without phenol red 
or sodium bicarbonate. Store in the dark/covered bottle at 4 °C and examine 
periodically for contamination. 
 
Mycoplasm detection Mounting Fluid 
1.05 g citric acid/ 50ml 
1.41 g Na2HPO4.2H2O/ 50ml 
50 ml glycerol 
pH 5.5 ( Check periodically, pH critical for optimum fluorescence) 
Store at 2 - 8 °C 
 
4.11.2 Cell Cycle Analysis 
 
Staining solution 
0.1% Triton X-100 
2 mM MgCl2 












0.01 M PIPES buffer 
10 µg/ml propidium iodide 
 
4.11.3 Western blotting 
 
RIPA buffer 
1.75 g NaCl 
2 ml X-100 
500 ml SDS 
2 ml Tris (pH 7.5) 
2 g deoxycholate 
 
Protease inhibitor 
1 cOmplete Mini tablet (Roche, Cat. No. 04 693 124 001) was dissolved in 10ml 
dH2O to make a 10x solution. This was aliquated and stored at -20 °C. 
 
30% Acrylamide 
30 g acrylamide 
0.8 g bis-acrylamide 
0.1 g SDS 
Add dH2O and mix 

















5.9 g Tris 
0.4 g SDS 
pH to 8.0 and make up to 100 ml with dH2O 
Store at 4 °C 
 
Resolving Buffer 
36.2 g Tris 
0.8 g SDS 
pH to 8.9 and make up to 200 ml with dH2O 
Store at 4 °C 
 
5x Loading Buffer 
1.75 g Tris 
30 ml glycine 
Make up to 40 ml with dH2O 
pH to 6.8 with 1 N HCl 
Add H2O to 50 ml 
 
Loading Dye 
100 µl loading buffer 
50 µl β-mercaptoethanol 














10x Running Buffer 
40 g glycine 
63.2 g Tris 
10 g SDS or 100 ml 10% stock 
Make up to 1000 ml with dH2O 
Dilute 1 in 10 for 1x running buffer 
 
10x Transfer buffer 
144 g glycine 
38 g Tris 
Make up to 1000 ml with dH2O 
 
1x Transfer Buffer 
100 ml 10x transfer buffer 
200 ml isopropanol 
700 ml dH2O 
 
Gel stain solution 
50% methanol 
10% glacial acetic acid 
0.25% (w/v) Coomassie Blue 
 
Gel destain solution 
10% methanol 












10x Tris buffered saline (TBS) 
60.5 g Tris 
87.6 g NaCl 
pH to 7.5 
make up to 1000 ml with dH2O 
 
TBS/0.1% Tween 
100 ml 10x TBS 
900 ml dH2O 
1 ml Tween 20 
 
Blocking Solutions 
5 g fat free milk powder 
Dissolve in 100 ml TBS/0.1% Tween 
 
Fixer (AGFA G333C) 
Dilute 100ml stock with 400ml dH2O 
 
Developer (AGFA G128) 
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CONCLUSIONS AND FUTURE WORK 
 
 
The aim of this project was to sythesise new organometallic complexes of palladium, 
platinum and gold and evaluate these against oesophageal cancer cell lines. A series 
of new iminophosphine and tetradentate ligands have been synthesised in good yields 
and characterised by spectroscopic and analytical methods. The molecular structures 
of the new tetradentate ligands 65, 66 and 68 were also determined and have not been 
previously reported. A preliminary investigation of their coordination chemistry with 
palladium(II) and platinum(II) shows interesting reactivity and suggests great promise 
for future directions in synthesis.  
 
The palladium and platinum and gold complexes were prepared from reaction of the 
iminophosphine ligands 58-64 with PdCl2[COD], PdClMe[COD], PtCl2[COD], 
PtCl2[DMSO]2 and Au[tht]Cl to generate the respective neutral iminophosphine 
complexes. The complexes were fully characterised by spectroscopic methods (1H, 
13C-NMR, 31P-NMR, FTIR, and MS) and analytical methods (elemental analysis). 
The molecular structures of palladium complexes 74, 79 and 80; platinum complexes 
84, 86, 88 and gold complexes 91, 93 and 94 were determined by X-ray crystal 
structural analysis. To the best of our knowledge these have not been reported before 
and are therefore novel. On the basis of the analytical data, spectral studies and X-ray 
crystallography, it has been observed that the ligands coordinate to the metal atoms in 
a monobasic bidentate manner and thus possess square planar geometry for the 
palladium and platinum complexes. The gold(I) complexes however exhibit the 












The metal complexes were screened for their anticancer activities against WHCO1 
and KYSE450 oesophageal cancer cell lines. The chloromethyl palladium complexes 
were not very active and exhibited IC50 values in the range 11.0 – 68.5 µM for both 
cell lines. One of the major problems associated with several of the palladium 
complexes examined in this project, lies in the insolubility of the complexes in an 
aqueous medium. Given that solutions of the complexes are administered to biological 
systems, the choice of solvent is limited. The preparation of palladium salts or 
cyclodextrin inclusion complexes could potentially stabilise the complexes and render 
them soluble in an aqueous medium. 
 
The platinum and gold complexes were very active and block the proliferation of 
WHCO1 cells with an IC50 range of 2.5 - 9.4µM, and IC50 range of 2.2 - 7.6µM for 
the KYSE450 cell lines. These complexes kill oesophageal cancer cells, with little 
effect on normal fibroblast cells (DMB), with IC50 values > 100µM which is a very 
significant finding which shows that these novel complexes are selective towards 
oesophageal cancer cells.  However, a number of experiments still have to be 
performed to explore this observation in detail. We will test the complexes on other 
normal epithelial cells (EPC-2), fibroblasts cells (FG0) and other oesophageal cancer 
cell lines (WHCO5, WHCO6, KYSE70, KYSE180, KYSE410, KYSE520) to validate 
if selectivity is still maintained. Furthermore, although these results are very 





















Supporting Information: X-ray diffraction data is provided in the form of structure 
factor tables and tables of data on diskette, 
 
• Appendix 1 – X-ray data for ligand 65 
• Appendix 2 – X-ray data for ligand 66 
• Appendix 3 – X-ray data for ligand 68 
• Appendix 4 – X-ray data for complex 74 
• Appendix 5 – X-ray data for complex 79 
• Appendix 6 – X-ray data for complex 80 
• Appendix 7 – X-ray data for complex 84 
• Appendix 8 – X-ray data for complex 86 
• Appendix 9 – X-ray data for complex 88 
• Appendix 10 – X-ray data for complex 91 
• Appendix 11 – X-ray data for complex 93 
• Appendix 12 – X-ray data for complex 94 
 
